RO INTRO:
INTRODUCERE in lb ROMANA click aici- VA ROG SA O CITITI CLICK AICI pentru baza in limba ROmana(traducerea „aproximativa” in utilizand google translate).
EN INTRO:
Below you will find THOUSANDS of scientific studies and clinical trials (both „in vitro” and „in vivo”, both on animals and on humans) regarding just some of the treatments promoted by this website – in fact, you will find a solid scientific database, demonstrated by multiple independent studies to give you confidence you need in alternative medicine (confidence that should be based on facts(i.e independent studies) NOT on testimonials or „opinions” that are always subjective).
DATABASE CONTENTS:
PAGE 1:
- STUDIES regarding cancer causes(more evidence)
- Studies regarding Oxygen/Ozone and cancer
- STUDIES about MINERALS (ORGANIC) : organic Boron, organic Calcium,organic CESIUM, organic Chromium, organic Germanium, Organic Iodine, organic Iron, organic Magnesium, organic Manganese, organic Molybdenum, organic Selenium, organic Silicium, organic Vanadium, organic Zinc,etc.
- Examples: CALCIUM, CESIUM, GERMANIUM , POTASSIUM, RUBIDIUM, IODINE, SELENIUM,ZINC
PAGE 2:
- Vitamins in alphabetical order:
- Vitamin A
- B Vitamins
Vitamin B2 – Riboflavin, Vitamin B3(Niacin), Vitamin B5 ( pantotenic acid )(respiratory vitamins), Vitamin B6,B12, B17 - Vitamin C (very important vitamin, also respiratory vitamin)
- Vitamin D (very important vitamin)
- Vitamin E (respiratory vitamin)
- Vitamin F(including Omega 3)
- Vitamin K & Vitamin K antagonists
PAGE 3:
- Algae(Seaweed : Spirulina, Chlorella, Kombu(Fucoidan), etc.):
- Aloe Family( i.e. :Vera ,Arborescens)
- BetaGlucans(i.e.: Medicinal Mushrooms)
- Bee products( honey,polen, propolis, venom, royal jelly)
PAGE 4:
- Carotenoids
- Alpha-Carotene
- β-Carotene
- β-Cyptoxanthin
- Astaxanthin
- Canthaxanthin
- Lutein/Zeaxanthin
- Lycopene
- Coenzyme Q10
PAGE 5:
-
Flavonoids:
-
Flavonoid Subclass Dietary Flavonoids Anthocyanidins Cyanidin, Delphinidin, Malvidin, Pelargonidin, Peonidin, Petunidin Flavanols Monomers (Catechins):Catechin, Epicatechin, Epigallocatechin Epicatechin gallate, Epigallocatechin gallateDimers and Polymers:Theaflavins, Thearubigins,Proanthocyanidins Flavanones Hesperetin, Naringenin, Eriodictyol Flavonols Quercetin, Kaempferol, Myricetin, Isorhamnetin Flavones Apigenin, Luteolin Isoflavones Daidzein, Genistein, Glycitein
PAGE 6:
- Hydroxycinnamic Acids
- Chicoric acid
- Coumarin
- Ferulic acid
- Isoprenoides :Abscisic acid, Acorenone, Alloaromadendrene, Aromadendrene, Bergamotene, Bisabolene,Borneol, Bornyl acetate, Isoborneol, Cadinene, Camphene, Caranol, Carene, Carvacrol, Carvone,Pinocarvone, Caryophyllene, Cedrine, Cineole, Cinnamaldehyde, Cinnamate, Citral,Cinnamaldehyde, Cyclocitral, Citronella, Citronellyl acetate or butyrate or propionate, Copaene, Cresol, Cubebene, Cymene, Damascenone,Elemene, Estragol, Eugenol, Farnesene, Fencone, Geraniol, Germacrene, Hotrienol, Humulene, Ionol, Ionone, Isopinocamphone, Isopulegol, Linalool, Longifolene, Mentol, Neomenthol, Menthone, Isomenthone, Murolene, Myrcenol, Myrcene, Myrtenol, Neral, Nerol, Nerolidol, Nootkatone, Ocimene, Ocimenol, Perillaldehyde, Phellandrene, Pinene, Pinocamphone, Piperitol,Piperitone, Pristane, Pulegone, Sabinene, Sabinol, Santalol, Selinadiene, Selinene, Sinensal, Styrene, Terpinene, Terpineol, Terpinolene, Thymol, Tricyclene, Vanillin, Valencene,
- Lecithins
- Lignans (Silymarin)
- Monophenols
- Hydroxytyrosol
- Monoterpenes
- Geraniol
- Limonene
- Organosulfides
- Allicin
- Glutathione
- Indole-3-Carbinol & Di-Indole Methane
- Isothiocyanates
- Sulforaphane
- Phenolic Acids
- Capsaicin
- Ellagic acid
- Galic Acid
- Rosmarinic acid
- Tannic Acid
- Phytosterols
- Beta-Sitosterol
- Saponins
- Stilbenes: 1. Pterostilbene 2. RESVERATROL
- Oxindole alkaloids
- Styryl-lactones : Altholactone, Goniothalamin,etc
- Tannins:
- 1) the condensed tannins (Proanthocyanidin)
- 2) the hydrolysable tannins (as hydrolysable Ellagitannins, such as Woodfordin C (macrocyclic ellagitannin dimmer), Oenotheietc.Anthocyanins: Peonidine-3-glucoside, Cyanidin-3-glucoside , etc.
- Terpenes: Alisol B acetate, Atractylon, Atractylenolides, Betulinic acid, Bisabolol, Boswellic acid, Carnosic acid,Ferutidin, Ferutinin, Myristicin, Oleanolic acid, Parthenolide, Pomolic acid, Tymoquinone, …etc…
- Vanillys-phenols : Paradols, Gingerols, Yakuchinone B, Curcumin (diferuloyl methane), Capsaicin (homo-vanillic acid derivative : 8 methyl-N-Vanillyl-6-nonenamide),etc. Curcumin
- Triterpenoids :
-
Ursolic acid
- Other Phytochemicals
- Damnacanthal
- Digoxin
- Phytic acid
- Other things: melatonin
PAGE 7:
- Scientific studies on Anticarcinogenic natural substances
- Hundreds of studies about NATURAL substances with DEMONSTRATED chemopreventive effect:
- Hundreds of studies about NATURAL substances with DEMONSTRATED Chemotherapeutic effect:
- APOPTOSIS & hundreds of studies about NATURAL substances with DEMONSTRATED APOPTOTIC effect
- Hundreds of studies about NATURAL substances with DEMONSTRATED ANTIPROLIFERATIVE effect
- Scientific studies on Anti-Angiogenic
- Immune therapy & studies about NATURAL substances with DEMONSTRATED immune strengthening effect
PAGE 8:
- a list of about 1600 scientific papers quoted in the book of Dr. Nacci (see my book for more details) in thename of the “Evidence Based Medicine”, which provides this medical method:
_________________________________________________________________________________
========================================================================================================
STUDIES regarding cancer causes:
O. Warburg won the Nobel Prize in Medicine in 1931 for his discovery of the oxygen-transferring enzyme of cell respiration and prime cause of cancer cells- inadequate/improper oxygenation replaced by glucose fermentation, and was voted a second Nobel Prize in 1944 for his discovery of the active groups of the hydrogryuen transferring enzymes. www.nobelprize.org/nobel_prizes/medicine/laureates/1931/warburg-bio.html
Many universities, like Harvard, Oxford, Heidelberg has offered him honorary degrees. He is a Foreign member of the Royal Society if London, a Knight of the Order of Merit founded by Frederick the Great, and was awarded the Great Cross with Star and Shoulder ribbon of the Bundesrepublik.
His main interests are Chemistry and Physics of Life. In both fields no scientists has been more successful.
Excerpts from The Prime Cause and Prevention of Cancer:
Dr. Otto Warburg lecture delivered to Nobel Laureates on June 30, 1966 at Lindau, Lake Constance, Germany:
„There are prime and secondary causes of diseases. For example, the prime cause of the plague is the plague bacillus, but secondary causes of the plague are filth, rats, and the fleas that transfer the plague bacillus from rats to man.
By the prime cause of a disease, I mean one that is found in every case of the disease.
Cancer, above all other diseases, has countless secondary causes. Almost anything can cause cancer. But, even for cancer, there is only one prime cause. The prime cause of cancer is the replacement of the respiration of oxygen (oxidation of sugar) in normal body cells by fermentation of sugar.
All normal body cells meet their energy needs by respiration of oxygen, whereas cancer cells meet their energy needs in great part by fermentation. All normal body cells are thus obligate aerobes, whereas all cancer cells are partial anaerobes.
From the standpoint of the physics and chemistry of life this difference between normal and cancer cells is so great that one can scarcely picture a greater difference.
Oxygen gas, the donor of energy in plants and animals, is dethroned in the cancer cells and replaced by the energy yielding reaction of the lowest living forms, namely the fermentation of sugar. I
n every case, during the cancer development, the oxygen respiration always falls, fermentation appears, and the highly differentiated cells are transformed into fermenting anaerobes, which have lost all their body functions and retain only the now useless property of growth and replication.
Thus, when respiration disappears, life does not disappear, but the meaning of life disappears, and what remains are growing machines that destroy the body in which they grow. All carcinogens impair respiration directly or indirectly by deranging capillary circulation, a statement that is proven by the fact that no cancer cell exists without exhibiting impaired respiration. Of course, respiration cannot be repaired if it is impaired at the same time by a carcinogen.
To prevent cancer it is therefore proposed first to keep the speed of the blood stream so high that the venous blood still contains sufficient oxygen; second, to keep high the concentration of hemoglobin in the blood; third, to add always to the food, even of healthy people, the active groups of the respiratory enzymes; and to increase the doses of these groups, if a precancerous state has already developed. If at the same time exogenous carcinogens are excluded rigorously, then much of the endogenous cancer may be prevented today.
These proposals are in no way utopian. On the contrary, they may be realized by everybody, everywhere, at any hour. Unlike the prevention of many other diseases, the prevention of cancer requires no government help, and not much money. Many experts agree that one could prevent about 80% of all cancers in man, if one could keep away the known carcinogens from the normal body cells. But how can the remaining 20%, the so-called spontaneous cancers, be prevented? It is indisputable that all cancer could be prevented if the respiration of body cells were kept intact.”
Information Sources: www.alkalizeforhealth.net/Loxygen2.htm
For his discovery of the nature and mode of action of the respiratory enzyme, the Nobel Prize was awarded to Otto Warburg in 1931. This discovery opened up new ways in the fields of cellular metabolism and cellular respiration. He showed, among other things, that cancerous cells can live and develop, even in the absence of oxygen.
Otto Warburg, won his first Nobel Prize in 1931 for his discovery of the oxygen transferring enzyme of cell respiration and his second Nobel Prize in 1944 for his discovery of the hydrogen transferring enzyme.
His discoveries are quoted…as follows:
„But, even for cancer, there is only one primary cause. Summarized in a few words, the cause of cancer is the replacement of the respiration of oxygen in normal body cells by a fermentation of sugar. Because no cancer cell exists, the respiration of which is intact, it cannot be disputed that cancer could be prevented if the respiration of the body cells would be kept intact.” http://www.prostate90.com/sci_papers/warburg.html
Dr. Otto Warburg received the Nobel prize in 1931 for the discovery that unlike all other cells in the human body, cancer cells do not breathe oxygen. Cancer cells are anaerobic, which means that they derive their energy without needing oxygen.
Otto Wartburg’s research revealed that when a cell does not receive 60% of its normal oxygen needs, it goes to a mechanism of fermentation and uncontrolled increase. http://www.internethealthlibrary.com/Therapies/OxygenTherapy.htm
Many scientists have confirmed Dr. Otto Wartburg’s discovery, using various scientific methods and techniques(from Gaston Naessens using the Dark-field microscope to recent studies in 2012 ) :
long-term lack of oxygen in cells is the key driver of cancer growth.
Read more recent studies that confirm : http://drsircus.com/medicine/cancer/the-key-drivers-of-cancer-growth-are
Also read Cancer CAUSES (click here), for studies regarding indirect causes(i.e.:microbes, acidosis, free radicals, radiation, etc.)
==================================================================
Regarding cancer treatments:
Ozone/Oxygen Therapies
Oxygen is frequently called a cancer cell’s worst enemy, and a variety ways and means to increase the body’s oxygen content have been developed over the decades worldwide.
Many degenerative diseases of our time respond to oxygen therapy.
Some examples are injection of oxygen bearing compounds, ear insufflation, rectal insufflation, autohematherapy, bagging/tenting, steam sauna, drinking ozonated water etc.
Some eight thousand (8000) MDs and licensed health practitioners (including homeopathic physicians and naturopaths) in Germany use ozone in their practices, while some fifteen thousand European practitioners use ozone, either alone or as a complement to other therapies. Russian doctors have been utilizing ozone for the last 15 years. It is estimated that over 10 million ozone treatments have been given to over one million patients in Germany alone over the last forty years. The medical uses of ozone are well established in many of these countries.
EWOT means doing light exercise, such as on a treadmill or stationary bicycle, while breathing pure oxygen. EWOT produces the benefits of hydrogen peroxide therapy and you can do it at home
Ozone Therapy is a special form of cancer oxygen used to kill and stunt the growth of cancer cells. Oxygen usually prefers to come in pairs: O2. However, oxygen occasionally comes as a triad: O3. O3 or Ozone is much less stable than O2. O3 is looking for an opportunity to become O2 plus singlet oxygen (O). When this happens, singlet oxygen, O, combines with another singlet oxygen and forms O2 again. If no singlet oxygen is available, O combines with other surrounding molecules. This is called „oxidation,” and this form of cancer oxygen is particularly hard on cancer cells, killing some outright and stunting the growth of others. Ozone is administered rectally, intravenously and into the ear canal allowing ozone to absorb through the ear drum.
==================================================================
Minerals (organic) & High PH Therapies:
organic Boron, organic Calcium,organic CESIUM, organic Chromium, organic Germanium, Organic Iodine, organic Iron, organic Magnesium, organic Manganese, organic Molybdenum, organic Selenium, organic Silicium, organic Vanadium, organic Zinc,etc.
CALCIUM
Calcium is an alkaline mineral that carries oxygen to healthy cells, among others.
Every cancer treatment requires alkalinity to slow down the spread of the cancer.
While Cesium (See below) and few other treatments contain alkaline minerals, every other cancer treatment needs calcium to provide the alkalinity.The reason this is a required addition is that calcium, combined with Vitamin D, contains the critical alkalinity.
Though I am not in favor of calcium supplements I would select coral calcium .
Vitamin D is critical for the calcium to be absorbed(see below studies about Vitamin D ,CAlcium and cancer).
Vitamin D is BEST taken form exposure to natural sunlight( without any sunscreen or protection); the more sunshine , the better(avoi burning and exposure between 11am- 16 pm).
The vitamin D3 doses should NOT be elevated, but should always be the doses on the bottle.
If you taking a multi-vitamin, make sure you do not take too much Vitamin D or Vitamin D3.
These pills should be taken during meals. When taken with meals, apple juice or oranges should be consumed in order for the body to better absorb the calcium. Also, other fruits and vegetables should be consumed during the meal to insure the calcium is better absorbed.
The calcium product should be 100% coral calcium. There are some products that mix calcium from coral reefs with calcium from other sources. A cancer patient should not take unnecessary risks but should insure all of the calcium in the product is coral calcium.
No matter what else you do, I would also suggest the patient take at least two oranges a day (for the Vitamin D) and at least one banana a day (for the potassium).
This protocol is an optional treatment for anyone on one of the baking soda protocols.
The Robert Barefoot Coral Calcium Protocol For Treating Cancer click here
Studies on calcium and cancer
-
A prospective study of calcium intake and incident and fatal prostate cancer.
2006 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Dairy food, calcium, and risk of cancer in the NIH-AARP Diet and Health Study.
2009 Archives of internal medicine -
Verapamil inhibits L-type calcium channel mediated apoptosis in human colon cancercells.
2008 Diseases of the colon and rectum -
Dietary calcium, vitamin D, VDR genotypes and colorectal cancer.
2004 International journal of cancer. Journal international du cancer -
Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men.
2003 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women.
2009 The American journal of clinical nutrition -
ORAI1-mediated calcium influx in lactation and in breast cancer.
2011 Molecular cancer therapeutics -
Inverse association between prostate cancer and the use of calcium channel blockers.
2004 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
2007 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Calcium intake increases risk of prostate cancer among Singapore Chinese.
2010 Cancer research -
Serum calcium and the risk of prostate cancer.
2009 Cancer causes & control : CCC -
Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.
2008 Cochrane database of systematic reviews (Online) -
Serum calcium and breast cancer risk: results from a prospective cohort study of 7,847 women.
2007 Cancer causes & control : CCC -
A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland).
2007 International journal of cancer. Journal international du cancer -
Vitamin D, calcium, and breast cancer risk: a review.
2006 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.
2004 Cochrane database of systematic reviews (Online) -
Calcium channel blocker use and the risk of prostate cancer.
1998 American journal of hypertension -
Dietary calcium and vitamin D intake and risk of colorectal cancer: a prospective cohort study in women.
2002 Nutrition and cancer -
Proliferative signaling by store-operated calcium channels opposes colon cancer cell cytostasis induced by bacterial enterotoxins.
2005 The Journal of pharmacology and experimental therapeutics -
Calcium from diet and supplements is associated with reduced risk of colorectalcancer in a prospective cohort of women.
2005 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Extracellular calcium increases bisphosphonate-induced growth inhibition of breastcancer cells.
2008 Breast cancer research : BCR -
Serum calcium and tumour aggressiveness in breast cancer: a prospective study of 7847 women.
2009 European journal of cancer prevention : the official journal of the Europeancancer Prevention Organisation (ECP) -
Calcium, vitamin D and cancer.
2009 Anticancer research -
Meta-analysis of vitamin D, calcium and the prevention of breast cancer.
2010 Breast cancer research and treatment -
Genetic variation in calcium-sensing receptor and risk for colon cancer.
2008 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology -
Intakes of calcium and vitamin D and breast cancer risk in women.
2007 Archives of internal medicine -
Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women’s Health Initiative randomized trial.
2008 International journal of cancer. Journal international du cancer -
Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies.
2004 Journal of the National cancer Institute -
Intake of dairy products, calcium, and vitamin d and risk of breast cancer.
2002 Journal of the National cancer Institute -
Dietary calcium intake and breast cancer risk among Chinese women in Shanghai.
2003 Nutrition and cancer -
Calcium intake and risk of colon cancer in women and men.
2002 Journal of the National cancer Institute -
Calcium and dairy food intakes are inversely associated with colorectal cancer risk in the Cohort of Swedish Men.
2006 The American journal of clinical nutrition -
Intakes of calcium and vitamin D and risk of colorectal cancer in women.
2005 American journal of epidemiology -
Calcium plus vitamin D supplementation and the risk of breast cancer.
2008 Journal of the National cancer Institute -
Calcium plus vitamin D supplementation and the risk of colorectal cancer.
2006 The New England journal of medicine -
Dairy products, calcium, phosphorous, vitamin D, and risk of prostate cancer(Sweden)
1998 Cancer causes & control : CCC -
Calcium, dairy products, and the risk of prostate cancer.
2001 The Prostate -
Cancer risk and mortality in users of calcium channel blockers. A cohort study.
2000 CancerGrowth of heterotopic LNCaP prostate cancer tumor in nude mice is not affected by dietary calcium.
2001 The Prostate
Calcium signaling and T-type calcium channels in cancer cell cycling.
2008 World journal of gastroenterology : WJGSerum calcium and incident and fatal prostate cancer in the National Health and Nutrition Examination Survey.
2008 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyThe relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.
2010 British journal of cancerDoes calcium in drinking water modify the association between trihalomethanes and the risk of death from colon cancer?
2010 Journal of toxicology and environmental health. Part ASerum levels of vitamin D, PTH and calcium and breast cancer risk-a prospective nested case-control study.
2010 International journal of cancer. Journal international du cancer2-Aminoethoxydiphenyl borate perturbs hormone-sensitive calcium stores and blocks store-operated calcium influx pathways independent of cytoskeletal disruption in human A549 lung cancer cells.
2005 Biochemical pharmacologyKCl depolarization increases HIF-1 transcriptional activity via the calcium-independent pathway in SGC7901 gastric cancer cells.
2007 Tumour biology : the journal of the International Society for Oncodevelopmental Biology and MedicineRisk of prostate cancer in a randomized clinical trial of calcium supplementation.
2005 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyCalcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study.
2007 American journal of epidemiologyCalcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study.
2007 American journal of epidemiologyDietary vitamin D and calcium intake and premenopausal breast cancer risk in a German case-control study.
2007 Nutrition and cancerDifferential expression of calcium-related genes in gastric cancer cells transfected with cellular prion protein.
2007 Biochemistry and cell biology = Biochimie et biologie cellulaireCalcium, vitamin D, dairy products, and risk of colorectal cancer in the cancerPrevention Study II Nutrition Cohort (United States).
2003 Cancer causes & control : CCCExpression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation.
2002 The Journal of biological chemistryOverexpression of an alpha 1H (Cav3.2) T-type calcium channel during neuroendocrine differentiation of human prostate cancer cells.
2002 The Journal of biological chemistryAssociation of dairy products, lactose, and calcium with the risk of ovarian cancer.
2002 American journal of epidemiologyLack of association between suicidal ideation and enhanced platelet 5-HT2A receptor-mediated calcium mobilization in cancer patients with depression.
2002 Biological psychiatryA prospective study of total and ionized serum calcium and fatal prostate cancer.
2009 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyDietary calcium, vitamin D, and the risk of colorectal cancer.
2008 The American journal of clinical nutritionCalcium and magnesium in drinking water and risk of death from kidney cancer.
2011 Journal of toxicology and environmental health. Part AUFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer.
1999 Oncology (Williston Park, N.Y.)Calcium and vitamin D. Their potential roles in colon and breast cancer prevention.
1999 Annals of the New York Academy of SciencesThree sets of diagnostic criteria for major depression and correlations with serotonin-induced platelet calcium mobilization in cancer patients.
2001 PsychopharmacologyEffects of calcium and vitamin supplementation on colon cell proliferation in colorectal cancer.
2000 Cancer investigationDairy products, calcium, and prostate cancer risk in the Physicians’ Health Study.
2001 The American journal of clinical nutritionCalcium-sensing receptor activation induces nitric oxide production in H-500 Leydigcancer cells.
2005 American journal of physiology. Endocrinology and metabolismCalcium-induced apoptosis is delayed by HER1 receptor signalling through the Akt and PLC? pathways in bladder cancer cells.
2011 Scandinavian journal of clinical and laboratory investigationCollagen and calcium-binding EGF domains 1 is frequently inactivated in ovariancancer by aberrant promoter hypermethylation and modulates cell migration and survival.
2010 British journal of cancerResistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
2010 Molecular cancer therapeuticsAssociation between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan.
2010 Cancer scienceProstate cancer in African-American men and polymorphism in the calcium-sensing receptor.
2010 Cancer biology & therapyDoes a higher ratio of serum calcium to magnesium increase the risk for postmenopausal breast cancer?
2010 Medical hypothesesCalcium intake and prostate cancer risk in a long-term aging study: the Baltimore Longitudinal Study of Aging.
2002 UrologyDietary iron, zinc, and calcium and the risk of lung cancer.
2005 Epidemiology (Cambridge, Mass.)Involvement of calcium in the differential induction of heat shock protein 70 by heat shock protein 90 inhibitors, geldanamycin and radicicol, in human non-small cell lungcancer H460 cells.
2006 Journal of cellular biochemistryAccelerated bone resorption, due to dietary calcium deficiency, promotes breastcancer tumor growth in bone.
2007 Cancer researchMitochondrial localization of cyclooxygenase-2 and calcium-independent phospholipase A2 in human cancer cells: implication in apoptosis resistance.
2005 Experimental cell researchDairy products, calcium and the risk of breast cancer: results of the French SU.VI.MAX prospective study.
2007 Annals of nutrition & metabolismMeat and cancer: haemoglobin and haemin in a low-calcium diet promote colorectal carcinogenesis at the aberrant crypt stage in rats.
2003 CarcinogenesisCancer-related diseases of the eye: the role of calcium and calcium-binding proteins.
2004 Biochemical and biophysical research communicationsDairy, calcium, and vitamin D intake and postmenopausal breast cancer risk in thecancer Prevention Study II Nutrition Cohort.
2005 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyCoronary calcium screening using low-dose lung cancer screening: effectiveness of MDCT with retrospective reconstruction.
2008 AJR. American journal of roentgenologyDairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men.
2008 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyMAG-2 promotes invasion, mobility and adherence capability of lung cancer cells by MMP-2, CD44 and intracellular calcium in vitro.
2009 Oncology reportsCalcium, inorganic phosphates, alkaline and acid phosphatase activities in breastcancer patients in Calabar, Nigeria.
2010 African health sciencesCalcium, dairy foods, vitamin D, and colorectal cancer risk: the Fukuoka Colorectalcancer Study.
2008 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyDairy products, calcium intake, and breast cancer risk: a case-control study in China.
2011 Nutrition and cancerHot flashes in breast cancer survivors and an association with calcium supplement use.
2010 International journal of women’s healthCalcium and magnesium in drinking water and risk of death from prostate cancer.
2000 Journal of toxicology and environmental health. Part ACalcium channel blockers and cancer.
2000 The American journal of medicineParathyroid hormone may be a cancer promoter – an explanation for the decrease incancer risk associated with ultraviolet light, calcium, and vitamin D.
2000 Medical hypothesesAngiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer.
2000 Archives of internal medicineRed meat and colon cancer: dietary haem-induced colonic cytotoxicity and epithelial hyperproliferation are inhibited by calcium.
2001 CarcinogenesisCalcium and vitamin D intake and risk of colorectal cancer: the Multiethnic Cohort Study.
2007 American journal of epidemiologyThe role of the calcium-sensing receptor in the development and progression of cancer.
2009 Endocrine reviewsCaV3.2 T-type calcium channels are involved in calcium-dependent secretion of neuroendocrine prostate cancer cells.
2008 The Journal of biological chemistryGonadotropin-induced ovarian cancer cell migration and proliferation require extracellular signal-regulated kinase 1/2 activation regulated by calcium and protein kinase C{delta}.
2010 Endocrine-related cancerExtracellular calcium promotes the migration of breast cancer cells through the activation of the calcium sensing receptor.
2009 Experimental cell researchAnimal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into cancer and Nutrition.
2008 British journal of cancerGenetic variation in the retinoid X receptor and calcium-sensing receptor and risk of colorectal cancer in the Colon cancer Family Registry.
2010 CarcinogenesisEndoplasmic reticulum calcium transport ATPase expression during differentiation of colon cancer and leukaemia cells.
2004 Biochemical and biophysical research communicationsCalcium-sensing receptor A986S polymorphism in human rectal cancer.
2002 International journal of colorectal diseaseMultiple, disparate roles for calcium signaling in apoptosis of human prostate and cervical cancer cells exposed to diindolylmethane.
2006 Molecular cancer therapeuticsDietary calcium, phosphorus, vitamin D, dairy products and the risk of colorectal adenoma and cancer among French women of the E3N-EPIC prospective study.
2005 International journal of cancer. Journal international du cancerDietary intake of calcium, fiber and other micronutrients in relation to colorectalcancer risk: Results from the Shanghai Women’s Health Study.
2006 International journal of cancer. Journal international du cancerImpaired gap junction formation and intercellular calcium signaling in urinary bladdercancer cells can be improved by Gö6976.
2007 Cell communication & adhesionPromoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer.
2005 The ProstateExpression of the calcium receptor in human breast cancer–a potential new marker predicting the risk of bone metastases.
2006 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyEffect of histone H1 on the cytosolic calcium levels in human breast cancer MCF 7 cells.
2005 Life sciencesAssociations of energy, fat, calcium, and vitamin D with prostate cancer risk.
2002 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyVitamin D receptor start codon polymorphism and colorectal cancer risk: effect modification by dietary calcium and fat in Singapore Chinese.
2003 CarcinogenesisRelationship between serum calcium and CA 19-9 levels in colorectal cancer.
2004 World journal of gastroenterology : WJGTranslationally controlled tumor protein (TCTP) in the human prostate and prostatecancer cells: expression, distribution, and calcium binding activity.
2004 The ProstateThe prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D.
2004 CarcinogenesisMagnesium and calcium in drinking water and the risk of death from esophageal cancer.
2002 Magnesium research : official organ of the International Society for the Development of Research on MagnesiumRole of calcium in phototoxicity of 2-butylamino-2-demethoxy-hypocrellin A to human gastric cancer MGC-803 cells.
2003 Biochimica et biophysica actaMagnesium and calcium in drinking water and risk of death from ovarian cancer.
2004 Magnesium research : official organ of the International Society for the Development of Research on MagnesiumTGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells.
2008 American journal of physiology. Gastrointestinal and liver physiologyColorectal cancer risk and dietary intake of calcium, vitamin D, and dairy products: a meta-analysis of 26,335 cases from 60 observational studies.
2009 Nutrition and cancerCalcium-sensing receptor in cancer: good cop or bad cop?
2009 EndocrineHIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.
2009 Current cancer drug targetsCalcium transport and signaling in the mammary gland: targets for breast cancer.
2006 Biochimica et biophysica actaVitamin D receptor and calcium sensing receptor polymorphisms and the risk of colorectal cancer in European populations.
2009 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologyDairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies.
2008 Nutrition and cancerVitamin D, calcium and prevention of breast cancer: a review.
1999 Journal of the American College of NutritionDelayed micromolar elevation in intracellular calcium precedes induction of apoptosis in thapsigargin-treated breast cancer cells.
2000 Clinical cancer research : an official journal of the American Association forcancer ResearchUFT/oral calcium folinate plus weekly paclitaxel for metastatic breast cancer.
1999 Oncology (Williston Park, N.Y.)Paclitaxel and UFT plus oral calcium folinate in pretreated metastatic breast cancer.
1999 Oncology (Williston Park, N.Y.)Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk (United States).
2000 Cancer causes & control : CCCInhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells.
2001 International journal of cancer. Journal international du cancerAnimal products, calcium and protein and prostate cancer risk in The Netherlands Cohort Study.
1999 British journal of cancerCalcium signals in prostate cancer cells: specific activation by bone-matrix proteins.
2000 Cell calciumEnterotoxin preconditioning restores calcium-sensing receptor-mediated cytostasis in colon cancer cells.
2008 CarcinogenesisL-type calcium channel blockers reverse docetaxel and vincristine-induced multidrug resistance independent of ABCB1 expression in human lung cancer cell lines.
2010 Toxicology lettersClusterin: the missing link in the calcium-dependent resistance of cancer cells to apoptogenic stimuli.
2006 Post?py higieny i medycyny doswiadczalnej (Online)Calcium and survivin are involved in the induction of apoptosis by dihydroartemisinin in human lung cancer SPC-A-1 cells.
2007 Methods and findings in experimental and clinical pharmacologyCalcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer.
2007 The British journal of nutritionCalcium fructoborate: plant-based dietary boron as potential medicine for cancertherapy.
2011 Frontiers in bioscience (Scholar edition)Modulation of ATP-induced calcium signaling by progesterone in T47D-Y breastcancer cells.
2010 Molecular and cellular endocrinologyComparative effects of boric acid and calcium fructoborate on breast cancer cells.
2008 Biological trace element researchA combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results.
2010 Oncology reportsAnti-cancer drugs interfere with intracellular calcium signaling.
2009 NeurotoxicologyCalcium and colorectal cancer: some questions remain.
2004 Nutrition reviewsCritical roles of intracellular thiols and calcium in parthenolide-induced apoptosis in human colorectal cancer cells.
2004 Cancer lettersPhosphocitrate inhibits calcium hydroxyapatite induced mitogenesis and upregulation of matrix metalloproteinase-1, interleukin-1beta and cyclooxygenase-2 mRNA in human breast cancer cell lines.
2003 Breast cancer research and treatmentCalcium-sensing receptor induces messenger ribonucleic acid of human securin, pituitary tumor transforming gene, in rat testicular cancer.
2003 EndocrinologyExpression of plasma membrane calcium pump isoform mRNAs in breast cancer cell lines.
2002 Cellular signallingExpression of plasma membrane calcium pump isoform mRNAs in breast cancer cell lines.
2002 Cellular signallingLevels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer.
2007 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive OncologySarco/endoplasmic reticulum calcium-ATPase 2 expression as a tumor marker in colorectal cancer.
2006 The American journal of surgical pathologyCalcium/calmodulin-dependent kinase I and calcium/calmodulin-dependent kinase kinase participate in the control of cell cycle progression in MCF-7 human breastcancer cells.
2005 Cancer researchMitochondria, calcium, and calpain are key mediators of resveratrol-induced apoptosis in breast cancer.
2007 Molecular pharmacologyRelaxin downregulates the calcium binding protein S100A4 in MDA-MB-231 human breast cancer cells.
2005 Annals of the New York Academy of SciencesHigh calcium activates the EGF receptor potentially through the calcium-sensing receptor in Leydig cancer cells.
2005 Growth factors (Chur, Switzerland)Treatment of mcf-7 breast cancer cells with a red grape wine polyphenol fraction results in disruption of calcium homeostasis and cell cycle arrest causing selective cytotoxicity.
2006 Journal of agricultural and food chemistryNuclear translocation of telomerase reverse transcriptase and calcium signaling in repression of telomerase activity in human lung cancer cells by fungal immunomodulatory protein from Ganoderma tsugae.
2007 Biochemical pharmacologyAndrogens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells.
2006 Journal of andrologyThe role of calcium, P38 MAPK in dihydroartemisinin-induced apoptosis of lung cancerPC-14 cells.
2008 Cancer chemotherapy and pharmacologyCalbindin-D28k and calcium sensing receptor cooperate in MCF-7 human breastcancer cells.
2004 International journal of oncologyEarly development of cancer chemoprevention clinical trials: studies of dietarycalcium as a chemopreventive agent for human subjects.
2002 European journal of cancer prevention : the official journal of the Europeancancer Prevention Organisation (ECP)Specific mitochondrial calcium overload induces mitochondrial fission in prostatecancer cells.
2010 International journal of oncologyPrognostic significance of disordered calcium metabolism in hormone-refractory prostate cancer patients with metastatic bone disease.
2009 Prostate cancer and prostatic diseasesOverexpression of Bax induces down-regulation of store-operated calcium entry in prostate cancer cells.
2008 Journal of cellular physiologyEGR1 expression: A calcium and ERK1/2 mediated PPAR(?)-independent event involved in the antiproliferative effect of 15-deoxy-?12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells.
2011 Biochemical pharmacologyMilk and the risk and progression of cancer.
2011 Nestlé Nutrition workshop series. Paediatric programmeThe relationship between daily calcium intake and bone mineral density in men with prostate cancer.
2007 BJU internationalCalcium/calmodulin-dependent kinase II plays an important role in prostate cancercell survival.
2007 Cancer biology & therapyRoles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells.
2007 Archives of pharmacal researchNew insights into calcium, dairy and colon cancer.
2008 World journal of gastroenterology : WJGVariation in intakes of calcium, phosphorus, magnesium, iron and potassium in 10 countries in the European Prospective Investigation into cancer and Nutrition study.
2009 European journal of clinical nutritionCalcium wave signaling in cancer cells.
2010 Life sciencesRegulation of intracellular calcium in human breast cancer cells.
1998 EndocrineCalcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Health Hypertension Care Computing Project (DHCCP)
2000 Journal of human hypertensionCalcium and magnesium in drinking water and the risk of death from breast cancer.
2000 Journal of toxicology and environmental health. Part AUFT plus or minus calcium folinate for metastatic colorectal cancer in older patients.
1999 Oncology (Williston Park, N.Y.)Uracil/tegafur plus oral calcium folinate in advanced breast cancer.
1999 Oncology (Williston Park, N.Y.)Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer.
1999 Oncology (Williston Park, N.Y.)UFT plus calcium folinate/irinotecan in colorectal cancer.
1999 Oncology (Williston Park, N.Y.)Oxytocin does not induce a rise in intracellular free calcium in human breast cancercells.
1999 Research communications in molecular pathology and pharmacologyPharmacokinetic and pharmacodynamic comparison of two doses of calcium folinate combined with continuous fluorouracil infusion in patients with advanced colorectal cancer.
1999 Pharmacy world & science : PWSDairy foods and prevention of colon cancer: human studies.
1999 Journal of the American College of NutritionPreclinical and early human studies of calcium and colon cancer prevention.
1999 Annals of the New York Academy of SciencesExpression of CaT-like, a novel calcium-selective channel, correlates with the malignancy of prostate cancer.
2001 The Journal of biological chemistryStress protein GRP78 prevents apoptosis induced by calcium ionophore, ionomycin, but not by glycosylation inhibitor, tunicamycin, in human prostate cancer cells.
2000 Journal of cellular biochemistryPaclitaxel, UFT, and calcium folinate in metastatic breast cancer.
1999 Oncology (Williston Park, N.Y.)Preoperative UFT and calcium folinate and radiotherapy in rectal cancer.
1999 Oncology (Williston Park, N.Y.)Tamoxifen inhibits TRPV6 activity via estrogen receptor-independent pathways in TRPV6-expressing MCF-7 breast cancer cells.
2009 Molecular cancer research : MCRPlatelet-activating factor and metastasis: Calcium-independent phospholipase A2{beta} deficiency protects against breast cancer metastasis to the lung.
2011 American journal of physiology. Cell physiologyEffect of P2 receptor on the intracellular calcium increase by cancer cells in human umbilical vein endothelial cells.
2008 Naunyn-Schmiedeberg’s archives of pharmacologyCalcium signalling and cancer cell growth.
2007 Sub-cellular biochemistryCaveolae/caveolin-1 are important modulators of store-operated calcium entry in Hs578/T breast cancer cells.
2008 Journal of pharmacological sciencesA novel native store-operated calcium channel encoded by Orai3: selective requirement of Orai3 versus Orai1 in estrogen receptor-positive versus estrogen receptor-negative breast cancer cells.
2010 The Journal of biological chemistryCalcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells.
2002 The Journal of biological chemistryCancer cell contact causes oscillatory and polarized rise of cytoplasmic ionizedcalcium concentration in human umbilical vein endothelial cells.
2002 International journal of oncologyRole of endoplasmic reticulum calcium content in prostate cancer cell growth regulation by IGF and TNFalpha.
2004 Journal of cellular physiology[Role of calcium signal in apoptosis and protective mechanism of colon cancer cell line SW480 in response to 5-aminolevulinic acid-photodynamic therapy].
2006 Ai zheng = Aizheng = Chinese journal of cancerFunctional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor gamma and calcium signaling in human colorectal cancer cells.
2007 The Journal of biological chemistryTherapeutic advantage of combining calcium channel blockers and TRAIL in prostate cancer.
2006 Molecular cancer therapeuticsHigh-content kinetic calcium imaging in drug-sensitive and drug-resistant human breast cancer cells.
2006 Methods in enzymologyExtracellular calcium as a candidate mediator of prostate cancer skeletal metastasis.
2006 Cancer researchGrowth inhibition of human cancer cells in vitro by T-type calcium channel blockers.
2006 Bioorganic & medicinal chemistry lettersCaspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells.
2006 The Journal of biological chemistryThe Androgen-Regulated Calcium-Activated Nucleotidase 1 (CANT1) Is Commonly Overexpressed in Prostate cancer and Is Tumor-Biologically Relevant in Vitro.
2011 The American journal of pathologyDietary calcium supplementation for preventing colorectal cancer and adenomatous polyps.
2005 Cochrane database of systematic reviews (Online)[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].
2006 Gan to kagaku ryoho. cancer & chemotherapyCalcium/calmodulin-dependent protein kinases as potential targets in cancer therapy.
2005 Expert opinion on therapeutic targetsCalcium store contents control the expression of TRPC1, TRPC3 and TRPV6 proteins in LNCaP prostate cancer cell line.
2006 Cell calciumThe pharmacology and regulation of T type calcium channels: new opportunities for unique therapeutics for cancer.
2006 Cell calciumIntracellular pH and calcium signaling as molecular targets of diclofenac-induced apoptosis against colon cancer.
2011 European journal of cancer prevention : the official journal of the Europeancancer Prevention Organisation (ECP)Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort.
2005 The American journal of clinical nutritionEvidence on the operation of ATP-induced capacitative calcium entry in breast cancercells and its blockade by 17beta-estradiol.
2002 Journal of cellular biochemistryA Kunitz-type protease inhibitor, bikunin, inhibits ovarian cancer cell invasion by blocking the calcium-dependent transforming growth factor-beta 1 signaling cascade.
2003 The Journal of biological chemistryRetinoic acid increases expression of the calcium-binding protein S100P in human gastric cancer cells.
2003 Journal of biomedical scienceCalmodulin-androgen receptor (AR) interaction: calcium-dependent, calpain-mediated breakdown of AR in LNCaP prostate cancer cells.
2006 Cancer researchProspective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis.
2005 Journal of the National cancer Institute[Influence of Scutellaria barbata on calcium beaconage of cervix cancer cells].
2003 Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materialsDangerous nutrition? Calcium, vitamin D, and shark cartilage nutritional supplements and cancer-related hypercalcemia.
2003 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in CancerLysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancercells.
2008 Archives of pharmacal researchMethylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer.
2008 GastroenterologyDHA induces ER stress and growth arrest in human colon cancer cells: associations with cholesterol and calcium homeostasis.
2008 Journal of lipid researchIndependent and joint effects of serum 25-hydroxyvitamin D and calcium on ovariancancer risk: a prospective nested case-control study.
2010 European journal of cancer (Oxford, England : 1990)Key promoter elements involved in transcriptional activation of the cancer-related gene coding for S100P calcium-binding protein.
2008 Oncology reports[Selective Expression of Calcium-Binding Protein S100A7 in Lung Cancer.].
2009 Zhongguo fei ai za zhi = Chinese journal of lung cancerEnhanced S100 calcium-binding protein P expression sensitizes human bladdercancer cells to cisplatin.
2010 BJU internationalWestern-style diet-induced colonic tumors and their modulation by calcium and vitamin D in C57Bl/6 mice: a preclinical model for human sporadic colon cancer.
2009 Carcinogenesis[Therapeutic agents for disorders of bone and calcium metabolism–Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
2007 Clinical calciumUFT/oral calcium folinate plus radiation in pancreatic cancer.
1999 Oncology (Williston Park, N.Y.)UFT and oral calcium folinate as first-line chemotherapy for metastatic gastric cancer.
1999 Oncology (Williston Park, N.Y.)Characterization of calcium-mobilizing, purinergic P2Y(2) receptors in human ovariancancer cells.
2000 Molecular human reproductionImmunogenicity of P/Q-type calcium channel in small cell lung cancer: investigation of alpha1 subunit polyglutamine expansion.
1999 Tissue antigensUFT plus oral calcium folinate/vinorelbine for advanced breast cancer.
1999 Oncology (Williston Park, N.Y.)Calcium ionophore, ionomycin inhibits growth of human bladder cancer cells both in vitro and in vivo with alteration of Bcl-2 and Bax expression levels.
1999 The Journal of urologyIncreased prevalence of primary hyperparathyroidism in treated breast cancer.
2001 Journal of endocrinological investigationUFT plus calcium folinate plus radiotherapy for recurrent rectal cancer.
1999 Oncology (Williston Park, N.Y.)Calcium/calmodulin-dependent kinase II regulates notch-1 signaling in prostatecancer cells.
2009 Journal of cellular biochemistryCalcium Phosphate Nanocomposite Particles for In Vitro Imaging and Encapsulated Chemotherapeutic Drug Delivery to cancer Cells.
2008 Nano lettersRegulation of PSA secretion and survival signaling by calcium-independent phopholipase A(2)beta in prostate cancer cells.
2009 The ProstateA short primer on the calcium sensing receptor: an important cog in the colon cancerwheel?
2011 Digestive diseases and sciencesRole of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectalcancer patients.
2010 Oncology (Williston Park, N.Y.)Activation of P2X(7)-mediated apoptosis Inhibits DMBA/TPA-induced formation of skin papillomas and cancer in mice.
2009 BMC cancerSignificance of mitochondrial calcium and nitric oxide for apoptosis of human breastcancer cells induced by tamoxifen and etoposide.
2008 International journal of molecular medicineCalcium phosphate nanocomposite particles for in vitro imaging and encapsulated chemotherapeutic drug delivery to cancer cells.
2008 Nano lettersArtemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.
2009 British journal of pharmacologyA novel mechanism underlying phytate-mediated biological action-phytate hydrolysates induce intracellular calcium signaling by a Gaq protein-coupled receptor and phospholipase C-dependent mechanism in colorectal cancer cells.
2010 Molecular nutrition & food researchOral signs of intravenous chemotherapy with 5-Fluorouracil and Leucovorin calciumin colon cancer treatment.
2009 Medicina oral, patología oral y cirugía bucalInhibition of calcium-independent phospholipase A2 activates p38 MAPK signaling pathways during cytostasis in prostate cancer cells.
2010 Biochemical pharmacologyHu and voltage-gated calcium channel (VGCC) antibodies related to the prognosis of small-cell lung cancer.
2004 Journal of clinical oncology : official journal of the American Society of Clinical OncologyParticular sensitivity to calcium channel blockers of the fast inward voltage-dependent sodium current involved in the invasive properties of a metastastic breastcancer cell line.
2004 British journal of pharmacologyLack of evidence for the association of tumor necrosis factor-alpha gene promoter polymorphism with calcium oxalate stone and bladder cancer patients.
2001 Urological researchThe role of the calcium-sensing receptor in cancer.
2004 Cell calciumAdjuvant intraperitoneal chemotherapy with cisplatinum, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.
2002 American journal of clinical oncologyS100P calcium-binding protein overexpression is associated with immortalization of human breast epithelial cells in vitro and early stages of breast cancer development in vivo.
2000 International journal of oncologyAngiotensin II stimulation of Na+/K+ATPase activity and cell growth by calcium-independent pathway in MCF-7 breast cancer cells.
2002 The Journal of endocrinologyMolecular and functional characterization of the extracellular calcium-sensing receptor in human colon cancer cells.
2003 Oncology researchRoles for the calcium sensing receptor in primary and metastatic cancer.
2006 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical OncologyWnt5a secretion stimulated by the extracellular calcium-sensing receptor inhibits defective Wnt signaling in colon cancer cells.
2007 American journal of physiology. Gastrointestinal and liver physiologyCalcium and cancer: targeting Ca2+ transport.
2007 Nature reviews. CancerVitamin D and calcium intake in relation to risk of endometrial cancer: a systematic review of the literature.
2008 Preventive medicine[Clinical observation on treatment of advanced gastric cancer by combined use of Shenqi Fuzheng injection, docetaxel, flurouracil and calcium folinate].
2007 Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine / Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu banCalcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer.
2005 Clinical cancer research : an official journal of the American Association forcancer ResearchDrugs which inhibit osteoclast function suppress tumor growth through calciumreduction in bone.
2011 BoneBKCa channels activating at resting potential without calcium in LNCaP prostatecancer cells.
2005 The Journal of membrane biologyVitamin D and calcium supplementation reduces cancer risk: results of a randomized trial.
2007 The American journal of clinical nutritionCharacterization of calcium release-activated apoptosis of LNCaP prostate cancercells.
2000 The Journal of biological chemistryPrognostic significance of calcium-binding protein S100A4 in colorectal cancer.
2002 GastroenterologyChemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms.
2003 Nature reviews. CancerPrevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
2004 Clinical cancer research : an official journal of the American Association forcancer ResearchNear-infrared emitting fluorophore-doped calcium phosphate nanoparticles for in vivo imaging of human breast cancer.
2008 ACS nanoBRCA1 suppresses the expression of survivin and promotes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in human breast cancer cells.
2011 Cell calciumCalcium Mobilization in Ovarian cancer Cells in Response to Lysophospholipids.
2001 Methods in molecular medicineChildhood cancer survivors’ perceived barriers to improving exercise and dietary behaviors.
2008 Oncology nursing forumEpigenetic inactivation of calcium-sensing receptor in colorectal carcinogenesis.
2011 Modern pathology : an official journal of the United States and Canadian Academy of Pathology, IncCalcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo.
2008 Cancer gene therapyActivation of the calcium-sensing receptor by high calcium induced breast cancer cell proliferation and TRPC1 cation channel over-expression potentially through EGFR pathways.
2009 Archives of biochemistry and biophysicsVascular endothelial growth factor-C siRNA delivered via calcium carbonate nanoparticle effectively inhibits lymphangiogenesis and growth of colorectal cancer in vivo.
2009 Cancer biotherapy & radiopharmaceuticalsExpression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
2009 GastroenterologyIntrinsically disordered human C/EBP homologous protein regulates biological activity of colon cancer cells during calcium stress.
2008 Journal of molecular biologyAltered calcium metabolism in patients on long-term bisphosphonate therapy for metastatic breast cancer.
2009 Anticancer researchExtracellular signal-regulated kinases 1 and 2 and TRPC1 channels are required for calcium-sensing receptor-stimulated MCF-7 breast cancer cell proliferation.
2009 Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacologyThe platinum (II) complex [Pt(O,O’-acac)(?-acac)(DMS)] alters the intracellular calciumhomeostasis in MCF-7 breast cancer cells.
2011 Biochemical pharmacologyUpregulation of soluble resistance-related calcium-binding protein (sorcin) in gastric cancer.
2010 Medical oncology (Northwood, London, England)Increase in cytosolic calcium maintains plasma membrane integrity through the formation of microtubule ring structure in apoptotic cervical cancer cells induced by trichosanthin.
2009 Cell biology internationalSupplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis.
2010 Clinical therapeuticsDairy consumption and calcium intake and risk of breast cancer in a prospective cohort: the Norwegian Women and cancer study.
2010 Cancer causes & control : CCCCalcium sensing receptor down-regulates malignant cell behavior and promotes chemosensitivity in human breast cancer cells.
2009 Cell calciumThe effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
2011 European journal of cancer (Oxford, England : 1990)Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
2011 Journal of clinical oncology : official journal of the American Society of Clinical OncologyTransactivation of hsp70-1/2 in geldanamycin-treated human non-small cell lungcancer H460 cells: involvement of intracellular calcium and protein kinase C.
2005 Journal of cellular biochemistrySIMS ion microscopy in cancer research: single cell isotopic imaging for chemical composition, cytotoxicity and cell cycle recognition.
2001 Cellular and molecular biology (Noisy-le-Grand, France)Trp-p8, a novel prostate-specific gene, is up-regulated in prostate cancer and other malignancies and shares high homology with transient receptor potential calciumchannel proteins.
2001 Cancer researchCalreticulin expression is associated with androgen regulation of the sensitivity tocalcium ionophore-induced apoptosis in LNCaP prostate cancer cells.
1999 Cancer researchDietary calcium and growth modulation of human colon cancer cells: role of the extracellular calcium-sensing receptor.
2000 Cancer detection and prevention[A case of small cell lung cancer with paraneoplastic cerebellar degeneration and anti-voltage-gated calcium channel antibody].
2001 Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory SocietyDNA methylation and immunohistochemical analysis of the S100A4 calcium binding protein in human prostate cancer.
2007 The ProstateAltered intracellular calcium fluxes in pancreatic cancer induced diabetes mellitus: Relevance of the S100A8 N-terminal peptide (NT-S100A8).
2011 Journal of cellular physiologyPTH-independent hypercalcaemia and non-melanoma skin cancer.
2010 Journal of the European Academy of Dermatology and Venereology : JEADVCalcium, calcium-sensing receptor and colon cancer.
2009 Cancer lettersPreparation of magnetic and bioactive calcium zinc iron silicon oxide composite for hyperthermia treatment of bone cancer and repair of bone defects.
2011 Journal of materials science. Materials in medicineCalcium as a mediator of 1,25-dihydroxyvitamin D3-induced apoptosis.
2004 The Journal of steroid biochemistry and molecular biologyCapacitative calcium influx in human epithelial breast cancer and non-tumorigenic cells occurs through Ca2+ entry pathways with different permeabilities to divalent cations.
2003 Journal of cellular biochemistryNeridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
2004 Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchNeridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.
2004 Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral ResearchThe D1822V APC polymorphism interacts with fat, calcium, and fiber intakes in modulating the risk of colorectal cancer in Portuguese persons.
2007 The American journal of clinical nutritionEpidermal growth factor-induced neuroendocrine differentiation and apoptotic resistance of androgen-independent human prostate cancer cells.
2006 Endocrine-related cancerP/Q-type calcium channel antibodies, Lambert-Eaton myasthenic syndrome and survival in small cell lung cancer.
2005 Journal of neuroimmunologyDietary intake of calcium, vitamin D, phosphorus and the risk of prostate cancer.
2005 European urologyAre oral bisphosphonates effective in improving lumbar bone mineral density in breastcancer survivors with osteopenia or osteoporosis?
2005 Journal of obstetrics and gynaecology Canada : JOGC = Journal d’obstétrique et gynécologie du Canada : JOGCCharacterization of calcium-independent purinergic receptor-mediated apoptosis in hormone-refractory prostate cancer.
2008 BJU internationalExpression of the apoptotic calcium channel P2X7 in the glandular epithelium.
2005 Journal of molecular histologyAndrogen receptor protein is down-regulated by basic fibroblast growth factor in prostate cancer cells.
2000 British journal of cancerThe membrane-anchored serine protease, TMPRSS2, activates PAR-2 in prostatecancer cells.
2005 The Biochemical journalChemoprevention of colorectal cancer: systematic review and economic evaluation.
2010 Health technology assessment (Winchester, England)Successful administration of a low dose of calcium nadroparin in patients suffering from pulmonary embolism and brain metastases: a report of two cases.
2009 Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy PractitionersPlasma membrane Ca2+-ATPase expression during colon cancer cell line differentiation.
2007 Biochemical and biophysical research communicationsOxaliplatin: a review of its use in the management of metastatic colorectal cancer.
1999 Drugs & agingPMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer.
2010 Proceedings of the National Academy of Sciences of the United States of AmericaTissue carcinoembryonic antigen, calcium, copper and iron levels in cancerous lung patients.
2011 Zhongguo fei ai za zhi = Chinese journal of lung cancer[Two cases of stage IV breast cancer with severe hypercalcemia].
2006 Gan to kagaku ryoho. cancer & chemotherapyFamilial hypocalciuric hypercalcemia in a woman with metastatic breast cancer: a case report of mistaken identity.
2003 The Journal of clinical endocrinology and metabolismFamilial hypocalciuric hypercalcemia in a woman with metastatic breast cancer: a case report of mistaken identity.
2003 The Journal of clinical endocrinology and metabolismCapecitabine and tegafur + uracil: new preparations. Metastatic colorectal cancer: two oral fluorouracil precursors, few advantages.
2002 Prescrire internationalRole of notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells.
2005 Cancer researchEffect of vitamin E on tamoxifen-treated breast cancer cells.
2006 SurgeryCytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer.
2007 TheScientificWorldJournalZoledronic acid-induced severe hypocalcaemia in a prostate cancer patient with extensive osteoblastic bone metastases.
2005 Tennessee medicine : journal of the Tennessee Medical AssociationBinding of anti-GRP78 autoantibodies to cell surface GRP78 increases tissue factor procoagulant activity via the release of calcium from endoplasmic reticulum stores.
2010 The Journal of biological chemistryMS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.
2008 Cancer researchRegulation of intracellular calcium release and PP1alpha in a mechanism for 4-hydroxytamoxifen-induced cytotoxicity.
2007 Molecular and cellular biochemistryVitamin D and colon carcinogenesis.
2004 The Journal of nutritionscience.naturalnews.com/…/2341709_Calcium_plus_vitamin_D_ supplementation_and_the_risk_of_breast.html
Studies on CAlcium and APOTOSIS:
- An essential role for calcium flux in phagocytes for Apoptotic cell engulfment and the anti-inflammatory response.
2009 Cell death and differentiation - Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. 2002 Circulation
- Dopamine treatment of postischemic contractile dysfunction rapidly induces calcium-dependent pro-apoptotic signaling. 2002 Circulation
- Macrophage suppression following phagocytosis of Apoptotic neutrophils is mediated by the S100A9 calcium-binding protein. 2010 Immunobiology
- Nuclear calcium controls the apoptotic-like cell death induced by d-erythro-sphinganine in tobacco cells.
2010 Cell calcium - Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent Apoptotic signaling.
2006 Blood - Suppression of calcium release from inositol 1,4,5-trisphosphate-sensitive stores mediates the anti-apoptotic function of nuclear factor-kappaB.
2005 The Journal of biological chemistry - Aristolochic acid I-induced apoptosis in LLC-PK1 cells and amelioration of theApoptotic damage by calcium antagonist.
2000 Chinese medical journal - Apoptotic effects of Antrodia cinnamomea fruiting bodies extract are mediated through calcium and calpain-dependent pathways in Hep 3B cells.
2006 Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association - Honeybee venom induces calcium-dependent but caspase-independent Apoptotic cell death in human melanoma A2058 cells.
2008 Toxicon : official journal of the International Society on Toxinology - Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas.
2010 Brain research - The anti-apoptotic effects of nordihydroguaiaretic acid: inhibition of cPLA(2) activation during TNF-induced apoptosis arises from inhibition of calcium signaling.
2005 Life sciences - Calcium-dependent Apoptotic gene expression in cerulein-treated AR42J cells.
2003 Annals of the New York Academy of Sciences - Calcium ionophoretic and Apoptotic effects of ferutinin in the human Jurkat T-cell line.
2004 Biochemical pharmacology - Basic fibroblast growth factor (bFGF) regulation of the plasma membrane calciumATPase (PMCA) as part of an anti-apoptotic mechanism of action.
2003 Biochemical pharmacology - Basic fibroblast growth factor (bFGF) regulation of the plasma membrane calciumATPase (PMCA) as part of an anti-apoptotic mechanism of action.
2003 Biochemical pharmacology - Anti-apoptotic effect of benidipine, a long-lasting vasodilating calcium antagonist, in ischaemic/reperfused myocardial cells.
2001 British journal of pharmacology - Mitochondria, calcium and nitric oxide in the Apoptotic pathway of esophageal carcinoma cells induced by As2O3.
2002 International journal of molecular medicine - Calcium-independent phospholipase A2 localizes in and protects mitochondria duringApoptotic induction by staurosporine.
2006 The Journal of biological chemistry - Expression of the Apoptotic calcium channel P2X7 in the glandular epithelium.
2005 Journal of molecular histology - Fas mRNA expression and calcium influx change in H2O2-induced Apoptotichepatocytes in vitro.
2005 World journal of gastroenterology : WJG - Calcium signaling-induced Smad3 nuclear accumulation induces acetylcholinesterase transcription in Apoptotic HeLa cells.
2009 Cellular and molecular life sciences : CMLS - The release of calcium from the endoplasmic reticulum induced by amyloid-beta and prion peptides activates the mitochondrial Apoptotic pathway.
2008 Neurobiology of disease - Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells.
2006 The Journal of biological chemistry - Nitric oxide and calcium ions in Apoptotic esophageal carcinoma cells induced by arsenite.
2002 World journal of gastroenterology : WJG - Apoptotic effect of ethanol is potentiated by caffeine-induced calcium release in rat astrocytes.
2006 Neuroscience letters - Synchronous progression of calcium transient-dependent beating and sarcomere destruction in Apoptotic adult cardiomyocytes.
2006 American journal of physiology. Heart and circulatory physiology - Calcium ionophores lead to apoptotic-like changes in Tilapia pituitary cells.
1999 General and comparative endocrinology - The effect of calcium on Fas-mediated apoptosis and secondary necrosis of Jurkat cells.
2001 International journal of molecular medicine - MAPK activation and Apoptotic alterations in hearts subjected to calcium paradox are attenuated by taurine.
2006 Cardiovascular research - Increase in cytosolic calcium maintains plasma membrane integrity through the formation of microtubule ring structure in Apoptotic cervical cancer cells induced by trichosanthin.
2009 Cell biology international - 190 EXPRESSION OF Apoptotic GENES IS MEDIATED BY CALCIUM-BINDING PROTEINS, CALBINDINS, IN THE UTERUS OF CALBINDIN-D9k AND CALBINDIN-D28k KNOCKOUT MICE.
2011 Reproduction, fertility, and development - Antimicrobial peptide-induced Apoptotic death of leishmania results from calcium-de pend ent, caspase-independent mitochondrial toxicity.
2009 The Journal of biological chemistry - Bovine lactadherin as a calcium-independent imaging agent of phosphatidylserine expressed on the surface of Apoptotic HeLa cells.
2009 The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society - Epidermal growth factor-induced neuroendocrine differentiation and Apoptoticresistance of androgen-independent human prostate cancer cells.
2006 Endocrine-related cancer - LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and Apoptotic cells.
2006 The Biochemical journal - Tributyltin induces Apoptotic signaling in hepatocytes through pathways involving the endoplasmic reticulum and mitochondria.
2007 Toxicology and applied pharmacology - Mitochondria, calcium and pro-apoptotic proteins as mediators in cell death signaling.
2003 Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica … [et al.] - The effect of inhibiting topoisomerase I and II on the anti-apoptotic response associated with pro-inflammatory crystals of calcium pyrophosphate dihydrate in human neutrophils.
2003 Inflammation research : official journal of the European Histamine Research Society … [et al.] - Caspase-3-induced truncation of type 1 inositol trisphosphate receptor acceleratesApoptotic cell death and induces inositol trisphosphate-independent calcium release during apoptosis.
2004 The Journal of biological chemistry - Stringent time-dependent transregulation of calcium calmodulin kinase II (CaMKII) is implicated in anti-apoptotic control.
2008 Biochimica et biophysica acta - Targeting Bcl-2-IP3 receptor interaction to reverse Bcl-2’s inhibition of Apoptoticcalcium signals.
2008 Molecular cell - Beauvericin induces cytotoxic effects in human acute lymphoblastic leukemia cells through cytochrome c release, caspase 3 activation: the causative role of calcium.
2004 Cancer letters - Apoptotic and antiapoptotic mechanisms in stroke.
2000 Cell and tissue research - The anti-apoptotic protein HAX-1 is a regulator of cardiac function.
2009 Proceedings of the National Academy of Sciences of the United States of America - Transglutaminase 2 inhibits apoptosis induced by calcium- overload through down-regulation of Bax.
2010 Experimental & molecular medicine - Calcium as a mediator of apoptosis in bovine oocytes and preimplantation embryos.
2003 Endocrine
CESIUM
I felt it only fair to mention the protocol of Robert R. Barefoot, the co-author of the excellent book: The Calcium Factor: The Scientific Secret of Health and Youth. The other author of this book is Dr. Carl J. Reich, M.D., who worked with Nobel Prize winner Dr. Otto Warburg before Warburg’s death.
Robert R. Barefoot is a big supporter of using calcium, namely coral calcium, in treating cancer. However, he also said the following in chapter 17 of his book:
„A terminal cancer patient, for example, may be cured over a 6 month period by consuming the proper nutrients, but may only have 3 weeks to live. This situation requires a more potent nutrient treatment such as cesium chloride, for example. Cesium chloride is a natural salt, and where it is found, cancer does not exist. This is because cesium is the most caustic mineral that exists, and when it enters the body, it seeks out all of the acidic cancer hotspots, dousing the fire of cancer, thereby terminating the cancer within days. Also, when dimethyl sulfoxide (DMSO) is rubbed near a painful cancer, the pain is removed and the DMSO causes the cesium to penetrate the cancer tumor much faster, thereby terminating the cancer much faster…”
The Calcium Factor: The Scientific Secret of Health and Youth, page 144
He also stated in his book: „The author has witnessed numerous people with terminal cancers who have employed the above program successfully.”
When it comes to the treatment of advanced cancer, stage IV cancers, rapidly growing cancers which have spread significantly, high mortality types of cancers or cancers that have spread to the bones Cesium Chloride protocol is one of the most proven existing cancer treatments.
This treatment can be used by patients with new cancer diagnosis and by patients fed by feeding tubes or patients fed IntraVenously .
Technical details( http://www.killcancercells.com/?gclid=CI_u4oH0jbkCFQgQ3godEDQAtg) :
WHAT IS CESIUM CHLORIDE
Cesium is a rare, naturally occurring element of alkali metal, similar in chemical structure to lithium, sodium, and potassium. Cesium chloride is a salt form of this element.
Cesium chloride is most commonly associated with High pH Therapy and cancer, due to the work of Keith Brewer, Otto Warburg, and H.E.Sartori, among others. They found that cancer cells thrive in an anaerobic (low oxygen) environment with low pH values, and that raising the cell pH makes it hard for cancer cells to survive. Cesium, being one of the most alkaline elements, has a high pH value and is also readily taken up by cancer cells, thus raising their pH to a level at which they can no longer survive.
See also : http://www.essense-of-life.com/moreinfo/minerals/cesium.htm
WHAT IS HIGH PH THERAPY
The cells of the body can only live within a certain pH range or they will die. When we eat or drink, we affect our body’s pH values. When we take in something acidic, or of low pH (low oxygen) values, the body either has to pull alkaline minerals from within itself to neutralize the acid, or store the acid somewhere in the tissue. If you drink an acidic soda at pH 2.5, it takes 32 glasses of water at pH 10 to neutralize the acid. And, as one’s pH drops, the cells’ oxygen levels also drop, and its ability to function properly and heal itself diminishes drastically. The pH number is an exponent number of 10; therefore, a small difference in pH translates to a big difference in the number of oxygen or OH- ions. A difference of 1 in a pH value means ten times the difference in the number of OH- ions, a difference of 2 means one hundred times the difference in the number of OH- ions. In other words, blood with a pH value of 7.45 contains 64.9% more oxygen than blood with a pH value of 7.30. http://www.stopcancer.com/toc.htm
How CESIUM CLORIDE WORKS
„A normal cell undergoes an adverse change when it can no longer use the oxygen to convert glucose into energy by oxidation .. In the absence of oxygen the cell returns to a primitive nutritional program to sustain itself, converting glucose, by fermentation. lactic acid produced by fermentation lowers the cell pH (acid / alkaline balance) and destroys the ability of DNA and RNA to control cell division [..] cancer cells begin to multiply uncontrollably and lactic acid simultaneously causes intense local pain and destroys cell enzymes .. Therefore, cancer appears as a rapidly growing mass of cells on the outside with a core cell death. ” http://www.cancer-coverup.com/fighters/cesium-science.htm
In the absence of oxygen, glucose is subjected to fermentation and creates lactic acid. This causes the pH to drop in the cell between 7.3 – 7.2 , down to 7 – 6.5, and in more advanced stages of cancer and metastasis sites pH can be lower than 6.0 and even 5.7. http://www.alkalizeforhealth.net/Loxygen3.htm
The pH scale ranges from 0 to 14, with numbers below 7 representing an acidic (low oxygen) condition and above 7 representing an alkaline, or oxygenated, condition. When cesium is taken up by cancer cells, it raises the pH, or oxygen content, of the cell. The cells that die are absorbed and eliminated by the body. Cesium has been used to raise the pH of the body as an alternative or complementary cancer treatment or therapy for breast cancer, lung cancer, prostate cancer, colon cancer, pancreatic cancer, liver cancer, skin cancer, ovarian cancer, stomach cancer, cervical cancer, brain cancer, kidney cancer, testicular cancer, bone cancer, throat cancer, thyroid cancer, gastrointestinal cancer, cancers of the bladder and gallbladder, metastatic melanoma, and cancers in animals including feline, canine, and equine cancer. Keith Brewer, Otto Warburg, and H.E.Sartori all contributed to the concept of high pH therapy. http://www.essense-of-life.com/moreinfo/minerals/cesium.htm
Cancerous tissues are acidic, whereas healthy tissues are alkaline. At a pH slightly above 7.4 cancer cells become dormant and at pH 8.5 cancer cells will die while healthy cells will live. Potassium, rubidium, and especially cesium are most efficiently taken up by cancer cells. Glucose can still enter a cancer cell, but oxygen cannot. The cell thus becomes anaerobic. In the absence of oxygen, the glucose undergoes fermentation to lactic acid. The cell pH then drops to 7 and finally down to 6.5. cesium, rubidium and potassium, all having high pH values, are able to enter cells inthis state and raise their pH. http://www.mwt.net/~drbrewer/highpH.htm
Acidity (nature of cancer cells) , is what cesium chloride treats primarily!
Cesium is a very alkaline mineral (like Rubidium,Potassium and Calcium )!
In particular, with regards to stopping the spread of cancer , cesium chloride is one of the best cancer treatments.
Cesium Chloride Protocol directly targets cancer cells. Normal cells do not ingest cesium chloride.
Cesium has been proven to get into cancer cells, when other nutrients can’t and:
1) makes the cancer cells alkaline (blood is not made alkaline, only inside the cancer cells)
2) limits glucose intake of cancer cells (starving them, thus making them ” sick ” due to lack of food),
3) neutralizes lactic acid (due to uncontrolled multiplication of cells) and, therefore cachexia cycle,
4) stops the fermentation ( side effect on glucose limitation).
The theory behind anti-cancer treatment cesium site is largely the result of Dr. A. Keith Brewer, PhD.
KEITH BREWER
Excerpts from „The High pH Therapy for Cancer Tests on Mice and Humans”
Steps Leading to the Formation of Cancer Cells:
1. Glucose can still enter the cell, but oxygen cannot. The cell thus becomes anaerobic.
2. In the absence of oxygen, the glucose undergoes fermentation to lactic acid. The cell pH then drops to 7 and finally down to 6.5.
3. In the acid medium the DNA loses its positive and negative radical sequence. In addition, the amino acids entering the cell are changed. As a consequence, the RNA is changed and the cell completely loses its control mechanism. Chromosomal aberrations may occur.
4. In the acid medium the various cell enzymes are completely changed into very toxic compounds. These toxins kill the cells in the main body of the tumor mass. A tumor therefore consists of a thin layer of rapidly growing cells surrounding the dead mass. The acid toxins leak out from the tumor mass and poison the host. They thus give rise to the pains generally associated with cancer.
Mass spectrographic and isotope studies have shown that potassium, rubidium, and especially cesium are most efficiently taken up by cancer cells. This uptake was enhanced by Vitamins A and C as well as salts of zinc and selenium. The quantity of cesium taken up was sufficient to raise the cell to the 8 pH range, where cell mitosis ceases and the life of the cell is short.
Tests on mice fed cesium and rubidium showed marked shrinkage in the tumor masses within 2 weeks. In addition, the mice showed none of the side effects of cancer.
In tests on mice, tumors implanted where significantly smaller at the end of the test in mice fed Rubidium than the controls. In addition, the test animals were showing none of the adverse effects of having cancer. Similar experiments with cesium chloride had similar successful results.
Tests have been carried out on over 30 humans. In each case the tumor masses disappeared.
Also, all pains and effects associated with cancer disappeared within 12 to 36 hours.
The more chemotherapy and morphine the patient had taken, the longer the withdrawal period.
Many tests on humans have been carried out by H. Nieper in Hannover, Germany and by H. Sartori in Washington, DC.
It has been observed that all pains associated with cancer disappear within 12 to 24 hours.
In these tests 2 gram doses of Cesium Chloride were administered three times per day after eating. In most cases 5 to 10 grams of Vitamin C and 100,000 units of Vitamin A, along with 50 to 100 mg of zinc, were also administered. Nieper and Sartori were also administering nitrilosides in the form of laetrile. There are good reasons to believe that the laetrile may be more effective than the vitamins in enhancing the pickup of cesium by the cells.
In addition to the loss of pains, the physical results are a rapid shrinkage of the tumor masses.
The material comprising the tumors is secreted as uric acid in the urine; the uric acid content of the urine increases many fold.
About 50% of the patients were pronounced terminal, and were not able to work. Of these, a majority have gone back to work.
Two side effects have been observed in some of the patients.
These are first nausea, and the second diarrhea. Both depend upon the general condition of the digestive tract.
There are a number of areas where the incidences of cancer are very low:
The Hopi Indians of Arizona have a very low incidence of cancer: 1 in 1000 as compared to 1 in 4 for the USA as a whole. Analysis of their diet shows that it meets the requirements for the high pH therapy. Hopi food is very high in potassium and exceptionally high in rubidium. Since the soil is volcanic it must also be very rich in cesium.
Some 20 years ago the incidence of cancer among the Pueblo Indians was the same as that for the Hopi Indians, but they have adopted a modern American diet and now have the same cancer rate as the rest of the US. Supermarket foods is essentially lacking rubidium and cesium and low in potassium.
The same, Hunza of North Pakistan and their diet also meets the requirements of the High pH therapy. They are essentially vegetarians, and are great fruit eaters, eating ordinarily 40 apricots per day; they always eat the kernels(laetrile), either directly or as a meal. They drink at least 4 liters of mineral spring waters which abound in the area and has been found to be very rich in cesium. Since the soil is volcanic in nature, it must be concluded that it will be rich in Cesium and Rubidium, as well as Potassium.
The Indians of Central America and on the highland of Peru and Equador also have very low incidences of cancer. The soil in these areas is volcanic with fruit in the area very high in rubidium and cesium.
Cases have been reliably reported where people with advance inoperable cancer have gone to live with these Indians, and found that all tumor masses disappear within a very few months. Clearly the food there meets the high pH requirements.
At the 1978 Stockholm Conference on Food and Cancer it was concluded that there is definitely a connection between no cancer and high PH theraphy(food+ alkaline minerals:calcium Cesium , Rubidium,Potassium.
Cesium and Rubidium salts, when present in the adjacent fluids, the pH of cancer cells will rise to the point where the life of the cell is short, and that they will also neutralize the acid toxins formed in the tumor mass and render them nontoxic.
Studies of the food intake in areas where the incidences of cancer are very low showed that it met the requirements for the high pH therapy.
Cesium, rubidium and potassium cations (positively charged ions) are all strong electron receptors which can be attracted into the membrane because of the negative potential gradient which exists across all living membranes.
The ready uptake of cesium and rubidium by the cancer cells lead the writer to the High pH therapy. This consists of feeding the patient close to 6 g of Cesium Chloride or Rubidium Chloride per day . It is sufficient however to give rise to the pH in the cancer cells, bringing them up in a few days to the 8 or above where the life of the cell is short. In addition, the presence of Cesium and Rubidium salts in the body fluids neutralizes the acid toxins leaking out of the tumor mass and renders them nontoxic.
In later writing, Dr. Brewer wrote: „The goal of the high pH therapy is the transport of large quantities of Cs+ Rb+ and glucose-free K+ across the membranes of cancer cells. During high pH therapy, Dr. H. Nieper, M.D., observed a loss of potassium which should be replaced.” Two booklets discussing Dr. Brewer’s final theories about cesium are available from the Brewer Science Library: „High pH Cancer Therapy with Cesium,” and „Cancer Its Nature and a Proposed Treatment,” both by A. Keith Brewer, Ph.D. http://www.mwt.net/~drbrewer/highpH.htm
POTASSIUM, RUBIDIUM, GERMANIUM
Mass spectrographic and isotope studies have shown that potassium, rubidium, and especially cesium are most efficiently taken up by cancer cells.
Rubidium is an alkaline trace mineral related with cesium and potassium chemically. In cancer cells, only water, sugar, potassium, cesium and rubidium are able to enter the cells, therefore rubidium is one on the minerals used in high pH therapy. In studies with mice, rubidium has helped decrease tumor growth. http://www.essense-of-life.com/moreinfo/minerals/rubidium.htm
Germanium improves oxygen flow to tissues, boosting circulation, which improves stamina and endurance. It also has antioxidant properties. www.essense-of-life.com/moreinfo/minerals/germanium.htm
Potassium is necessary for the transmission of nerve impulses that provide smooth coordinated muscle movement. Potassium also helps widen the blood vessels during exercise, thereby increasing blood flow to help carry away heat, and it is used to convert blood glucose to glycogen. http://www.essense-of-life.com/moreinfo/minerals/potassium.htm
Potassium, rubidium, and especially cesium are most efficiently taken up by cancer cells. Glucose can still enter the cell, but oxygen cannot. The cell thus becomes anaerobic. In the absence of oxygen, the glucose undergoes fermentation to lactic acid. The cell pH then drops to 7 and finally down to 6.5. cesium, rubidium and potassium, all having high pH values, are able to enter cells inthis state and raise their pH.
Information Sources:
http://www.mwt.net/~drbrewer/highpH.htm
Elements below potassium in the Electromotive Series, like calcium, are only taken up sparingly, if at all, by cancer cells.
Therefore potassium, which transports glucose, can readily enter cancer cells, but Calcium, which transports oxygen, cannot.
Dr. Brewer used the powder of ionic cesium, not a liquid form , thus has not been as effective as compared with liquid ionic cesium chloride.
The key difference is how big the group of cesium atoms are. If a group is too large (often met with powdered versions), cesium does not penetrate inside the cancer cells. Cesium simply does not work unless it enters within cancer cells.
Liquid ionic cesium chloride makes cancer cells highly alkaline (pH> 8.0) so that the immune system attacks them and kills them (thinking they are sick).
Tehnically, cesium chloride does not directly kill cancer but allows immune system to destroy cancer cells.
Yet probably, cesium chloride recovers normal cells from cancer cells(as cancer microbes cannot survive in higly alkaline environment and once they die due to alkalinity, nothing prevents a cell from creating normal ATP energy) . This is the ideal way to cure cancer because of low toxicity to the body
Cesium chloride not only kills cancer cells , it immediately stops the metastasis of cancer, can start shrinking tumor masses within weeks , and almost always stops the pain within 24 to 48 hours, depending of the pain.
„Many human trials have been carried out by [late] Dr. H. Nieper in Hannover, Germany, … as well as a number of other physicians Overall, the results were satisfactory Oart f .. He noted that all pains associated with cancer disappear between 12 and 24 hours, except in very few cases where there were problems of morphine waiver, which requires a few more hours. „
Many celebrities and executives in America went to Germany to be treated by Dr. Nieper, including a U.S. president. Dr. Nieper died in 1998.
http://www.cancer-coverup.com/brewer/printbrewerreport.htm
Cesium treatment achieved a cure rate of 50% in patients with very advanced cancer, some already in a coma. 47 of the 50 patients were „hopeless” and some had only days to live .Doctors have given very high doses of cesium . http://www.newswithviews.com/Howenstine/james14.htm
H.E. SARTORI – HUMAN STUDIES
Excepts from „Cesium Therapy in Cancer Patients”
Treatment was performed on 50 patients during the last three years at Life Sciences Universal Medical Clinics in Rockville MD and in Washington D.C. All patients were terminal subjects with generalized metastatic disease. 47 of the 50 patients studies had received maximal modalities of treatment, i.e., surgery, radiation, and various chemotherapy, before metabolic Cesium-treatment was initiated. Three patients were comatose and 14 of the patients were considered terminal due to previous treatments outcome and cancer complications.
The Cesium-treatment was given in conjunction of other supportive compounds under diet control in addition to the utilization of specific compounds to produce adequate circulation and oxygenation. According to individual cases Cesium Chloride was given at daily dosages of 6 to 9 grams in 3 equally divided doses, with vitamin A-emulsion (100,000 to 300,000 U), vitamin C (4 to 30 grams), zinc (80 to 100 mg) selenium (600 to 1,200 mcg) and amygdalin (1,500 mg) in addition to other supplementations according to the specific needs of the patient. The diet consisted mainly of whole grains, vegetables, linolenic acid rich oils (linseed, walnut, soy, wheat germ) and other supplemental food. To increase efficiency of the treatment and improve the circulation and oxygenation, the patients received the chelating agent EDTA, dimethylsulfoxide (DMSO) and also a combination of vitamin K and Mg salts.
The 50 cancer patients studied over 3 years had generalized metastatic disease, except for 3 patients. Initial death occurrences for the initial 2 week treatment was in the same order and magnitude of these recorded for the 12 month period. The percent of survival of breast, colon, prostate, pancreas, and lung cancer accounted to approximately, 50% recovery which was higher than that noted for liver cancer and the lymphoma patients treated. An overall 50% recovery from cancer by the Cesium-therapy was determined in the 50 patients treated. Data from the autopsy made indicated the absence of tumors in patient dying within 14 days of the Cesium-treatment. One of the most striking effects of the treatment was the disappearance of pain in all patients within 1 to 3 days after initiation of the Cesium-therapy.
These studies were performed under my direction, initiated in April, 1981.
Twenty-eight patients were initially treated with Cesium Chloride between April, 1981 to October, 1982. They were subjected to various cancer therapies, e.g., surgery, radiation, and chemotherapy, and were considered terminal cases with metastatic disease except for 3 patients who were not previously treated. Three patients were comatose at the time of the Cesium treatment. Thirteen patients died within less than 2 weeks of treatment. Each patient showed a reduction in tumor mass by the Cesium-treatment. Of the breast cancer patients, the most impressive effect was seen on a female patient who was comatose at the beginning of the Cesium-treatment and was considered a terminal case. The Cesium-therapy, with other ingredients used, was immediately instituted by nasogastric route because there was no cooperation from the patient. The daily Cesium Chloride dose given amounted to 30 grams, 10 grams given 3 times daily. The patient was able to leave after 5 days of treatment. However the patient’s fall on the floor resulted in complications, i.e., fracture of the neck, and death. The autopsy revealed that the cancer metastasis had essentially eaten away her hip bone causing this tragic accident. The autopsy performed also showed the presence of very little cancer tissue.
The next most frequent cancer treated was of unknown primary.
Treatment of 8 cases showed a death rate of 2 within 14 days of treatment and an additional 2 deaths within 12 months while 4 of the patients are still living. In one case, an autopsy was made in a patient after one week of Cesium-treatment and showed a complete disappearance of the cancer. There were 7 cases of colon cancer patients who were treated with Cesium Chloride. Two of these patients died within 14 days, one of the patients had previous massive chemotherapy, and little time was available to restore her metabolic condition. The previous existing infiltration of the abdominal wall disappeared. However, no consent was given for an autopsy.
In one lymphoma case the patient displayed an unusually large abdomen which was hard and he weighed approximately 250 pounds. The massively enlarged abdomen began to decline in volume, i.e., a loss of approximately 120 pounds of body weight was noted after 3 months of the Cesium- therapy. The spleen which was originally maximally enlarged and reaching into the pelvis was reduced to almost normal size. The liver position was down to about the level of the umbilicus and was also reduced to normal size in 3 months. The patient is still living after 3 years after his discharge. Unfortunately, there is no follow-up on this patient and he is being maintained on chemotherapy.
The results presented demonstrate the rate of efficacy of Cesium Chloride in cancer therapy.
The total 50 TERMINAL cancer cases studied show an impressive 50% survival rate. This confirms the work of Messiha reported in these proceedings showing that the higher the dose it is, the more effective it seems to be. The autopsy obtained from the patient whose death was attributed to traumatic fracture of the neck, indicated that cancer had been initially further advanced resulting in bone destruction. However, the absence of cancer after the massive Cesium Chloride dose used in this case is demonstrable of the Cesium-therapy. It appears that both dosage, i.e., as much as 30 grams/day and route of drug administration, i.e., nasogastric pathway, might have contributed to the patients rapid recovery. It should be noted, however, that Cesium Chloride dose regimens should no exceed 20 to 40 grams due to side effects, mainly nausea, and diarrhea. The authors personal experience with Cesium Chloride after an acute dose of 40 prams Cesium Chloride indicate that extensive nausea and parethesia around the mouth are the major side effects. This is probably due to K depletion. The usual dose used in the clinic ranges from 2 to 3 grams given by mouth 3 times daily. At a later time, at which time there is no indication of cancer presence, the Cesium Chloride dosage will be reduced to a preventative dose between .5 and 1 gram a day.
The lymphoma case presented shows that Cesium Chloride efficiently reduced massive enlargements of spleen and liver as well as maximal ascites, causing an abdominal configuration of a tight, hard hemisphere, to almost normalize after 3 months of therapy. This period of time was required to eliminate such a massive volume resulting in the reduction of the body weight noted.
The clinical efficacy of Cesium Chloride high pH metabolic therapy is best demonstrated by a recent case of primary liver cancer (not included in the 50 cases reported in this study). The patient was a 39 year old female teacher who was terminal. She was brought on a stretcher on April 25, 1984 with a large liver tumor extending approximately 3 cm below the umbilical level. The treatment was then immediately instituted. This consisted of administration of Cesium Chloride, Beta-carotene, Vitamin C, Zn, Se, Mn, Cr, and K salts by the oral route in addition to a concomitant massive IV doses of ascorbate, K, Mg, Zn, Cn, Mn, Cr salts, B complex vitamins, folic acid, DMSO and heparin. After 5 consecutive treatment regimens EDTA was introduced to the therapy and the minerals present in the solution were discontinued. On May 10, 1984, the patient was discharged, returned home walking without assistance and displaying a smile on her face. The liver tumor had shrunk to 5 cm above the umbilicus. The determination of alphafetoprotein (AFP), a specific marker for liver cancer, rare embronal cancer and teratomas, decreased from the unusually high value of 39,000 units, compared to normal levels of 13 units, measured before initiation of Cesium-therapy, to 5000 units obtained on the last day of treatment.
The mechanism of action of Cesium in cancer has been little studied. That both Cs+ and Rb+ can specifically enter the cancer cells and embryonic cells but not normal adult cells has been demonstrated by Brewer. The cancer cells contain high amounts of hydrogen ions rendering them acidic and they also contain high Na+ levels than found in normal cells. If Cs+ or Rb+ can enter the cancer cells then the pH increases from as low as 5.5 to over pH 7.0. At a pH of 7.6 the cancer cell division will stop, at a pH of 8.0 to 8.5 the lifespan of it is considerably shortened (only hours). In one case, the author has observed the shrinkage of metastases of breast cancer after one hour of Cesium-treatment. Two days later wrinkles of the skin appeared where the tumor was present. In another case of a colon cancer with massive metastasis, of massive infiltration of the abdominal wall, liver and other tissues, seemed to have been reduced within 24 hours and continuing rapidly until the demise of the patient on the 14th day of the Cesium-treatment.
The uric acid levels measured at the onset of treatment was approximately 3.5 units which was increased to over 20 units, suggesting massive breakdowns of DNA, which produces the uric acid output. Therefore, destruction of nuclear acids, as reflected by a significant rise in the uric acid, may be used as a predictive measurement for treatment outcome. The failure of uric acid elevation may be indicative of lack of destruction of cancer cells. This has proven to be a very consistent finding in our clinic. http://www.advancedhealthplan.com/2cesiumchlorideforcancer2.html
MORE about CESIUM as well as a POWERFUL(STAGE IV) cancer treatment in my book.
ORGANIC GERMANIUM
There is an ample bibliography about organic Germanium: 107, 110, 119, 139, 174, 193, 237, 249, 269, 336, 357, 386, 399, 440, 441, 460, 476). for studies cited see last page of database.
SEE also: Mainwaring MG: Complete remission of pulmonary spindle cell carcinoma after treatment with oral germanium sesquioxide, Chest, 117, pp. 591-593, 2000; Chest, 117, pp. 307-308, 2000
Organic and inorganic forms of Germanium
For any therapy, only very pure organic Germanium should be used. The heavy metals (Pb, As, Hg, Cd) should be almost absent, and if they are present should only be in well defined and negligible quantities (<0,1ppm); moreover there must be no traces of Germanium oxide (GeO2).
Inorganic Germanium is toxic for the kidney cells.In its inorganic from Germanium is present in the soil, rocks and coal, together with other minerals from which it can be extracted and transformed industrially into organic Germanium.
Natural organic Germanium
Organic Germanium is found naturally in Allium sativum, Allium cepa, Panax ginseng, Pfaffia paniculataOrganic Germanium is found naturally in some oriental mushrooms: Ganoderma lucidum, Grifola frondosa but this are dangerous
The immune stimulating properties of organic Germanium
The most important property manifests itself in the stimulation of the immune system.
Especially with regard to the Natural killers, the increase in cytolytic ability already begins from the second day, reaching its peak on the fourth day, finally exhausting itself a week from the last administration; an increase of 30% can be seen in the cytolysis, compared to control groups treated with a placebo.
Studies on the anti-cancer effect of Germanium have also shown the role it plays in activating the T lymphocytes, the macrophages, the lymphokines and Gamma interferon: Germanium stimulates the T lymphocytes to produce lymphokine, MIF (Migration Inhibition Factor), MAF (Macrophage Activation Factor), chemotactic factors, CSF (Colony Stimulating
Factors) and lymphotoxins.
The subsequent Immune Cascade also establishes an activation of the macrophages which take part in the lysis of the cancer cells in an effective ratio of 1:1, like cytotoxic T lymphocytes, Natural killers and Killers. On the other hand,NO activation of the
granulocytes has been shown, but the more difficult capacity for anti-cancer activation is known, which requires a strength ratio of 40:1 between the granulocytes and the cancer cells.
Anti-oxidant property of organic Germanium
The specific action of Germanium 132 is on a biochemical level, since it renders oxygen available for the cells, with the important implications therefore for cancer. Among these are a large number of degenerative pathologies, pathologies of the metabolism or caused by some deficiency. In particular, its biochemical characteristic is that it acts as a semiconductor in the transport processes of the electrons inside the cells, thus allowing the formation of ATP with the final production of non toxic molecular substances (water). Its anti-oxidant actionagainst cysteine is also important.
Cell respiration refers to the catabolic processes by means of which the nutritive substances, glucose for example, are broken up inside the cells, releasing energy which is then used to form Adenosine-Tri-Phosphate (ATP, cell energy).
With organic Germanium an exothermic reaction takes place, which supplies oxygen and hydrogen to the individual cells of the organism. The stable and continuous flow of oxygen and hydrogen to all parts of the organism facilitates and strengthens oxidation and reduction inside the cells: oxidation takes place either with the acquisition of oxygen or with the loss of hydrogen.
Any reaction which creates energy inside a cell is an oxidant reaction.
Oxidation can happen in two ways:
1) the combination of oxygen with other elements
2) the removal of hydrogen atoms from the compounds.
Basically, oxidation of nutritive substances is the gradual removal of pairs of hydrogen atoms from the support molecules, because when the pairs of hydrogen atoms are removed, they take with them their electron pairs. In this way oxidation of glucose in Krebs’ cycle occurs with the gradual removal of hydrogen atoms.
Where a substance loses electrons, becoming oxidated and losing energy, there is another substance which acquires them, thus becoming reduced, that is to say, acquiring energy.
The hydrogen atoms which are removed are sent to the electron transport chain, which converts the energy taken from the oxygen, to transport the electrons along the whole length of the chain.
In the end the hydrogen atoms which are removed combine with the molecular oxygen (creating water), and the resulting energy is freed as ATP, and thus available for the cells.
The immune cells, such as the very delicate lymphocytes, thus acquire an energy capacity which enables them to do their work even in a hypoxic environment such as cancer tissue, famously characterized by High Interstitial Fluid Pressure (H.-I.F.P. see: see: Jain R.K.: Barrier to Drug Deliver y in Solid Tumors, Scientific American, Science, July,1994). Vice versa the cancer cells, which have become oxidated both because of the removal of hydrogen and also by the endocell molecular reaction with oxygen, both induced by the presence of organic Germanium, as a result are more exposed to the phenomena of apoptosis and pseudo-apoptosis, being poor in enzymatic complexes which would perform an endo-nuclear repair of their own DNA, which on the contrary are characteristic of normal cells which have not been degenerated by cancer.
Anti-ischemic properties of organic Germanium
It acts as an electro-nutrient in hypoxic states, which are frequent in chronic degenerative pathologies, such as cardio-vascular or neuro-vascular pathologies or those of the metabolism in general.
Organic Germanium stimulates the ability to increase the availability of oxygen for the cells and helps eliminate unpaired electrons. This makes it particularly invaluable in cases of acute ischemia (miocardic infarct, strokes and asphyxiation by carbon monoxide).
Modifications of the biochemical and functional parameters of the organism induced by organic Germanium
The catalytic effects on the use of oxygen are seen in the renormalization of the biochemical and functional parameters of the organism in a time-frame of between 4 to 6 weeks:
1) Regularization of the partial pressure of carbon dioxide in the blood.
2) Regularization of the values of hematic glucose, above all in diabetic patients.
3) Reduction of the triglycerides.
4) Regularization of total cholesterol with an increase in the ratio of HDL/LDL.
5) Normalization of bilirubin.
6) Normalization of uric acid.
7) Regularization Na / K, Ca / Mg.
8) Increase in haemoglobin.
9) Lymphocite rebalance in chronic infectious diseases. (HIV/AIDS).
10) Protection from oxidative damage induced on the DNA by ionizing radiation.
Anti-amyloidosis property of organic Germanium
Amyloidosis is often induced by Chemo-Therapy or radio-therapy.
Germanium protects against the accumulation of amyloid substances, a process which is generated by a protein imbalance in the catabolism and often associated with chronic inflammatory conditions.
Analgesic property of organic Germanium
Organic Germanium has analgesic effects, acting as a neuro-modulator. This happens through the inhibition of enzymes (peptidase such as Aminopeptidase, Carboxypeptidase, dipeptidil- Aminopeptidase and dipeptidil-Carboxypeptidase [also known as Enkefalinase B and D]) which downgrade the endorphins.
Since it is difficult to find natural organic Germanium, and it is very expensive, the following proposal could be useful: to use inorganic Germanium (which is much less expensive than organic Germanium) in the cultivation of plants with a great capacity for trace-mineral uptake. The cultivation of Equisetum arvense, Medicago sativa, Rosmarinus officinalis and Aloe arborescens could be particularly useful.
IODINE
(NaturalNews) If you or a woman close to you were advised to have a double mastectomy performed in order to prevent breast cancer, shouldn’t another option be available? Medical mutilations have been performed lately on women told they are genetically predisposed to getting breast cancer.
That other option could be a good diet with supplemental iodine. Exactly why iodine offers the other option for preventing breast cancer regardless of genetics is referenced later in this article.
Dr. David Brownstein could be called Dr. Iodine for all he’s done to inform others of the importance of iodine through interviews and his book Iodine: Why You Need It; Why You Can’t Live Without It.
Dr. Mark Sircus, who occasionally contributes articles to Natural News, constantly promotes bicarbonate of soda, magnesium, and iodine as more important and effective for health than most realize.
Now, Dr. Jeffrey Dach has grabbed the iodine talking stick, producing several international clinical, lab, and case study reports that demonstrate the efficacy of iodine ingestion for breast cancer.
Dr. Dach on iodine
Salt used to be iodized with elemental iodine to prevent goiter, but no more. So what little protection that offered has vanished. Dr. Dach notes that iodized salt is not sufficient for supplementing iodine.
Iodine’s RDA (Recommended Dietary Allowance) is 150 mcg (micrograms) per day. Dr. Guy Abraham, who initially mentored Dr. Brownstien, insists we should be taking in 12.5 mg (milligrams) of elemental iodine daily. This is 100 times greater than our RDA.
It’s also the estimated iodine per individual intake from seaweed and seafood among Japan’s population. Japan has the lowest rates of thyroid, prostate, and breast cancer. Some might argue that the Japanese get their iodine from food, but iodine supplements are unsafe.
Well, the FDA recommends 165 mg of iodine to prevent thyroid cancer in the event of a radiation emergency, and iodine has been used medicinally with even higher doses in the past.
Speaking of thyroid cancer, there has been an upsurge of thyroid nodules, leading to complete removal of thyroid glands to determine whether the nodules are cancerous.
Some biopsy! Even if no cancer is detected, the person is sentenced to a lifetime of synthetic prescription thyroid hormones. Iodine can prevent that unhealthy scenario.
In addition to preventing some cancers, there are several studies and actual case histories demonstrating iodine’s ability to cure breast cancer.
Lab studies and breast cancer case histories
Here’s that option for stemming genetically predisposed breast cancer. Iodine has been determined to actually alter breast cancer associated gene expressions. It turns off cancer promoting genes and turns on genes that promote cancer cell apoptosis or cellular destruction. (http://www.medsci.org/v05p0189)
Another study proves that large iodine intake does not adversely affect thyroid hormone production or quality. The researchers did this to allay concerns in the medical profession about potential downsides for using iodine against breast cancer. Downsides don’t prevent using chemo and radiation though.
Dr. Dach lists many international in vivo studies using rats, epidemiological human surveys, and in vitro (petri dish) lab studies demonstrating the efficacy and safety of ingesting elemental iodine for cancerous tumors. All of these studies, with a few actual case histories, are available in Dr. Jeffrey Dach’s articles sourced below:
http://jeffreydach.com/2007/05/05/jeffreydachdrdachiodine.aspx
Dr. Guy Abraham developed a product called Idoral. And Dr. Edward Group, DC, ND, lists four types of iodine supplements that vary in bio-availability: Nascent iodine, Lugol’s solution, potassium iodide, and transformative nano-colloidal detoxified iodine.
The cancer industry’s willful denial of iodine for breast cancer is not because it’s ineffective and dangerous. It’s because supplemental iodine can’t be patented.
- Relevance of Iodine intake as a reputed predisposing factor for thyroid cancer.
2007 Arquivos brasileiros de endocrinologia e metabologia - Influence of Iodine deficiency and Iodine prophylaxis on thyroid cancer histotypes and incidence in endemic goiter area.
2003 Journal of endocrinological investigation - Comparison of Iodine contents in gastric cancer and surrounding normal tissues.
2005 Clinical chemistry and laboratory medicine : CCLM / FESCC - Iodine induces apoptosis via regulating MAPKs-related p53, p21, and Bcl-xL in thyroidcancer cells.
2010 Molecular and cellular endocrinology - Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine.
2008 International journal of medical sciences - [Three-year follow-up results of visual inspection with acetic acid/Lugol’s Iodine(VIA/VILI) used as an alternative screening method for cervical cancer in rural areas].
2010 Chinese journal of cancer - Iodine prophylaxis–the protective factor against stomach cancer in Iodine deficient areas.
2007 European journal of nutrition - Transcutaneous Iodine absorption in adult patients with thyroid cancer disinfected with povidone-iodine at operation.
2005 Thyroid : official journal of the American Thyroid Association - Incidence of thyroid cancer in the selected areas of Iodine deficiency in Poland.
2003 Journal of endocrinological investigation - The thyroid, Iodine and breast cancer.
2003 Breast cancer research : BCR - [Geographic differences in Iodine supply in the Silesia terrain in relation to thyroidcancer risk].
2001 Wiadomosci lekarskie (Warsaw, Poland : 1960) - Iodine and cancer.
2001 Thyroid : official journal of the American Thyroid Association - Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model.
2008 Endocrine pathology - Urinary Iodine and Goiter Prevalence in Belarus: Experience of the Belarus-American Cohort Study of Thyroid cancer and Other Thyroid Diseases Following the Chornobyl Nuclear Accident.
2011 Thyroid : official journal of the American Thyroid Association - Second primary malignancy risk after radioactive Iodine treatment for thyroid cancer: a systematic review and meta-analysis.
2009 Thyroid : official journal of the American Thyroid Association - Amifostine for salivary glands in high-dose radioactive Iodine treated differentiated thyroid cancer.
2009 Cochrane database of systematic reviews (Online) - Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid cancer Study.
2001 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Hypothesis: iodine, selenium and the development of breast cancer.
2000 Cancer causes & control : CCC - Association of high Iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.
2009 The Journal of clinical endocrinology and metabolism - Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive Iodine remnant ablation for well-differentiated thyroid cancer.
2004 The Journal of clinical endocrinology and metabolism - [A comparative study of endoscopic image stained by Iodine and histopathology in early esophageal cancer and precancerous lesions (dysplasia)].
2004 Zhonghua zhong liu za zhi [Chinese journal of oncology] - [Comparative epidemiological study on thyroid cancer in areas with different Iodineintakes].
2001 Zhonghua yi xue za zhi - A prospective study of Iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey.
2007 Nutrition and cancer - Blood and urine Iodine levels in patients with gastric cancer.
2006 Biological trace element research - The role of Iodine and delta-iodolactone in growth and apoptosis of malignant thyroid epithelial cells and breast cancer cells.
2010 Hormones (Athens, Greece) - Early esophageal cancer can be detected by screening endoscopy assisted with narrow-band imaging (NBI).
2009 Hepato-gastroenterology - Long-term comparative cancer mortality after use of radio-iodine in the treatment of hyperthyroidism, a fully reported multicenter study.2001 Journal of insurance medicine (New York, N.Y.)
- FISH analysis of 1cen-1q12 breakage, chromosome 1 numerical abnormalities and centromeric content of micronuclei in buccal cells from thyroid cancer and hyperthyroidism patients treated with radioactive iodine.
1999 Mutagenesis - Evaluation of 18fluoro-2-deoxyglucose positron emission tomography in Iodine scan negative, differentiated thyroid cancer recurrence.
2009 The Journal of laryngology and otology - [(90)Yttrium-DOTA]-TOC response is associated with survival benefit in iodine-refractory thyroid cancer: long-term results of a phase 2 clinical trial.
2009 Cancer - Dietary Iodine restriction in preparation for radioactive Iodine treatment or scanning in well-differentiated thyroid cancer: a systematic review.
2010 Thyroid : official journal of the American Thyroid Association - Quantitative analysis of the color change after Iodine staining for diagnosing esophageal high-grade intraepithelial neoplasia and invasive cancer.
2009 Gastrointestinal endoscopy - Iodine mediated mechanisms and thyroid carcinoma.
2009 Critical reviews in clinical laboratory sciences - Differentiated thyroid cancer and outcome in Iodine deficiency.
2004 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - Iodine excretion in regions of Ukraine affected by the Chornobyl Accident: experience of the Ukrainian-American cohort study of thyroid cancer and other thyroid diseases.
2005 Thyroid : official journal of the American Thyroid Association - Normal gallbladder visualization during post-ablative iodine-131 scan of thyroid cancer.
2005 Journal of Korean medical science - Usefulness of magnifying endoscopy for iodine-unstained lesions in a high-risk esophageal cancer population.
2010 World journal of gastroenterology : WJG - The impact of thyroid cancer and post-surgical radioactive Iodine treatment on the lives of thyroid cancer survivors: a qualitative study.
2009 PloS one - [Correlation between endemic Iodine deficiency and radiation-induced thyroid cancerin children and adolescents].
2002 Voprosy onkologii - Cytogenetic damage after 131-iodine treatment for hyperthyroidism and thyroid cancer. A study using the micronucleus test.
1999 European journal of nuclear medicine - Endoscopic screening for early esophageal cancer by Iodine staining in patients with other current or prior primary cancers.
2001 Gastrointestinal endoscopy - Increasing the effectiveness of radioactive Iodine therapy in the treatment of thyroidcancer using Trichostatin A, a histone deacetylase inhibitor.
2002 Surgery - Thyroid cancer after diagnostic administration of iodine-131 in childhood.
2001 Radiation research - Thyroid cancer: patients’ experiences of receiving iodine-131 therapy.
2000 Oncology nursing forum - Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer.
2010 European journal of nuclear medicine and molecular imaging - The seven-year preliminary results of brachytherapy with Iodine-125 seeds for localized prostate cancer treated at a Brazilian single-center.
2007 International braz j urol : official journal of the Brazilian Society of Urology - Radio-iodine therapy in differentiated thyroid cancer: indications and procedures.
2008 Best practice & research. Clinical endocrinology & metabolism - Use of Lugol’s Iodine in oral cancer diagnosis: an overview.
2010 Oral oncology - The sodium-iodine symporter and the proton-pump inhibitors in – related to the side effects of- the treatment of thyroid cancer with iodine-131.
2007 Hellenic journal of nuclear medicine - [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroidcancer (version 2)].
2003 Nuklearmedizin. Nuclear medicine - The use of ionized Iodine for cancer prevention and eradication.
2002 Medical hypotheses - Iodine 131 ((131)I) as adjuvant therapy of differentiated thyroid cancer.
2004 Surgical oncology clinics of North America - A risk-adapted approach to the use of radioactive Iodine and external beam radiation in the treatment of well-differentiated thyroid cancer.
2011 Cancer control : journal of the Moffitt cancer Center - Treatment with drugs able to reduce Iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid.
2006 The Journal of clinical endocrinology and metabolism - Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.
2005 Journal of clinical oncology : official journal of the American Society of Clinical Oncology - [Evaluation on the visual inspection with Lugol’s Iodine in cervical cancer screening program].
2006 Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi - Inhibition of N-methyl-N-nitrosourea-induced mammary carcinogenesis by molecularIodine (I2) but not by iodide (I-) treatment Evidence that I2 prevents cancerpromotion.
2005 Molecular and cellular endocrinology - The incidence of hyperthyroidism in patients with thyroid cancer in an area of Iodinedeficiency.
2006 Journal of surgical oncology - The role of positron emission tomography scanning in patients with radioactiveIodine scan-negative, recurrent differentiated thyroid cancer.
2007 The American surgeon - Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer.
2007 European radiology - Urinary Iodine in patients with differentiated thyroid cancer (DTC) during L-thyroxine treatment.
2010 Endokrynologia Polska - Intraoperative radiofrequency ablation combined with 125 Iodine seed implantation for unresectable pancreatic cancer.
2010 World journal of gastroenterology : WJG - [Determination of urinary Iodine concentration by inductively coupled plasma-mass spectrometry in thyroid cancer patients on low-iodine diet].
2010 The Korean journal of laboratory medicine - Lack of association between urinary Iodine excretion and successful thyroid ablation in thyroid cancer patients.
2010 The Journal of clinical endocrinology and metabolism - Use of methotrexate to treat isolated Graves ophthalmopathy developing years after thyroidectomy and Iodine 131 treatment of papillary thyroid cancer.
2008 Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - [Study on the Iodine 125 uptake of H460 lung cancer cell line by co-transfection with the human sodium/iodide symporter and the human thyroperoxidase].
2010 Zhongguo fei ai za zhi = Chinese journal of lung cancer - Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
2009 European journal of radiology - [Thyroid cancer after Chernobyl: is Iodine 131 the only culprit ? Impact on clinical practice].
2008 Bulletin du cancer - How Can We Meet the Information Needs of Patients with Early Stage Papillary Thyroidcancer Considering Radioactive Iodine Remnant Ablation?
2010 Clinical endocrinology - Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent Iodineimplants.
2010 BJU international - Autonomously functioning thyroid nodule treated with radioactive Iodine and later diagnosed as papillary thyroid cancer.
2008 Hormones (Athens, Greece) - A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplastic effect of Iodine in mammary cancer.
2009 Prostaglandins & other lipid mediators - Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer.
2001 Clinical nuclear medicine - Effect of povidone-iodine on anastomotic tumor growth in an experimental model of colorectal cancer surgery.
1999 Anticancer research - Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study.
1999 Surgery today - [Non-iodine-absorbing metastasis of differentiated thyroid cancer–therapeutic probe with 13-cis retinoic acid].
2001 Wiadomosci lekarskie (Warsaw, Poland : 1960) - [Permanent Iodine 125 implant brachytherapy in localized prostate cancer: results of the first 4 years of experience].
2004 Progrès en urologie : journal de l’Association française d’urologie et de la Société française d’urologie - Value of technetium scintigraphy and Iodine uptake measurement during follow-up of differentiated thyroid cancer.
2004 Annals of nuclear medicine - Phase I radioimmunotherapy trial with iodine-131–labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer.
2002 Clinical colorectal cancer - Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
1999 Journal of clinical oncology : official journal of the American Society of Clinical Oncology - Efficacy of high therapeutic doses of iodine-131 in patients with differentiated thyroidcancer and detectable serum thyroglobulin.
2001 European journal of nuclear medicine - Equal induction and persistence of chromosome aberrations involving chromosomes 1, 4 and 10 in thyroid cancer patients treated with radioactive iodine.
2000 Mutation research - Sequential treatment of superior vena cava syndrome caused by of non-small cell carcinoma lung cancer (NSCLC) with vascular stenting and iodine-125 implantation.
2009 Technology in cancer research & treatment - An updated systematic review and commentary examining the effectiveness of radioactive Iodine remnant ablation in well-differentiated thyroid cancer.
2008 Endocrinology and metabolism clinics of North America - Clinical efficacy of CT-guided iodine-125 seed implantation therapy in patients with advanced pancreatic cancer.
2010 European radiology - The effectiveness of radioactive Iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
2010 Thyroid : official journal of the American Thyroid Association - Empiric radioactive Iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
2006 Journal of nuclear medicine : official publication, Society of Nuclear Medicine - Radioactive Iodine therapy in poorly differentiated thyroid cancer.
2007 Nature clinical practice. Oncology - Advantage of a residualizing Iodine radiolabel in the therapy of a colon cancerxenograft targeted with an anticarcinoembryonic antigen monoclonal antibody.
2005 Clinical cancer research : an official journal of the American Association forcancer Research - Valproic acid induces the expression of the Na+/I- symporter and Iodine uptake in poorly differentiated thyroid cancer cells.
2004 The Journal of clinical endocrinology and metabolism - Changing management in patients with papillary thyroid cancer.
2007 Current treatment options in oncology - Use of iodine-123 as a diagnostic tracer for neck and whole-body scanning in patients with well-differentiated thyroid cancer.
1998 Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists - Iodine 125 versus palladium 103 implants for prostate cancer: clinical outcomes and complications.
2004 Cancer journal (Sudbury, Mass.) - Test characteristics of visual inspection with 4% acetic acid (VIA) and Lugol’s Iodine(VILI) in cervical cancer screening in Kerala, India.
2003 International journal of cancer. Journal international du cancer - Therapy of hepatocellular cancer with iodine-131-Lipiodol.
2004 Romanian journal of gastroenterology - Iodine seed prostate brachytherapy: an alternative first-line choice for early prostate cancer.
2004 Prostate cancer and prostatic diseases - In vitro and in vivo targeting properties of iodine-123- or iodine-131-labeled monoclonal antibody 14C5 in a non-small cell lung cancer and colon carcinoma model.
2005 Clinical cancer research : an official journal of the American Association forcancer Research - Treatment with rhenium-188-perrhenate and iodine-131 of NIS-expressing mammarycancer in a mouse model remarkably inhibited tumor growth.
2005 Nuclear medicine and biology - Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing Iodine radiolabel.
2004 Breast cancer research and treatment - Prognostic factors of papillary and follicular thyroid cancer: differences in an iodine-replete endemic goiter region.
2004 Endocrine-related cancer - Dosimetry-guided radioactive Iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach.2003 Journal of nuclear medicine : official publication, Society of Nuclear Medicine
- Immunogenicity of Iodine 131 chimeric tumor necrosis therapy monoclonal antibody in advanced lung cancer patients.
2008 Cancer immunology, immunotherapy : CII - Childhood thyroid cancers and radioactive Iodine therapy: necessity of precautious radiation health risk management.
2007 Endocrine journal - Comparison of Iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancerpatients.
2006 Clinical endocrinology - Evaluation of dosimetric parameters and disease response after 125 Iodinetransperineal brachytherapy for low- and intermediate-risk prostate cancer.
2009 International journal of radiation oncology, biology, physics - Evaluation of visual inspection with acetic acid and Lugol’s Iodine as cervical cancerscreening tools in a low-resource setting.
2010 Tropical doctor - Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
2010 International journal of radiation oncology, biology, physics - [Cryosurgery combined with Iodine-125 seed implantation in the treatment of unresectable lung cancer.].
2008 Zhongguo fei ai za zhi = Chinese journal of lung cancer - Randomized trial to assess the efficacy of intraoperative steroid use in decreasing acute urinary retention after transperineal radioactive iodine-125 implantation for prostate cancer.
2008 Cancer - Iodine uptake in the chest in the follow-up of well-differentiated thyroid cancer.
2011 Revista espanola de medicina nuclear - Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients.
2009 International journal of urology : official journal of the Japanese Urological Association - Outcomes from Gleason 7, intermediate risk, localized prostate cancer treated with Iodine-125 monotherapy over 10 years.
2010 Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - [Experimental study on apoptosis of gastric cancer cell line MKN45 induced by continuous irradiation from iodine-125 seeds].
2009 Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition - Adjuvant radioimmunotherapy trial with iodine-131-labeled anti-carcinoembryonic antigen monoclonal antibody F6 F(ab’)2 after resection of liver metastases from colorectal cancer.
2008 Clinical cancer research : an official journal of the American Association forcancer Research - Synthesis and initial tumor affinity testing of iodine-123 labelled EGFR-affine agents as potential imaging probes for hormone-refractory prostate cancer.
2010 European journal of medicinal chemistry - Parathyroid changes after high dose radioactive Iodine in patients with thyroid cancer.
2009 Annals of nuclear medicine - [Clinical outcome of intermediate risk prostate cancer treated with Iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
2010 Cancer radiothérapie : journal de la Société française de radiothérapie oncologique - Antineoplastic effect of Iodine in mammary cancer: participation of 6-iodolactone (6-IL) and peroxisome proliferator-activated receptors (PPAR).
2009 Molecular cancer - Correlation between pre- and postimplant dosimetry for iodine-125 seed implants for localized prostate cancer.
2009 International journal of radiation oncology, biology, physics - Estrogen receptor status in primary breast cancer: Iodine 123-labeled cis-11beta-methoxy-17alpha-iodovinyl estradiol scintigraphy.
2001 Radiology - Failure of TSH rise prior to radio-iodine therapy for thyroid cancer: implications for treatment.
1999 Clinical oncology (Royal College of Radiologists (Great Britain)) - Radioimmunotherapy in medullary thyroid cancer using bispecific antibody andIodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial.
1999 Clinical cancer research : an official journal of the American Association forcancer Research - Thyroid cancer and thyroiditis in Salta, Argentina: a 40-yr study in relation to Iodineprophylaxis.
2002 Endocrine pathology - Effectiveness of preoperative radioactive Iodine (131I) therapy for locally advanced papillary thyroid cancer: a case report.
1998 Thyroid : official journal of the American Thyroid Association - Correlation of medical dosimetry quality indicators to the local tumor control in patients with prostate cancer treated with iodine-125 interstitial implants.
1998 Medical physics - Long-term potency after iodine-125 radiotherapy for prostate cancer and role of sildenafil citrate.
2003 Urology - Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
2001 Thyroid : official journal of the American Thyroid Association - Povidone-iodine instillation for management of pelvic lymphocele after pelvic lymphadenectomy for staging prostate cancer.
2003 Archives of andrology - Povidone-iodine instillation for management of pelvic lymphocele after pelvic lymphadenectomy for staging prostate cancer.
2003 Archives of andrology - Establishment of radioactive astatine and Iodine uptake in cancer cell lines expressing the human sodium/iodide symporter.
2002 European journal of nuclear medicine and molecular imaging - [Environmental radiation exposure of a thyroid cancer patient resulting from adjuvantIodine radiotherapy].
2001 Wiadomosci lekarskie (Warsaw, Poland : 1960) - Iodine-125 brachytherapy for localized prostate cancer and urinary morbidity: a prospective comparison of two seed implant methods-preplanning and intraoperative planning.
2003 Urology - Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role ofIodine content in L-thyroxine in the outcome of ablation.
2003 The Journal of clinical endocrinology and metabolism - [The efficacy of radio-iodine-therapy in patients with differentiated form cancer of thyroid gland in various after thyroidectomy].
2002 Klinichna khirurhiia / Ministerstvo okhorony zdorov’ia Ukraïny, Naukove tovarystvo khirurhiv Ukraïny - Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy.
2000 Mutagenesis - Papillary thyroid cancer with chest metastases only detected using radioactive iodine.
2004 Chang Gung medical journal - Value of protein-bound radioactive Iodine measurements in the management of differentiated thyroid cancer treated with (131)I.
2001 The British journal of radiology - Marking the axilla with radioactive Iodine seeds (MARI procedure) may reduce the need for axillary dissection after neoadjuvant chemotherapy for breast cancer.
2010 The British journal of surgery - Radiosynthesis and biological evaluation of a promising sigma(2)-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer.
2010 Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine - Chronic myeloid leukemia following radioactive Iodine (131)i therapy of thyroid cancer.
1991 Leukemia & lymphoma - Comparison of whole body scintigraphy with Tc-99m-methoxyisobutylisonitrile and iodine-131 NA in patients with differentiated thyroid cancer.
2007 The gulf journal of oncology - Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
2010 Clinical cancer research : an official journal of the American Association forcancer Research - Outpatient administration of radioactive Iodine after total thyroidectomy for pediatric thyroid cancer: a report of three cases.
2009 International journal of pediatric otorhinolaryngology - Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy.
2010 Brachytherapy - [Sodium-iodine symporter in thyroid, normal and cancer tissues and its relation to nuclear medicine and to gene cloning treatment].
2009 Hellenic journal of nuclear medicine - Decision aid on radioactive Iodine treatment for early stage papillary thyroid cancer–a randomized controlled trial.
2010 Trials - Cesium 131 versus Iodine 125 implants for prostate cancer: evaluation of early PSA response.
2010 The Canadian journal of urology - Differentiated thyroid cancer: comparison of therapeutic Iodine 131 biological elimination after discontinuation of levothyroxine versus administration of recombinant human thyrotropin.
2006 Annals of nuclear medicine - The role of radioactive Iodine therapy in young patients with papillary thyroid cancer.
2009 Clinical nuclear medicine - A screening study of thyroid cancer and other thyroid diseases among individuals exposed in utero to iodine-131 from Chernobyl fallout.
2009 The Journal of clinical endocrinology and metabolism - Treatment of local and regional recurrences of differentiated thyroid cancer by radio-guided surgery with iodine-131.
2006 Nuclear medicine review. Central & Eastern Europe : journal of Bulgarian, Czech, Macedonian, Polish, Romanian, Russian, Slovak, Yugoslav societies of nuclear medicine and Ukrainian Society of Radiology - [Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroidcancer (version 3)].
2007 Nuklearmedizin. Nuclear medicine - Autoimmune thyroiditis and exposure to Iodine 131 in the Ukrainian cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: results from the first screening cycle (1998-2000).
2006 The Journal of clinical endocrinology and metabolism - Epiphrenic diverticulum: potential pitfall in thyroid cancer iodine-131 scintigraphy.
2005 Clinical nuclear medicine - Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachytherapy for localized prostate cancer.
2006 Urology - The impact of hormone therapy on post-implant dosimetry and outcome following Iodine-125 implant monotherapy for localised prostate cancer.
2005 Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - Iodine-131 radio-guided surgery in differentiated thyroid cancer: outcome on 31 patients and review of the literature.
2007 Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie - Outcome of ablation of thyroid remnants with 100 mCi (3.7 GBq) iodine-131 in patients with thyroid cancer.
2005 Annals of nuclear medicine - Prospective comparison of two gamma probes for intraoperative detection of 18F-FDG: in vitro assessment and clinical evaluation in differentiated thyroid cancerpatients with iodine-negative recurrence.
2007 European journal of nuclear medicine and molecular imaging - Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems.
2008 European journal of nuclear medicine and molecular imaging - Prevention of peritoneal carcinomatosis from colon cancer cell seeding using a pirarubicin solution in rats and nude mice.
2004 World journal of surgery - Functional expression of sodium iodide symporter (NIS) in human breast cancertissue.
2003 Breast cancer research and treatment - Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases.
2004 European journal of nuclear medicine and molecular imaging - Iodine-125 brachytherapy for prostate cancer: first published Australian experience.
2004 Australasian radiology - Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive Iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.
2002 Journal of endocrinological investigation - Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive Iodine administration to patients with differentiated thyroid cancer.
2004 The Journal of clinical endocrinology and metabolism - Novel iodine-124 labeled EGFR inhibitors as potential PET agents for molecular imaging in cancer.
2004 Bioorganic & medicinal chemistry - 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
2007 Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association - Feasibility of a randomized trial on adjuvant radio-iodine therapy in differentiated thyroid cancer.
2003 Clinical endocrinology - Breast cancer proteomics by laser capture microdissection, sample pooling, 54-cm IPG IEF, and differential Iodine radioisotope detection.
2006 Electrophoresis - A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer.
2007 The Journal of clinical endocrinology and metabolism - An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy Iodine implantation as monotherapies for localized prostate cancer.
2007 The Journal of urology - Solitary focus in the liver in a thyroid cancer patient after a whole body scan with 131 iodine.
2007 Revista española de medicina nuclear - A systematic review of the gonadal effects of therapeutic radioactive Iodine in male thyroid cancer survivors.
2008 Clinical endocrinology - Prognostic factors and the effect of treatment with radioactive Iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
2005 Clinical endocrinology - [Insterstitial brachytherapy of localised prostate cancer using Iodine 125 permanent implants].
2005 Cancer radiothérapie : journal de la Société française de radiothérapie oncologique - [Epidemiology of thyroid tumors: effect of environmental Iodine intake].
2007 Nippon rinsho. Japanese journal of clinical medicine - Should ‘low-risk’ thyroid cancer patients with residual thyroglobulin be re-treated with Iodine 131?
2007 Clinical endocrinology - Radioprotection using iodine-131 for thyroid cancer and hyperthyroidism: a review.
2008 Clinical journal of oncology nursing - A systematic review examining the effects of therapeutic radioactive Iodine on ovarian function and future pregnancy in female thyroid cancer survivors.
2008 Clinical endocrinology - Tolerance of the aorta using intraoperative iodine-125 interstitial brachytherapy incancer of the lung.
2008 Brachytherapy - [Preparation of iodine-125 labeled anti-human CD40 monoclonal antibody 5H6 and its binding properties in ovary cancer cell line HO8910 in vitro].
2008 Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology - Limited cytoprotective effects of amifostine in high-dose radioactive Iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan.
2008 Thyroid : official journal of the American Thyroid Association - Late side effects of radioactive Iodine on salivary gland function in patients with thyroid cancer.
2011 Head & neck - Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of Iodine 131-labeled F(ab’)2 and pretargeted bivalent hapten and evaluation of repeated injections.
1999 Clinical cancer research : an official journal of the American Association forcancer Research - Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
2000 The Journal of clinical endocrinology and metabolism - Epidemiology of thyroid diseases in Iodine sufficiency.
1998 Thyroid : official journal of the American Thyroid Association - Limitations of peritoneal lavage with antiseptics in prevention of recurrent colorectalcancer caused by tumor-cell seeding: experimental study in rats.
2000 Diseases of the colon and rectum - Breast uptake of iodine-131 mimicking lung metastases in a thyroid cancer patient with a pituitary tumour.
2001 The British journal of radiology - [Use of recombinant human TSH for stimulation of Iodine radioisotope uptake in metastases of thyroid cancer during therapy with 131I].
2001 Wiadomosci lekarskie (Warsaw, Poland : 1960) - Low-iodine diet revisited: importance in nuclear medicine imaging and management.
2008 Clinical nuclear medicine - Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.
2010 Cochrane database of systematic reviews (Online) - [Usefulness of isotope diagnosis, ultrasound neck investigation and thyroglobulin assays in quantification of patients operated on for differentiated thyroid cancer and prepared for radioiodine treatment].
2003 Polskie Archiwum Medycyny Wewnetrznej - Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer.
2004 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - Long-term radioiodine retention and regression of liver cancer after sodium iodide symporter gene transfer in wistar rats.
2004 Cancer research - Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive Iodine therapy.
2011 Cancer - [Thyroid diseases in sub-Saharan Africa].
2007 Santé (Montrouge, France) - [Iodine deficiency and thyroid neoplasms in the Krakow region].
2001 Wiadomosci lekarskie (Warsaw, Poland : 1960)
Iodine alters gene expression in the MCF7 breast cancer cell line: evidence for an anti-estrogen effect of iodine. 2008 International journal of medical sciences
|
A prospective study of Iodine status, thyroid function, and prostate cancer risk: follow-up of the First National Health and Nutrition Examination Survey.
|
Studies on Iodine and Apoptotic
SELENIUM
One of the most effective naturally occurring weapons against cancer is, like most healthy things, something many of us are not getting enough of. The mineral selenium has been shown in multiple studies to be an effective tool in warding off various types of cancer, including breast, esophageal, stomach, prostate, liver and bladder cancers. Not many people get the recommended dose of 200 micrograms a day. Most Americans only get between 60 and 100 micrograms of selenium daily from dietary sources, according to the Life Extension Foundation’s Disease Prevention and Treatment. That means daily supplements might be worth considering.
Selenium & Chemotherapy
In addition to preventing the onset of the disease, selenium has also been shown to aid in slowing cancer’s progression in patients that already have it. According to the Life Extension Foundation, the use of selenium during chemotherapy in combination with vitamin A and vitamin E can reduce the toxicity of chemotherapy drugs. The mineral also helps „enhance the effectiveness of chemo, radiation, and hyperthermia while minimizing damage to the patient’s normal cells; thus making therapy more of a ‘selective toxin,'” says Patrick Quillin in Beating Cancer with Nutrition.A 1996 study by Dr. Larry Clark of the University of Arizona showed just how effective selenium can be in protecting against cancer.
In the study of 1,300 older people, the occurrence of cancer among those who took 200 micrograms of selenium daily for about seven years was reduced by 42 percent compared to those given a placebo. Cancer deaths for those taking the selenium were cut almost in half, according to the study that was published in the Journal of the American Medical Association.While the study concluded the mineral helped protect against all types of cancer, it had particularly powerful impacts on prostate, colorectal and lung cancers. Jean Carper, in Miracle Cures, called Dr. Clark’s findings an „unprecedented cancer intervention study” that „bumped up the respectability of using supplements against cancer several notches.”
Ask Dr Weil by Andrew Weil MD, page 207
Cancer And Natural Medicine by John Boik, page 146
Cancer Therapy by Ralph W Moss PhD, page 112
Carcinogens Human Diet by National Research Council, page 100
Diet Nutrition Cancer by National Research Council, page 168
Prescription For Dietary Wellness by Phyllis A Balch, page 44Laboratory studies have shown that selenium can inhibit the growth of breast, cervical, colon, and skin cancer.Antioxidants Against Cancer by Ralph Moss PhD, page 79Selenium is protective against many types of cancers, promotes apoptosis, is a powerful antioxidant, and improves quality of life during aggressive cancer therapies According to P.D. Whanger (professor of agricultural chemistry), nearly 200 animal studies have been conducted to evaluate the effects of supernutritional levels of selenium on experimental carcinogenesis using chemical, viral, and transplantable tumor models. Two thirds of the studies found that high levels of selenium reduced the development of tumors at least moderately (14-35% compared to controls) and, in most cases, significantly (by more than 35%) (Whanger 1998).
Disease Prevention And Treatment by Life Extension Foundation, page 242
Selenium has been used in combination with vitamin A and vitamin E to reduce the toxicity of chemotherapy drugs, particularly Adriamycin (Faure et al. 1996; Vanella et al. 1997). The synergistic effect of vitamin E and selenium together to enhance the immune system is greater than either alone. A new form of selenium is Se-methylselenocysteine (SeMC), a naturally occurring selenium compound found to be an effective chemopreventive agent. SeMC is a selenoamino acid that is synthesized by plants such as garlic and broccoli. SeMC has been shown to induce apoptosis in certain ovarian cancer cells (Yeo et al. 2002) and to be effective against breast cancer cell growth both in vivo and in vitro (Sinha et al. 1999). SeMC has also demonstrated significant anticarcinogenic activity against mammary tumorigenesis (Sinha et al. 1997). Moreover, a study has demonstrated that SeMC is one of the most effective selenium chemopreventive compounds, inducing apoptosis in leukemia HL-60 cell lines (Jung et al. 2001a). Some of the most impressive data suggest that exposure to SeMC blocks clonal expansion of premalignant lesions at an early stage. This is achieved by simultaneously modulating certain molecular pathways that are responsible for inhibiting cell proliferation and enhancing apoptosis (Ip et al. 2001). Unlike selenomethionine, which is incorporated into protein in place of methionine, SeMC is not incorporated into any protein, thereby offering a completely bioavailable compound for preventing cancer. Therefore, 200—400 mcg of SeMC a day is suggested for cancer patients. Please note that selenium also possesses antioxidant properties, so its use before, during, or immediately after chemotherapy could theoretically inhibit the actions of certain chemotherapy drugs.
Disease Prevention And Treatment by Life Extension Foundation, page 277
Scientists have confirmed that vitamins C and E along with the mineral selenium afford some prostate cancer prevention. This is not surprising to anyone who understands diet, biochemistry, and how antioxidants work. Glutathione peroxidase destroys free radicals and superoxides. Its name means that it destroys peroxides (the potent oxidants that form in tissues) and uses glutathione as a helper. Glutathione requires selenium to function; and wherever selenium is at work, vitamin E can’t be far away because they function together.
20 Natural Ways To Reduce The Risk Of Prostate Cancer By James Scala PHD, page 54
Men with higher intakes of antioxi-dants such as vitamin C, vitamin E, and the trace mineral selenium have lower levels of prostate cancer.
Alternative Cures by Bill Gottlieb, page 519
Selenium Statistics
In a December 1996 article in the Journal of the American Medical Association, Dr. Larry Clark presented evidence that supplemental selenium could reduce cancer death rates by as much as 50%. 1,312 patients were given 200 mcg. of selenium daily. The patients receiving selenium had a rise of 67% in their blood selenium level.
A Physicians Guide To Natural Health Products That Work By James Howenstine MD, page 148
The patients receiving selenium had a 67% decrease in cancer of the prostate, a 58 percent decrease in colon or rectal cancer and a 45% decrease in lung cancer. This suggests that possibly up to 100,000 lives a year might be saved in the USA by the simple addition of selenium to the diet.
A Physicians Guide To Natural Health Products That Work By James Howenstine MD, page 149
An article in the Journal of the American Medical Association (JAMA) by Clark et al. (1996) showed that 200 mcg of supplemental selenium a day reduced overall cancer mortality by 50% in humans compared to a placebo group not receiving supplemental selenium. This 9-year study demonstrated that a low-cost mineral supplement could cut the risk of dying from cancer in half in certain individuals.
Disease Prevention And Treatment by Life Extension Foundation, page 1255
In a recent five-year study of nearly 30,000 rural Chinese people, researchers from the NCI found that daily doses of these three nutrients reduced cancer deaths by 13%.
Alternative Medicine by Burton Goldberg, page 590
But what if you already have cancer? Again, the research shows a prolongation of lifespan with proper supplementation. In a study in Cancer Letters (Evangelou et al. 1997), animals with malignant tumors given high doses of vitamins C and E and selenium manifested a significant prolongation of the mean survival time. Complete remission of tumors developed in 16.8% of the animals.
Disease Prevention And Treatment by Life Extension Foundation, page 1256
Dr. Raymond Shamberger was also among the first to discover the link between low selenium content in the soil and increasing numbers of deaths from cancer. In 1976, he pointed out that the cities and states with high selenium content in the soil also had significantly lower rates of cancer, especially of the digestive and urinary systems.
Antioxidants Against Cancer by Ralph Moss PhD, page 77
A Powerful Antioxidant „selenium is a crucial mineral in the battle against prostate cancer,” says Dr. Schachter. In one study of hundreds of men, a daily intake of 200 micrograms of selenium cut the incidence of prostate cancer by 60 percent.
Alternative Cures by Bill Gottlieb, page 518
The statistics for breast cancer are particularly striking. „The higher the selenium, the lower the breast cancer,” said Prof. Ladas. Similar associations have been found with leukemia, as well as cancers of the intestines, rectum, ovary, prostate, lung, pancreas, skin and bladder. In Yugoslavia, scientists studied 33 patients with breast cancer. These women had selenium levels in their bloodstream only half those of healthy volunteers.
Cancer Therapy by Ralph W Moss PhD, page 112
Although the study failed to show the effectiveness of selenium in altering the course of either basal or squamous cell carcinoma, selenium impacted the incidence of other types of malignancies with amazing success (Clark et al. 1996). The overall reduction in cancer incidence was 37% in the selenium-supplemented group; a 50% reduction in cancer mortality was observed over a 10-year period. The following are the site-specific reductions in cancer incidence observed in the study: colon-rectal cancers (58%), lung cancer (46%), and prostate cancer (63%). A selenium deficiency appears to increase the risk of prostate cancer fourfold to fivefold. It was determined that, as the male population ages, selenium levels decrease, paralleling an increase in prostate cancer (Brooks et al. 2001).
Disease Prevention And Treatment by Life Extension Foundation, page 242
In a study published in the journal of the National Cancer Institute, the relationship between serum levels of selenium and the development of upper digestive tract cancer was explored (Mark et al, 2000). The relative risk of esophageal cancer was 0.56 in individuals in the highest quartile of selenium level compared with those in the lowest quartile. The corresponding relative risk of gastric cardia cancer was 0.47. Based on the data, the researchers calculate that 26.4% of esophageal and gastric cardia cancers are attributable to low selenium levels.
Disease Prevention And Treatment by Life Extension Foundation, page 242
For a more detailed article about SELENIUM & cancer click here.
Studies regarding Selenium & cancer
- [Serum and lung tissue Selenium measurements in subjects with lung cancer from Xuanwei, China].
2011 Zhongguo fei ai za zhi = Chinese journal of lung cancer - Selenium, folate, and colon cancer.
2009 Nutrition and cancer - A randomized, controlled chemoprevention trial of Selenium in familial prostate cancer: Rationale, recruitment, and design issues.
2001 Urology - Selenium levels of patients with newly diagnosed prostate cancer compared with control group.
2004 Urology - Defining the Optimal Selenium Dose for Prostate cancer Risk Reduction: Insights from the U-Shaped Relationship between Selenium Status, DNA Damage, and Apoptosis.
2009 Dose-response : a publication of International Hormesis Society - Selenium and selenium-antagonistic elements in nutritional cancer prevention.
2009 Critical reviews in biotechnology - Serum Selenium and risk of prostate cancer-a nested case-control study.
2007 The American journal of clinical nutrition - Mechanisms of Selenium down-regulation of androgen receptor signaling in prostate cancer.
2006 Molecular cancer therapeutics - Prostate cancer risk and DNA damage: translational significance of Seleniumsupplementation in a canine model.
2005 Carcinogenesis - Selenium and vitamin E supplements for prostate cancer: evidence or embellishment?
2002 Urology - Selenium in cancer prevention: a review of the evidence and mechanism of action.
2005 The Proceedings of the Nutrition Society - Making sense of sex and supplements: differences in the anticarcinogenic effects ofSelenium in men and women.
2004 Mutation research - Baseline characteristics and the effect of Selenium supplementation on cancerincidence in a randomized clinical trial: a summary report of the Nutritional Prevention of cancer Trial.
2002 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Toenail Selenium and breast cancer-a case-control study in Finland.
2000 European journal of clinical nutrition - Predictors of serum Selenium in cigarette smokers and the lack of association with lung and prostate cancer risk.
2001 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients.
2006 Cochrane database of systematic reviews (Online) - Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer.
2009 Journal of clinical oncology : official journal of the American Society of Clinical Oncology - Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.
2005 Cancer research - Selenium binding protein 1 in ovarian cancer.
2006 International journal of cancer. Journal international du cancer - Apoptosis is a critical cellular event in cancer chemoprevention and chemotherapy bySelenium compounds.
2004 Current cancer drug targets - Selenium in breast cancer.
2003 Oncology - Speciation and bioavailability of Selenium in yeast-based intervention agents used incancer chemoprevention studies.
2004 Journal of AOAC International - Cross-species global and subset gene expression profiling identifies genes involved in prostate cancer response to selenium.
2004 BMC genomics - Selenium and lung cancer: a quantitative analysis of heterogeneity in the current epidemiological literature.
2004 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Environmental factors, health-related habits, and serum Selenium levels in cancerpatients and healthy controls.
1999 Biological trace element research - Enhanced lung cancer cell killing by the combination of Selenium and ionizing radiation.
2007 Oncology reports - Plasma Selenium concentration and prostate cancer risk: results from the European Prospective Investigation into cancer and Nutrition (EPIC).
2008 The American journal of clinical nutrition - Serum Selenium level and prostate cancer: a case-control study.
2008 Nutrition and cancer - Microarray Data Mining for Potential Selenium Targets in Chemoprevention of Prostate Cancer.
2005 Cancer genomics & proteomics - Relationship between Selenium and breast cancer: a case-control study in the Klang Valley.
2009 Singapore medical journal - Use of Selenium in chemoprevention of bladder cancer.
2006 The lancet oncology - Vitamin E and Selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.
2008 Cancer causes & control : CCC - The protective role of Selenium on genetic damage and on cancer.
2001 Mutation research - Effect of Selenium in combination with Adriamycin or Taxol on several differentcancer cells.
2000 Anticancer research - A prospective study of plasma Selenium levels and prostate cancer risk.
2004 Journal of the National cancer Institute - Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase.
2004 Biochemical and biophysical research communications - Toenail Selenium concentration and lung cancer in male smokers (Finland).
2002 Cancer causes & control : CCC - Selenium derivatives as cancer preventive agents.
2005 Current medicinal chemistry. Anti-cancer agents - Selenium supplementation, baseline plasma Selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of cancer Trial.
2003 BJU international - Association between breast cancer and vitamin C, vitamin E and Selenium levels: results of a case-control study in India.
2005 Asian Pacific journal of cancer prevention : APJCP - The antioxidative role of Selenium in pathogenesis of cancer of the female reproductive system.
2007 Neoplasma - Histamine and Selenium in lung cancer.
2006 Anticancer research - Self-organizing maps classification of epidemiological data and toenail Seleniumcontent monitored on cancer and healthy patients from Poland.
2010 Journal of environmental science and health. Part A, Toxic/hazardous substances & environmental engineering - Plasma Selenium measurements in subjects from areas with contrasting gastriccancer risks in Colombia.
2008 Archives of medical research - Ingestion of Selenium and other antioxidants during prostate cancer radiotherapy: a good thing?
2010 Cancer treatment reviews - Selenium and risk of bladder cancer: a population-based case-control study.
2009 Cancer prevention research (Philadelphia, Pa.) - Selenium and the prevention of prostate and colorectal cancer.
2008 Molecular nutrition & food research - Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort.
2009 Cancer causes & control : CCC - Selenium and Vitamin E cancer Prevention Trial: a nutrient approach to prostatecancer prevention.
2009 Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer - Selenium regulates cyclooxygenase-2 and extracellular signal-regulated kinase signaling pathways by activating AMP-activated protein kinase in colon cancer cells.
2006 Cancer research - A nutrient approach to prostate cancer prevention: The Selenium and Vitamin Ecancer Prevention Trial (SELECT).
2010 Nutrition and cancer - Update on prostate cancer chemoprevention.
2006 Pharmacotherapy - Delineating the mechanism by which Selenium deactivates Akt in prostate cancercells.
2006 Molecular cancer therapeutics - Selenium and vitamin E cancer prevention trial.
2004 Annals of the New York Academy of Sciences - Monomethylated Selenium inhibits growth of LNCaP human prostate cancerxenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
2006 The Prostate - The Selenium and vitamin E cancer prevention trial.
2003 World journal of urology - SELECT: the Selenium and vitamin E cancer prevention trial.
2003 Urologic oncology - A case–control study of Selenium in nails and prostate cancer risk in British men.
2004 British journal of cancer - Prostate cancer and selenium.
2002 The Urologic clinics of North America - [Effect of Selenium dioxide on proliferation, apoptosis, and elomerase activity of human lung cancer cell line in vitro].
2003 Ai zheng = Aizheng = Chinese journal of cancer - Toenail Selenium levels and the subsequent risk of prostate cancer: a prospective cohort study.
2003 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - The epidemiology of Selenium and human cancer.
2000 Tumori - Selenium and cancer: some nutritional aspects.
2000 Nutrition (Burbank, Los Angeles County, Calif.) - Molecular epidemiologic studies within the Selenium and Vitamin E cancerPrevention Trial (SELECT).
2001 Cancer causes & control : CCC - Selenium supplementation and secondary prevention of nonmelanoma skin cancerin a randomized trial.
2003 Journal of the National cancer Institute - Review of vitamin E and Selenium in the prevention of prostate cancer: implications of the Selenium and vitamin E chemoprevention trial.
2002 Integrative cancer therapies - Serum Selenium and cancer mortality: a nested case-control study within an age- and sex-stratified sample of the Belgian adult population.
2004 European journal of clinical nutrition - Selenium is effective in inducing lymphocyte progression through cell cycle in cancerpatients: potential mechanisms for its activity.
2004 Journal of experimental therapeutics & oncology - Clinical models for testing chemopreventative agents in prostate cancer and overview of SELECT: the Selenium and Vitamin E cancer Prevention Trial.
2003 Recent results in cancer research. Fortschritte der Krebsforschung. Progrès dans les recherches sur le cancer - DNA stability and serum Selenium levels in a high-risk group for prostate cancer.
2004 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - [Effect of Selenium and zinc on the proliferation of human esophageal cancer Eca109 cell line in vitro].
2008 Nan fang yi ke da xue xue bao = Journal of Southern Medical University - Inorganic Selenium retards progression of experimental hormone refractory prostate cancer.
2004 The Journal of urology - Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.
2009 Journal of the National cancer Institute - Null activity of Selenium and vitamin e as cancer chemopreventive agents in the rat prostate.
2010 Cancer prevention research (Philadelphia, Pa.) - Selenium compounds activate ATM-dependent DNA damage response via the mismatch repair protein hMLH1 in colorectal cancer cells.
2010 The Journal of biological chemistry - Negation of the cancer-preventive actions of Selenium by over-expression of protein kinase Cepsilon and selenoprotein thioredoxin reductase.
2009 Carcinogenesis - Selenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin Ecancer Prevention Trial) status.
2011 Molecular medicine (Cambridge, Mass.) - Is prostate cancer prevention with Selenium all in the genes?
2010 Cancer prevention research (Philadelphia, Pa.) - Selenium disrupts estrogen receptor (alpha) signaling and potentiates tamoxifen antagonism in endometrial cancer cells and tamoxifen-resistant breast cancer cells.
2005 Molecular cancer therapeutics - Serum Selenium measurements in women with early-stage breast cancer with and without chemotherapy-induced ovarian failure.
2006 Breast cancer research and treatment - Hemolysate thioredoxin reductase and glutathione peroxidase activities correlate with serum Selenium in a group of New Zealand men at high prostate cancer risk.
2006 The Journal of nutrition - Cancer chemoprevention: Selenium as a prooxidant, not an antioxidant.
2006 Medical hypotheses - Selenium sensitizes MCF-7 breast cancer cells to doxorubicin-induced apoptosis through modulation of phospho-Akt and its downstream substrates.
2007 Molecular cancer therapeutics - Cancer chemoprevention by garlic and garlic-containing sulfur and Seleniumcompounds.
2006 The Journal of nutrition - Molecular targets for Selenium in cancer prevention.
2001 Nutrition and cancer - Selenium, copper, and zinc concentrations in intestinal cancer tissue and in colon and rectum polyps.
2003 Biological trace element research - Status of Selenium in prostate cancer prevention.
2004 British journal of cancer - Serum tocopherols, Selenium and lung cancer risk among tin miners in China.
2000 Cancer causes & control : CCC - Serum Selenium levels in patients with head and neck cancer.
2002 The Journal of otolaryngology - Serum Selenium levels in patients with head and neck cancer.
2002 The Journal of otolaryngologyChemical speciation influences comparative activity of selenium-enriched garlic and yeast in mammary cancer prevention.
2000 Journal of agricultural and food chemistry - Selenium and prostate cancer prevention.
1999 Seminars in urologic oncology - Death receptor 5 regulation during selenium-mediated apoptosis in human prostatecancer cells.
2002 Cancer biology & therapy - Cell cycle arrest biomarkers in human lung cancer cells after treatment withSelenium in culture.
2003 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Prospective study of serum Selenium concentrations and esophageal and gastric cardia cancer, heart disease, stroke, and total death.
2004 The American journal of clinical nutrition - Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial.
2006 International journal of cancer. Journal international du cancer - Delineation of the molecular basis for selenium-induced growth arrest in human prostate cancer cells by oligonucleotide array.
2003 Cancer research - Synergistic effect of vitamin E and Selenium in human prostate cancer cell lines.
2004 Prostate cancer and prostatic diseases - The role of Selenium in cancer and viral infection prevention.
2005 International journal of occupational medicine and environmental health - Enhanced tight junction function in human breast cancer cells by antioxidant,Selenium and polyunsaturated lipid.
2007 Journal of cellular biochemistry - Are men with low Selenium levels at increased risk of prostate cancer?
2006 European journal of cancer (Oxford, England : 1990) - Dietary zinc, copper and selenium, and risk of lung cancer.
2007 International journal of cancer. Journal international du cancer - The Selenium analog of the chemopreventive compound S,S’-(1,4-phenylenebis[1,2-ethanediyl])bisisothiourea is a remarkable inducer of apoptosis and inhibitor of cell growth in human non-small cell lung cancer.
2009 Chemico-biological interactions - The Outcome of Selenium and Vitamin E cancer Prevention Trial (SELECT) reveals the need for better understanding of Selenium biology.
2009 Molecular interventions - Efficacy of antioxidant vitamins and Selenium supplement in prostate cancerprevention: a meta-analysis of randomized controlled trials.
2010 Nutrition and cancer - Selenium and the selenoprotein thioredoxin reductase in the prevention, treatment and diagnostics of cancer.
2010 Antioxidants & redox signaling - Selenium and colon cancer–from chemoprevention to new treatment modality.
2008 Anti-cancer agents in medicinal chemistry - Toenail Selenium levels and gastric cancer risk in Cali, Colombia.
2008 The Journal of toxicological sciences - The nutritional prevention of cancer: 400 mcg per day Selenium treatment.
2008 Nutrition and cancer - Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKalpha1.
2010 Carcinogenesis - Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34.
2010 Nutrition and cancer - A large prospective study of SEP15 genetic variation, interaction with plasmaSelenium levels, and prostate cancer risk and survival.
2010 Cancer prevention research (Philadelphia, Pa.) - Lung cancer risk associated with Selenium status is modified in smoking individuals by Sep15 polymorphism.
2008 European journal of nutrition - Interactive effects of Selenium and cadmium on mammary tumor development and growth in MMTV-infected female mice. A model study on the roles of cadmium andSelenium in human breast cancer.
2008 Biological trace element research - Design and progress of a trial of Selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.
2006 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - The relevance of Selenium to immunity, cancer, and infectious/inflammatory diseases.
2005 Canadian journal of dietetic practice and research : a publication of Dietitians of Canada = Revue canadienne de la pratique et de la recherche en diététique : une publication des Diététistes du Canada - Investigation of the Selenium metabolism in cancer cell lines.
2011 Metallomics : integrated biometal science - Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells.
2009 BMC cancer - Survivin gene silencing sensitizes prostate cancer cells to Selenium growth inhibition.
2010 BMC cancer - Selenium and cancer chemoprevention: hypotheses integrating the actions of selenoproteins and Selenium metabolites in epithelial and non-epithelial target cells.
2005 Antioxidants & redox signaling - Larry Clark’s legacy: randomized controlled, selenium-based prostate cancerchemoprevention trials.
2001 Nutrition and cancer - Activities of structurally-related lipophilic Selenium compounds as cancerchemopreventive agents.
1998 Anticancer research - Hypothesis: iodine, Selenium and the development of breast cancer.
2000 Cancer causes & control : CCC - An intervention study to prevent gastric cancer by micro-selenium and large dose of allitridum.
2004 Chinese medical journal - Selenium biochemistry and cancer: a review of the literature.
2004 Alternative medicine review : a journal of clinical therapeutic - Cancer-protective properties of high-selenium broccoli.
2001 Journal of agricultural and food chemistry - Effects of Selenium and zinc supplementation on nutritional status in patients withcancer of digestive tract.
2001 European journal of clinical nutrition - Selenium from high Selenium broccoli protects rats from colon cancer.
2000 The Journal of nutrition - Serum Selenium and subsequent risk of prostate cancer.
2000 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Randomized, controlled chemoprevention trials in populations at very high risk for prostate cancer: Elevated prostate-specific antigen and high-grade prostatic intraepithelial neoplasia.
2001 Urology - Selenium and prevention of prostate cancer in high-risk men: the Negative Biopsy Study.
2003 Anti-cancer drugs - Designing the Selenium and Vitamin E cancer Prevention Trial (SELECT).
2005 Journal of the National cancer Institute - Selenium/cadmium ratios in human prostates: indicators of prostate cancer risk of smokers and nonsmokers, and relevance to the cancer protective effects of selenium.
2005 Biological trace element research - Timing of supplementation of Selenium and isoflavones determines prostate cancerrisk factor reduction in rats.
2008 Nutrition & metabolism - Selenium metabolites in urine of cancer patients receiving L-selenomethionine at high doses.
2007 Toxicology and applied pharmacology - Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter.
2007 Molecular cancer therapeutics - Androgen receptor signaling intensity is a key factor in determining the sensitivity of prostate cancer cells to Selenium inhibition of growth and cancer-specific biomarkers.
2005 Molecular cancer therapeutics - Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer.
2007 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Magnetic Resonance and Fluorescence-Protein Imaging of the Anti-angiogenic and Anti-tumor Efficacy of Selenium in an Orthotopic Model of Human Colon Cancer.
2011 Anticancer research - Antiproliferative effects of Selenium compounds in colon cancer cells: comparison of different cytotoxicity assays.
2009 Toxicology in vitro : an international journal published in association with BIBRA - Mechanisms of Selenium chemoprevention and therapy in prostate cancer.
2008 Molecular nutrition & food research - Selenium modifies the osteoblast inflammatory stress response to bone metastatic breast cancer.
2009 Carcinogenesis - Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells.
2010 Bioorganic & medicinal chemistry letters - The effects of diet on Selenium concentration in serum in patients with cancer.
2009 Nutrition and cancer - Combination of vitamin E and Selenium causes an induction of apoptosis of human prostate cancer cells by enhancing Bax/Bcl-2 ratio.
2008 The Prostate - Genistein-selenium combination induces growth arrest in prostate cancer cells.
2010 Journal of medicinal food - Extracellular thiol-assisted Selenium uptake dependent on the x(c)- cystine transporter explains the cancer-specific cytotoxicity of selenite.
2009 Proceedings of the National Academy of Sciences of the United States of America - Potential stages for prostate cancer prevention with selenium: implications forcancer survivors.
2009 Cancer research - Inorganic Selenium sensitizes prostate cancer cells to TRAIL-induced apoptosis through superoxide/p53/Bax-mediated activation of mitochondrial pathway.
2006 Molecular cancer therapeutics - Differential involvement of reactive oxygen species in apoptosis induced by two classes of Selenium compounds in human prostate cancer cells.
2007 International journal of cancer. Journal international du cancer - Selenium status and the risk of esophageal and gastric cancer subtypes: the Netherlands cohort study.
2010 Gastroenterology - Serum levels of Selenium in patients with breast cancer before and after treatment of external beam radiotherapy.
2010 Annals of oncology : official journal of the European Society for Medical Oncology / ESMO - Centralized blood processing for the Selenium and vitamin E cancer prevention trial: effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability.
2005 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Methylation-mediated silencing of genes is not altered by Selenium treatment of prostate cancer cells.
2007 Anticancer research - Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings.
2004 Journal of cellular biochemistry - Selenium and its relationship to cancer: an update.
2004 The British journal of nutrition - Minority recruitment to the Selenium and Vitamin E cancer Prevention Trial (SELECT).
2005 Clinical trials (London, England) - Chemical forms of Selenium for cancer prevention.
2005 Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) - Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium.
2004 Integrative cancer therapies - Redox-mediated effects of Selenium on apoptosis and cell cycle in the LNCaP human prostate cancer cell line.
2001 Cancer research - In vitro and in vivo studies of methylseleninic acid: evidence that a monomethylatedSelenium metabolite is critical for cancer chemoprevention.
2000 Cancer research - Caspases as key executors of methyl selenium-induced apoptosis (anoikis) of DU-145 prostate cancer cells.
2001 Cancer research - Dietary Selenium reduces the formation of aberrant crypts in rats administered 3,2′-dimethyl-4-aminobiphenyl.
1999 Toxicology and applied pharmacology - Selenium and selenomethionine levels in prostate cancer patients.
2004 Cancer detection and prevention - Inhibition of telomerase activity in endometrial cancer cells by selenium-cisplatin conjugate despite suppression of its DNA-damaging activity by sodium ascorbate.
2002 Teratogenesis, carcinogenesis, and mutagenesis - Selenium-Rich Foods: A Promising Approach to Colorectal cancer Prevention.
2011 Current pharmaceutical biotechnology - Synergy between Selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells.
2003 Cancer research - Synergy between Selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells.
2003 Cancer research - Chemopreventive effect of selenium-enriched Japanese radish sprout against breastcancer induced by 7,12-dimethylbenz[a]anthracene in rats.
2007 The Tohoku journal of experimental medicine - Apoptotic cellular events for Selenium compounds involved in cancer prevention.
2007 Journal of bioenergetics and biomembranes - Selenium is critical for cancer-signaling gene expression but not cell proliferation in human colon Caco-2 cells.
2007 BioFactors (Oxford, England) - High Selenium reduces NF-kappaB-regulated gene expression in uninduced human prostate cancer cells.
2007 Nutrition and cancer - Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.
2008 Gynecologic oncology - Selenium compounds and selenoproteins in cancer.
2008 Chemistry & biodiversity - Deoxycholic acid and Selenium metabolite methylselenol exert common and distinct effects on cell cycle, apoptosis, and MAP kinase pathway in HCT116 human coloncancer cells.
2010 Nutrition and cancer - In vivo molecular mediators of cancer growth suppression and apoptosis bySelenium in mammary and prostate models: lack of involvement of gadd genes.
2009 Molecular cancer therapeutics - Expression of selenium-binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer.
2008 Molecular nutrition & food research - Selenium as a chemoprotective anti-cancer agent: reality or wishful thinking?
2010 Neoplasma - A comparative study of Selenium concentration and glutathione peroxidase activity in normal and breast cancer patients.
2009 Public health nutrition - Organoselenium compounds in cancer chemoprevention.
2008 Mini reviews in medicinal chemistry - No effect of Selenium supplementation on serum glucose levels in men with prostate cancer.
2010 The American journal of medicine - Selenium and bladder cancer risk: a meta-analysis.
2010 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Fabrication and biofunctionalization of selenium-polypyrrole core-shell nanoparticles for targeting and imaging of cancer cells.
2008 Journal of nanoscience and nanotechnology - Impact of supplemental site grants to increase African American accrual for theSelenium and Vitamin E cancer Prevention Trial.
2010 Clinical trials (London, England) - Role of caspases in 5-FU and selenium-induced growth inhibition of colorectal cancercells.
2008 Anticancer research - Selenium supplementation may increase the efficacy of cetuximab in metastatic colorectal cancer patients.
2005 Medical hypotheses - Toenail Selenium concentrations and bladder cancer risk in women and men.
2005 British journal of cancer - Intake of Selenium in the prevention of prostate cancer: a systematic review and meta-analysis.
2005 Cancer causes & control : CCC - Ovine pulmonary adenocarcinoma as an animal model of progressive lung cancer and the impact of nutritional Selenium supply.
2010 Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) - Interactive effects of Selenium and chromium on mammary tumor development and growth in MMTV-infected female mice and their relevance to human cancer.
2006 Biological trace element research - Both selenoproteins and low molecular weight selenocompounds reduce coloncancer risk in mice with genetically impaired selenoprotein expression.
2006 The Journal of nutrition - Reduction of cancer risk by consumption of selenium-enriched plants: enrichment of broccoli with Selenium increases the anticarcinogenic properties of broccoli.
2003 Journal of medicinal food - Antiangiogenic activity of Selenium in cancer chemoprevention: metabolite-specific effects.
2001 Nutrition and cancer - Impact of Selenium and cancer-prevention findings on the nutrition-health paradigm.
2001 Nutrition and cancer - The prevalence of low Selenium levels in newly diagnosed pediatric cancer patients.
2003 Pediatric hematology and oncology - An analysis of cancer prevention by selenium.
2001 BioFactors (Oxford, England) - Selenoprotein levels in patients with colorectal adenomas and cancer.
2002 The American journal of gastroenterology - The role of PC-SPES, selenium, and vitamin E in prostate cancer.
2002 Oncology (Williston Park, N.Y.) - Molecular mechanisms of cancer prevention by Selenium compounds.
2001 Nutrition and cancer - Drug-resistant human lung cancer cells are more sensitive to Selenium cytotoxicity. Effects on thioredoxin reductase and glutathione reductase.
2002 Biochemical pharmacology - Effect of Selenium and vitamin E on risk of prostate cancer and other cancers: theSelenium and Vitamin E cancer Prevention Trial (SELECT).
2009 JAMA : the journal of the American Medical Association - Whole blood Selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissueSelenium levels (PTSL) in patients with PC and BPH.
2009 Acta oncologica (Stockholm, Sweden) - Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells.
2008 The Journal of biological chemistry - Selenium: from cancer prevention to DNA damage.
2006 Toxicology - Selenium: epidemiology and basic science.
2004 The Journal of urology - Serum Selenium in head and neck cancer patients–a new marker of tumor activity?
2005 Anticancer research - Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA.
2006 British journal of cancer - Serum Selenium levels and all-cause, cancer, and cardiovascular mortality among US adults.
2008 Archives of internal medicine - Current issues of Selenium in cancer chemoprevention.
2010 BioFactors (Oxford, England) - Increased consumption of wheat biofortified with Selenium does not modify biomarkers of cancer risk, oxidative stress, or immune function in healthy Australian males.
2009 Environmental and molecular mutagenesis - Serum and tissue Selenium levels in gastric cancer patients and correlation with CEA.
2009 Anticancer research - Methylselenol, a Selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancersignaling genes.
2009 The Journal of nutrition - [The role of selenoproteins in cancer.].
2010 Revista da Associação Médica Brasileira (1992) - Determination of Selenium content in aqueous extract of medicinal plants used as herbal supplement for cancer patients.
2010 Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association - [Preventive effects of 4 Se-enriched plants on rat stomach cancer induced by MNNG–1. inhibitary effects of different Selenium resources on rat aneuploid cell incidence in mucosal epithelium of gastric antrum].
2007 Wei sheng yan jiu = Journal of hygiene research - Effect of long-term Selenium yeast intervention on activity and gene expression of antioxidant and xenobiotic metabolising enzymes in healthy elderly volunteers from the Danish Prevention of cancer by Intervention by Selenium (PRECISE) pilot study.
2008 The British journal of nutrition - [Preventive effects of 4 Se-enriched plants on rat stomach cancer induced by MNNG–3. Se accumulation and distribution in rats of different Selenium resources for prevention of stomach cancer].
2008 Wei sheng yan jiu = Journal of hygiene research - High serum Selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program.
2006 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Mechanisms of mammary cancer chemoprevention by organoselenium compounds.
2004 Mutation research - Selenium as an element in the treatment of ovarian cancer in women receiving chemotherapy.
2004 Gynecologic oncology - Environmental hypothesis: is poor dietary Selenium intake an underlying factor for arsenicosis and cancer in Bangladesh and West Bengal, India?
2004 The Science of the total environment - Selenium metabolism, selenoproteins and mechanisms of cancer prevention: complexities with thioredoxin reductase.
1999 Carcinogenesis - Effect of Selenium on the immunocompetence of patients with head and neck cancerand on adoptive immunotherapy of early and established lesions.
2001 BioFactors (Oxford, England) - [The prevention of primary liver cancer by Selenium in high risk populations].
2000 Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine] - Serum Selenium and the risk of cervical cancer among women in the United States.
2002 Cancer causes & control : CCC - Osteopontin is a potential target gene in mouse mammary cancer chemoprevention by Se-methylselenocysteine.
2004 Breast cancer research : BCR - Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair.
2007 Molecular cancer therapeutics - Selenium activates p53 and p38 pathways and induces caspase-independent cell death in cervical cancer cells.
2008 Cell biology and toxicology - [Preventive effects of 4 Se-enriched plants on rat stomach cancer induced by MNNG 2. Safety of different Selenium resources for prevention of stomach cancer].
2008 Wei sheng yan jiu = Journal of hygiene research - Uptake, Distribution, and Speciation of Selenoamino Acids by Human cancer Cells: X-ray Absorption and Fluorescence Methods.
2011 Biochemistry - A Lowering of Breast and Ovarian cancer Risk in Women with a BRCA1 Mutation bySelenium Supplementation of Diet.
2006 Hereditary cancer in clinical practice - SelSA, Selenium analogs of SAHA as potent histone deacetylase inhibitors.
2010 Bioorganic & medicinal chemistry letters - Differential effects of Selenium on benign and malignant prostate epithelial cells: stimulation of LNCaP cell growth by noncytotoxic, low selenite concentrations.
2009 Nutrition and cancer - Kinase Regulation by Sulfur and Selenium Containing Compounds.
2011 Current cancer drug targets - Protein kinase C as a molecular target for cancer prevention by selenocompounds.
2001 Nutrition and cancer - Serum antioxidants and skin cancer risk: an 8-year community-based follow-up study.
2009 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Dynamics of antioxidants in patients with acute pancreatitis and in patients operated for colorectal cancer: a clinical study.
2005 Nutrition (Burbank, Los Angeles County, Calif.) - Selenium and inhibition of disease progression in men diagnosed with prostate carcinoma: study design and baseline characteristics of the ‘Watchful Waiting’ Study.
2003 Anti-cancer drugs - Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model.
2006 Proceedings of the National Academy of Sciences of the United States of America - Selenoprotein expression is regulated at multiple levels in prostate cells.
2006 Cell research
Studies on Selenium and prostate cancer
http://science.naturalnews.com/S/selenium_and_prostate_cancer.html
Studies on Selenium and colon cancer
http://science.naturalnews.com/S/selenium_and_colon_cancer.html
Studies on Selenium and breast cancer
http://science.naturalnews.com/S/selenium_and_breast_cancer.html
Studies on Selenium and Gastric cancer – Natural News Science
Studies on Selenium and Anti-Tumor
http://science.naturalnews.com/S/selenium_and_Anti-Tumor.html
Studies on Selenium and Anti-Angiogenic
http://science.naturalnews.com/S/selenium_and_Anti-Angiogenic.html
Studies on Selenium and Apoptotic
Studies on Selenium and Chemotherapeutic
http://science.naturalnews.com/S/selenium_and_Chemotherapeutic.html
There is also an extensive bibliography on Selenium (see last page of DATABASE) :
79,108,112,129,133,136,143,156,228,229,276,338,339,364,367,404,405,407,443,452,458,501,510,511)
ZINC
Zinc acts as a membrane stabiliser, and also as a thymic factor (581).
It is therefore important for the production of T lymphocytes.
With low Zinc content, the working of the fagocytes, cell immunity, antibody immunity and the whole Immune Cascade is reduced (582).
Working together with vitamin E, it inhibits the production of inflammatory prostoglandins and leucotriens.
It is also a component of Superoxide Dismutasis (SOD) and takes part in over 200 known enzymatic reactions, of which many are anti-oxidative and repair DNA.
Organic Zinc is necessary for Laetrile therapy (vitamin B17).
For more details about Zinc and natural sources see this article Zinc (click here)
for studies cited above see last page of database.
Studies on Zinc and cancer
- Profiling of zinc-altered gene expression in human prostate normal vs. cancer cells: a time course study.
2009 The Journal of nutritional biochemistry - Zinc salts differentially modulate DNA damage in normal and cancer cells.
2009 Cell biology international - Zinc deficiency reduces paclitaxel efficacy in LNCaP prostate cancer cells.
2007 Cancer letters - Prevention of upper aerodigestive tract cancer in zinc-deficient rodents: inefficacy of genetic or pharmacological disruption of COX-2.
2008 International journal of cancer. Journal international du cancer - Prostate cancer in African American men is associated with downregulation of Zinctransporters.
2003 Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry - Dietary Zinc and prostate cancer in the TRAMP mouse model.
2010 Journal of medicinal food - The role of survivin and Bcl-2 in zinc-induced apoptosis in prostate cancer cells.
2010 Urologic oncology - Diverse effects of Zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.
2006 Carcinogenesis - Regulation of Zinc transporters by dietary Zinc supplement in breast cancer.
2007 Molecular biology reports - An ecological study of cancer mortality rates including indices for dietary iron and zinc.
2008 Anticancer research - Zinc in cancer prevention.
2009 Nutrition and cancer - Direct intra-tumoral injection of zinc-acetate halts tumor growth in a xenograft model of prostate cancer.
2009 Journal of experimental & clinical cancer research : CR - Evidence for a Zinc uptake transporter in human prostate cancer cells which is regulated by prolactin and testosterone.
1999 The Journal of biological chemistry - Cutaneous bleeding related to Zinc deficiency in two cases of advanced cancer.
1999 Cancer - Zinc intake from supplements and diet and prostate cancer.
2009 Nutrition and cancer - Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells.
2007 Cancer science - hZIP1 Zinc uptake transporter down regulation and Zinc depletion in prostate cancer.
2005 Molecular cancer - Aberrant expression of Zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression.
2007 Proceedings of the National Academy of Sciences of the United States of America - Motexafin gadolinium disrupts Zinc metabolism in human cancer cell lines.
2005 Cancer research - Zinc deficiency, DNA damage and cancer risk.
2004 The Journal of nutritional biochemistry - Nail molybdenum and Zinc contents in populations with low and moderate incidence of esophageal cancer.
2008 Archives of Iranian medicine - ZIP14 Zinc Transporter Downregulation and Zinc Depletion in the Development and Progression of Hepatocellular Cancer.
2011 Journal of gastrointestinal cancer - Dietary Zinc and prostate cancer survival in a Swedish cohort.
2011 The American journal of clinical nutrition - Zinc and prostatic cancer.
2009 Current opinion in clinical nutrition and metabolic care - Zinc as an anti-tumor agent in prostate cancer and in other cancers.
2007 Archives of biochemistry and biophysics - Zinc concentration in esophageal biopsy specimens measured by x-ray fluorescence and esophageal cancer risk.
2005 Journal of the National cancer Institute - Zinc: a promising agent in dietary chemoprevention of cancer.
2010 The Indian journal of medical research - Zinc supplement use and risk of prostate cancer.
2003 Journal of the National cancer Institute - Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of Zinc transporters.
2003 The Biochemical journal - Zinc and Zinc transporters in normal prostate and the pathogenesis of prostate cancer.
2005 Frontiers in bioscience : a journal and virtual library - Heme iron, Zinc and upper digestive tract cancer: the Iowa Women’s Health Study.
2005 International journal of cancer. Journal international du cancer - Association of vitamin A, vitamin C and Zinc with laryngeal cancer.
2003 Indian journal of cancer - Zinc finger protein 278, a potential oncogene in human colorectal cancer.
2008 Acta biochimica et biophysica Sinica - A novel imaging approach for early detection of prostate cancer based on endogenous Zinc sensing.
2010 Cancer research - Clinical assessment of the cancer diagnostic value of prostatic zinc: a comprehensive needle-biopsy study.
2008 The Prostate - Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality.2006 Epidemiology (Cambridge, Mass.)
- LNCaP prostate cancer cells are insensitive to zinc-induced senescence.
2008 Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) - Inhibition of aminopeptidase N (AP-N) and urokinase-type plasminogen activator (uPA) by Zinc suppresses the invasion activity in human urological cancer cells.
2001 Biological & pharmaceutical bulletin - Modern diets and diseases: NO-zinc balance. Under Th1, Zinc and nitrogen monoxide (NO) collectively protect against viruses, AIDS, autoimmunity, diabetes, allergies, asthma, infectious diseases, atherosclerosis and cancer.
1999 Medical hypotheses - Effect of Zinc on regulation of insulin-like growth factor signaling in human androgen-independent prostate cancer cells.
2010 Clinica chimica acta; international journal of clinical chemistry - [Effect of selenium and Zinc on the proliferation of human esophageal cancer Eca109 cell line in vitro].
2008 Nan fang yi ke da xue xue bao = Journal of Southern Medical University - ZIP7-mediated intracellular Zinc transport contributes to aberrant growth factor signaling in antihormone-resistant breast cancer Cells.
2008 Endocrinology - Heme iron, zinc, alcohol consumption, and colon cancer: Iowa Women’s Health Study.
2004 Journal of the National cancer Institute - The effects of oral Zinc sulphate during radiotherapy on anti-oxidant enzyme activities in patients with head and neck cancer: a prospective, randomised, placebo-controlled study.
2004 International journal of clinical practice - Extracellular Zinc stimulates ERK-dependent activation of p21(Cip/WAF1) and inhibits proliferation of colorectal cancer cells.
2002 British journal of pharmacology - Extracellular Zinc stimulates ERK-dependent activation of p21(Cip/WAF1) and inhibits proliferation of colorectal cancer cells.
2002 British journal of pharmacology - Regulation of Zinc transporters by dietary flaxseed lignan in human breast cancerxenografts.
2008 Molecular biology reports - Dietary iron, zinc, and calcium and the risk of lung cancer.
2005 Epidemiology (Cambridge, Mass.) - Interaction among heme iron, zinc, and supplemental vitamin C intake on the risk of lung cancer: Iowa Women’s Health Study.
2005 Nutrition and cancer - Dietary zinc, copper and selenium, and risk of lung cancer.
2007 International journal of cancer. Journal international du cancer - The emerging role of the LIV-1 subfamily of Zinc transporters in breast cancer.
2007 Molecular medicine (Cambridge, Mass.) - Expression of the Zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer.
2003 Oncogene - Serum iron, copper and Zinc concentrations and risk of cancer mortality in US adults.
2004 Annals of epidemiology - Selenium, copper, and Zinc concentrations in intestinal cancer tissue and in colon and rectum polyps.
2003 Biological trace element research - Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: Potential implication for prostate cancer therapy.
2011 The Prostate - Zinc transporters and cancer: a potential role for ZIP7 as a hub for tyrosine kinase activation.
2009 Trends in molecular medicine - Depletion of intracellular Zinc increases expression of tumorigenic cytokines VEGF, IL-6 and IL-8 in prostate cancer cells via NF-kappaB-dependent pathway.
2008 The Prostate - Evolutionary conservation of Zinc finger transcription factor binding sites in promoters of genes co-expressed with WT1 in prostate cancer.
2008 BMC genomics - Antiproliferative and apoptotic effects of zinc-citrate compound (CIZAR(R)) on human epithelial ovarian cancer cell line, OVCAR-3.
2006 Gynecologic oncology - In vitro toxicity testing of Zinc tetrasulfophthalocyanines in fibroblast and keratinocyte cells for the treatment of melanoma cancer by photodynamic therapy.
2011 Journal of photochemistry and photobiology. B, Biology - The pilot trial of the prevention of the increase in electrical taste thresholds by Zinccontaining fluid infusion during chemotherapy to treat primary lung cancer.
2003 Journal of experimental & clinical cancer research : CR - Measurement of serum Zinc improves prostate cancer detection efficiency in patients with PSA levels between 4 ng/mL and 10 ng/mL.
2005 Asian journal of andrology - Zinc depletion efficiently inhibits pancreatic cancer cell growth by increasing the ratio of antiproliferative/proliferative genes.
2008 Journal of cellular biochemistry - Cancer-associated mutations in the MDM2 Zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
2007 Molecular and cellular biology - Genetic polymorphisms in the Rb-binding Zinc finger gene RIZ and the risk of lung cancer.
2007 Carcinogenesis - The Zinc finger domain of Wilms’ tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancercells.
2007 Breast cancer research : BCR - Increased Zinc finger protein zFOC1 transcripts in gastric cancer compared with normal gastric tissue.
2003 Molecular pathology : MP - Serum and tissue levels of six trace elements and copper/zinc ratio in patients with cervical cancer and uterine myoma.
2003 Biological trace element research - Stable expression of C/EBPalpha in prostate cancer cells down-regulates metallothionein and increases zinc-induced toxicity.
2005 The Prostate - ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through Zinc finger transcription factor CREB.
2010 Clinical cancer research : an official journal of the American Association forcancer Research - Regulatory role of Zinc on the biokinetics and biodistribution of (65)zn during the initiation of experimentally induced colon cancer.
2011 Nutrition and cancer - The important role of the apoptotic effects of Zinc in the development of cancers.
2009 Journal of cellular biochemistry - High cadmium / Zinc ratio in cigarette smokers: potential implications as a biomarker of risk of prostate cancer.
2008 Nigerian journal of physiological sciences : official publication of the Physiological Society of Nigeria - Zinc is decreased in prostate cancer: an established relationship of prostate cancer!
2011 Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry - Soil Zinc content, groundwater usage, and prostate cancer incidence in South Carolina.
2009 Cancer causes & control : CCC - A distinct role in breast cancer for two LIV-1 family Zinc transporters.
2008 Biochemical Society transactions - Evolutionary divergence in the broad complex, tramtrack and bric à brac/poxviruses and Zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer.
1999 FEBS letters - Induction of apoptosis and necrosis by Zinc in human thyroid cancer cell lines.
2001 The Journal of endocrinology - Role of Zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve.
2004 Prostate cancer and prostatic diseases - Effects of selenium and Zinc supplementation on nutritional status in patients withcancer of digestive tract.
2001 European journal of clinical nutrition - Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein.
1999 Journal of the National cancer Institute - Aminopeptidase N regulated by Zinc in human prostate participates in tumor cell invasion.
2001 International journal of cancer. Journal international du cancer - Zinc inhibits nuclear factor-kappa B activation and sensitizes prostate cancer cells to cytotoxic agents.
2002 Clinical cancer research : an official journal of the American Association forcancer Research - IGF-1 induces expression of zinc-finger protein 143 in colon cancer cells through phosphatidylinositide 3-kinase and reactive oxygen species.
2010 Experimental & molecular medicine - Function of the zinc-finger transcription factor SNAI2 in cancer and development.
2007 Annual review of genetics - Role of p53 and reactive oxygen species in apoptotic response to copper and Zinc in epithelial breast cancer cells.
2005 Apoptosis : an international journal on programmed cell death - The RNA-binding zinc-finger protein tristetraprolin regulates AU-rich mRNAs involved in breast cancer-related processes.
2010 Oncogene - Regulation of metallothionein and Zinc transporter expression in human prostatecancer cells and tissues.
2003 Cancer letters - Regulation of metallothionein and Zinc transporter expression in human prostatecancer cells and tissues.
2003 Cancer letters - Serum copper/zinc superoxide dismutase (Cu/Zn SOD) and gastric cancer risk: a case-control study.
2002 Japanese journal of cancer research : Gann - Role of Zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator.
2004 Biochemical pharmacology - The SLUG zinc-finger protein represses E-cadherin in breast cancer.
2002 Cancer research - Levels of zinc, selenium, calcium, and iron in benign breast tissue and risk of subsequent breast cancer.
2007 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Consequences of radiotherapy on nutritional status, dietary intake, serum Zinc and copper levels in patients with gastrointestinal tract and head and neck cancer.
2007 Saudi medical journal - Cytotoxic effects of intra and extracellular Zinc chelation on human breast cancercells.
2007 European journal of pharmacology - Effect of oral Zinc supplementation on agents of oropharyngeal infection in patients receiving radiotherapy for head and neck cancer.
2003 The Journal of international medical research - Zinc stabilizes adenomatous polyposis coli (APC) protein levels and induces cell cycle arrest in colon cancer cells.
2004 Journal of cellular biochemistry - Investigation of Zinc bis(1,4-didecylbenzo)-bis(2,3-pyrido) Porphyrazine for Application as Photosensitizer in Photodynamic Therapy of Cancer.
2008 Metal-based drugs - Myeloid Zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer.
2010 Molecular cancer research : MCR - Evaluation of Zinc status in whole blood and scalp hair of female cancer patients.
2007 Clinica chimica acta; international journal of clinical chemistry - Amplification of Zinc finger gene 217 (ZNF217) and cancer: when good fingers go bad.
2007 Biochimica et biophysica acta - Modulation of telomerase activity by Zinc in human prostatic and renal cancer cells.
2000 Biochemical pharmacology - Alpha-difluoromethylornithine induction of apoptosis: a mechanism which reverses pre-established cell proliferation and cancer initiation in esophageal carcinogenesis in zinc-deficient rats.
2001 Cancer epidemiology, biomarkers & prevention : a publication of the American Association for cancer Research, cosponsored by the American Society of Preventive Oncology - Zinc alpha-2-glycoprotein is expressed by malignant prostatic epithelium and may serve as a potential serum marker for prostate cancer.
2001 Clinical cancer research : an official journal of the American Association forcancer Research - Systemic Zinc redistribution and dyshomeostasis in cancer cachexia.
2010 Journal of cachexia, sarcopenia and muscle - Serum copper and Zinc content in non-small cell lung cancer: abnormalities and clinical correlates.
1999 Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace / Fondazione clinica del lavoro, IRCCS [and] Istituto di clinica tisiologica e malattie apparato respiratorio, Università di Napoli, Secondo ateneo - Mutations in zinc-binding domains of p53 as a prognostic marker of esophageal-cancer patients.
2000 Japanese journal of cancer research : Gann - The Zinc finger protein ras-responsive element binding protein-1 is a coregulator of the androgen receptor: implications for the role of the Ras pathway in enhancing androgenic signaling in prostate cancer.
2007 Molecular endocrinology (Baltimore, Md.) - Restoring the metabolic disturbance of zinc: may not only contribute to the prevention of esophageal squamous cell cancer.
2008 Medical hypotheses - Zinc-binding compounds induce cancer cell death via distinct modes of action.
2008 Cancer letters - Expression of RIZ1 protein (Retinoblastoma-interacting zinc-finger protein 1) in prostate cancer epithelial cells changes with cancer grade progression and is modulated in vitro by DHT and E2.
2009 Journal of cellular physiology - Interaction of cadmium and Zinc in biological samples of smokers and chewing tobacco female mouth cancer patients.
2010 Journal of hazardous materials - Evaluation of cadmium and Zinc in biological samples of tobacco and alcohol user male mouth cancer patients.
2010 Human & experimental toxicology - The zinc-finger protein KCMF1 is overexpressed during pancreatic cancerdevelopment and downregulation of KCMF1 inhibits pancreatic cancer development in mice.
2010 Oncogene - Extracellular Zinc and zinc-citrate, acting through a putative zinc-sensing receptor, regulate growth and survival of prostate cancer cells.
2008 Carcinogenesis - hZIP1 Zinc transporter down-regulation in prostate cancer involves the overexpression of ras responsive element binding protein-1 (RREB-1).
2011 The Prostate - Transcriptional silencing of Zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression.
2003 Cancer research - Oxidase activity of ceruloplasmin and concentrations of copper and Zinc in serum ofcancer patients.
2001 Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) - [Expression and function of Zinc ribbon gene ZNRD1 in drug-resistant gastric cancercells].
2003 Zhonghua zhong liu za zhi [Chinese journal of oncology] - Differential modulation of zinc-stimulated p21(Cip/WAF1) and cyclin D1 induction by inhibition of PI3 kinase in HT-29 colorectal cancer cells.
2002 Experimental & molecular medicine - The Zinc finger protein OZF (ZNF146) is overexpressed in colorectal cancer.
2003 The Journal of pathology - The clinical value of the determinations in the serum of Zinc concentration in women with breast cancer.
2001 Folia histochemica et cytobiologica / Polish Academy of Sciences, Polish Histochemical and Cytochemical Society - Suppression of breast cancer by chemical modulation of vulnerable Zinc fingers in estrogen receptor.
2004 Nature medicine - Engineering Zinc finger protein transcription factors to downregulate the epithelial glycoprotein-2 promoter as a novel anti-cancer treatment.
2007 Molecular carcinogenesis - Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancerfollowing radical prostatectomy.
2006 Journal of the National cancer Institute - Overexpression of manganese or copper-zinc superoxide dismutase inhibits breastcancer growth.
2006 Free radical biology & medicine - Expression levels of the putative Zinc transporter LIV-1 are associated with a better outcome of breast cancer patients.
2005 International journal of cancer. Journal international du cancer - Zinc phthalocyanine/magnetic fluid complex: a promising dual nanostructured system for cancer treatment.
2006 Journal of nanoscience and nanotechnology - Calretinin gene promoter activity is differently regulated in neurons and cancer cells. Role of AP2-like cis element and Zinc ions.
2004 Biochimica et biophysica acta - Zinc and metallothioneins in cancer.
2003 Annales Universitatis Mariae Curie-Sklodowska. Sectio D: Medicina - Novel cancer antiangiotherapy using the VEGF promoter-targeted artificial zinc-finger protein and oncolytic adenovirus.
2008 Molecular therapy : the journal of the American Society of Gene Therapy - The comparative study of serum iron, copper, and Zinc levels between bladder cancerpatients and a control group.
2010 International urology and nephrology - Changes in protein tyrosine phosphatase type IVA member 1 and Zinc finger protein 36 C3H type-like 1 expression demonstrate altered estrogen and progestin effect in medroxyprogesterone acetate-resistant and estrogen-independent breast cancer cell models.
2009 Steroids - Transcriptional regulation of the major Zinc uptake protein hZip1 in prostate cancercells.
2009 Gene - Overexpression of the Zinc uptake transporter hZIP1 inhibits nuclear factor-kappaB and reduces the malignant potential of prostate cancer cells in vitro and in vivo.
2008 Clinical cancer research : an official journal of the American Association forcancer Research - Metallothionein expression and Zinc levels in invasive ductal breast carcinoma.
1999 Oncology reports - Characterization of a zinc-finger protein and its association with apoptosis in prostatecancer cells.
2000 Journal of the National cancer Institute - Prognostic significance of mutations in the p53 gene, particularly in the zinc-binding domains, in lymph node- and steroid receptor positive breast cancer patients. Austrian Breast cancer Study Group.
1999 European journal of cancer (Oxford, England : 1990) - Polyphenolic profile and antiproliferative activity of bioaccessible fractions of zinc-fortified fruit beverages in human colon cancer cell lines.
2010 Nutrición hospitalaria : organo oficial de la Sociedad Española de Nutrición Parenteral y Enteral - The role of glucocorticoids in the induction of zinc-alpha2-glycoprotein expression in adipose tissue in cancer cachexia.
2005 British journal of cancer - Identification and expression analysis of a novel CW-type Zinc finger protein MORC2 incancer cells.
2010 Anatomical record (Hoboken, N.J. : 2007) - Zinc-finger protein ZNF165 is a novel cancer-testis antigen capable of eliciting antibody response in hepatocellular carcinoma patients.
2004 British journal of cancer - Zinc transporter LIV-1: a link between cellular development and cancer progression.
2004 Trends in endocrinology and metabolism: TEM - Reactive oxygen species modulate Zn(2+)-induced apoptosis in cancer cells.
2002 Free radical biology & medicine - Differential regulation of signal transduction pathways in wild type and mutated p53 breast cancer epithelial cells by copper and zinc.
2004 Archives of biochemistry and biophysics - Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia.
2004 Proceedings of the National Academy of Sciences of the United States of America - Inhibition of heme oxygenase-1 by Zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL mice.
2007 International journal of cancer. Journal international du cancer - Toenail Zinc level and gastric cancer risk in Cali, Colombia.
2008 Journal of cancer research and clinical oncology - Zinc concentrations in serum during head and neck cancer progression.
2007 Anticancer research - Zinc induced apoptosis in HEP-2 cancer cells: the role of oxidative stress and mitochondria.
2005 BioFactors (Oxford, England) - Differential expression of manganese superoxide dismutase, copper/zinc superoxide dismutase, and catalase in gastric adenocarcinoma and normal gastric mucosa.
2007 European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - Evaluation of Zinc-alpha-2-Glycoprotein and Proteasome Subunit beta-Type 6 Expression in Prostate cancer Using Tissue Microarray Technology.
2010 Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry - Mechanisms of growth arrest by Zinc ribbon domain-containing 1 in gastric cancercells.
2007 Carcinogenesis - Dietary Zinc and prostate cancer risk: a case-control study from Italy.
2007 European urology - Does Zinc sulfate prevent therapy-induced taste alterations in head and neck cancerpatients? Results of phase III double-blind, placebo-controlled trial from the North Central cancer Treatment Group (N01C4).
2007 International journal of radiation oncology, biology, physics - Integrative genomic analyses on Ikaros and its expression related to solid cancerprognosis.
2010 Oncology reports - Preparation of magnetic and bioactive calcium Zinc iron silicon oxide composite for hyperthermia treatment of bone cancer and repair of bone defects.
2011 Journal of materials science. Materials in medicine - Dietary Zinc intake and brain cancer in adults: a case-control study.
2008 The British journal of nutrition - Dietary Zinc modulation of COX-2 expression and lingual and esophageal carcinogenesis in rats.
2005 Journal of the National cancer Institute - Copper, Zinc and superoxide dismutase in precancerous, benign diseases and gastric, colorectal and breast cancer.
1999 Neoplasma - Down-regulation of promoter 1.3 activity of the human aromatase gene in breast tissue by zinc-finger protein, snail (SnaH).
2001 Cancer research - Zinc deficiency potentiates induction and progression of lingual and esophageal tumors in p53-deficient mice.
2006 Carcinogenesis - Evaluation of distribution patterns for copper and Zinc in metallothionein and superoxide dismutase in chronic liver diseases and hepatocellular carcinoma using high-performance liquid chromatography (HPLC).
2005 Biological & pharmaceutical bulletin - The value of serum zinc, copper, ceruloplasmin levels in patients with gastrointestinal tract cancers.
2005 The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology - Overexpression of insulin-like growth factor II (IGFII) in ZR-75-1 human breast cancercells: higher threshold levels of receptor (IGFIR) are required for a proliferative response than for effects on specific gene expression.
1999 Cell proliferation - The retinoblastoma protein-interacting Zinc finger gene RIZ in 1p36-linked cancers.
1999 Frontiers in bioscience : a journal and virtual library - [Study on mortality by specific cause among workers at a lead and Zinc foundry in Sardinia].
2005 Giornale italiano di medicina del lavoro ed ergonomia - Comparative transcriptional study of the effects of high intracellular Zinc on prostate carcinoma cells.
2010 Oncology reports - An evaluation study of trace element content in colorectal liver metastases and surrounding normal livers by X-ray fluorescence.
2008 Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine
Studies on Zinc and Anti-Tumor
http://science.naturalnews.com/Z/Zinc_and_Anti-Tumor.html
Studies on Zinc and Radioprotective
http://science.naturalnews.com/Z/Zinc_and_Radioprotective.html
Studies on Zinc and Antineoplastic
http://science.naturalnews.com/Z/Zinc_and_Antineoplastic.html
Studies on Zinc and Antiproliferative
http://science.naturalnews.com/Z/Zinc_and_Antiproliferative.html
Studies on Zinc and Anti-Angiogenic
http://science.naturalnews.com/Z/Zinc_and_Anti-Angiogenic.html
Studies on Zinc and Apoptotic
http://science.naturalnews.com/Z/Zinc_and_Apoptotic.html
NEXT PAGE>>
SHARE, LIKE or Leave a COMMENT- BUTTONS below!
for studies cited above see last page of database.
Pingback: CESIUM | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: CALCIUM | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: Natural News Blogs ALTERNATIVE, COMPLEMENTARY and INTEGRATIVE cancer treatments » Natural News Blogs
Pingback: Un an de tratamente ANTIcancer | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: Dirt Cheap Protocol | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: Micsorarea tumorilor | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: introducere baza de date studii | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: Studii despre ineficienta tratamentelor conventionale anti cancer – operatie, chimioterapie, radioterapie, raditii – otrava toxica pentru pacienti (s) | CE-I CU NOI? – un blog educativ despre comportamentul uman
Pingback: Cancerul de prostata | TRATAMENTE CANCER EFICIENTE, NON - toxice
Pingback: Cancer, Metastasis, and Cancer Stem Cells | TRATAMENTE CANCER EFICIENTE, NON - toxice
Ar trebui un echilibru in sistematizare. Apoi ar trebui sa se vada principiile sistematizarii. Cu un pic de efort se poate ajunge la mai multa claritate. Pana acum treaba este foarte buna. As putea da si eu un modest ajutor.
ar trebui insa vand in vedere indiferenta (nepasarea) celor pentru care am prezentat aceste studii este foarte in regula(sunt aci studiisi trimiteri referitoare mla multe tratamente alternative- si cu PRO si CONTRA unde este cazul).Daca puteti contribui cu ceva nou, va invit
Degeaba scriu comentarii pe acest site, ele nu ajung aici. Tipul asta nu are nici cea mai vaga idee in legatura cu cancerul si care este cauza acestuia. Din fericire mai sunt persoane care prima data verifica informatiile apoi trag concluziile CORECTE.
De telenovele si sute de informatii fara relevanta nu are nevoie un bolnav de cancer.
Frate Ciprian,
Te rog scuza pe fratele tau Cristian( e mai prost asa- asa m-a lasat Dumnezeu, ce sa-i faci; intr-un comentariu anterior parca scriai ca :” Ai facut o munca titanica care merita respectul semenilor tai. Felicitari pt blog!” – ce sa mai inteleaga omul de la unul care are pareri azi asa si maine pe dos?!) .
Te rog impartaseste-ne si noua din concluziile tale CORECTE si cati bolnavi de cancer au ajutat aceste concluzii CORECTE.
Te rog lumineaza-ne si pe noi, nu ne lasa sa ne uitam la „telenovele si sute de informatii fara relevanta”.
Te rog sa o faci cu dovezi si rezultate, asa cum sunt citate in aceste ‘telenovele de pe aceasta pagina”, cu studii clinice si cazuri vindecate sau ajutate pe care le cunosti, asa cum am pus si eu cateva aici(cu analize si RMNuri inainte si dupa tratament etc) :
https://tratamenteanticancer.wordpress.com/vindec-cancer/
Asteptam cu totii sa ne impartasesti din concluziile tale CORECTE care sa ne lumineze sa nu mai ne piedem vremea cu telenovele-„Tratamentul cu clorura de cesiu a atins o rată de vindecare de 50% la pacienții cu cancer foarte avansat, din care unii erau deja în comă. 47 din cei 50 de pacienti au fost „fără speranță”, iar unii au avut doar câteva zile ramase trăit .” si asta in urma unor cazuri clinice . Daca asta e ‘nici cea mai vaga idee legat de cancer’ , asteptam cu mare interes de la tine sa ne arati metode cu mult mai puternice si concluziile CORECTE!!!
Doamne ajuta!
TE ROG IARTA-MA – M-AM ENERVAT . TE ROG SA NU IMI MAI DAI MOTIVE SA MA ENERVEZ PE VIITOR.
Ok. Din pacate, acum nu pot scrie romane sau telenovele, dar o sa revin cu detalii mai multe pe viitor. O sa sintetizez in putine fraze care este din punctul meu de vedere tratamentul adecvat impotriva cancerului.
(Cancerul, ca si „boala”, este produs de candida albicans, un fung/o ciuperca saprofita, adaptabila, mutagena, care in conditii de dereglare a florei intestinale, cauzata de folosirea de antibiotice, expunerea la clor(in special cel din piscine), alcool, folosirea unor medicamente ca prednison, cortizon, pastile hormonale/contraceptive, expunerea la pesticide, lucrul sau traiul intr-un mediu cu igrasie/mucegai, si folosirea unei diete promotoare de fungi cum ar fi consumul excesiv de lapte, paine, ciocolata, alcool, zahar, otet, branza, muraturi, alune, arahide, cafea, mere, banane, struguri.
Simtomele unei infectii cu candida(cea care cauzeaza cancerul in opinia mea) sunt:
-pofta excesiva dupa zahar, paine, lapte, branza, otet, ciocolata, alcool
-probleme cu somnul-insomnii(trezirea alerta in special intre orele 1-3 noaptea, precum si trezirile „din ora in ora”
-anxietate, atacuri de panica, frica/groaza
-reflux gastric (GERD)
-migrene, dureri de cap
-hypoglicemie
-depresie
-astm sau alergii
-dureri abdominale, flatulenta
-dureri articulare sau musculare
-sindrom premenstrual(PMS)
-durere pelvica cronica(endometrioza)
-probleme sexuale(lipsa dorintei de a face sex sau sexualitate excesiva)
-diabet
-constipatie sau diaree
-probleme ale pielii (eczeme, psoriasis)
-infectii recurente -la urechi, sinuzite, candidoze vaginale
-maini, nas, picioare reci (mai tot timpul)
-boli autoimune
-deficit de atentie sau hiperactivitate
-confuzie, iritabilitate
-batai neregulate ale inimii
-probleme cu memoria
– inconfortabilitate la orice temperatura
-ameteli
-nu te simti ok „in pielea ta”
-indecisivitate, dificultati de organizare sau de a face curat in zone murdare
-abdomen marit(„burta de bere”)
-colesterol crescut
O persoana care regaseste 3 sau mai multe simptome prezentate mai sus sufera de o infectie fungica acuta, care, in conditii propice se va dezvolta in cancer.
Ca si o paranteza, un pas in aparitia cancerului il are secretia de estrogen in locurile din organism unde sunt prezente leziuni(interne sau externe) mai bine spus locuri cu necroze(tesut mort) la care secretia de estrogen are rol de vindecare al zonei respective. Ciuperca, prin fluxul sanguin(scapa din intestine datorita faptului ca a ajuns sa se dezvolte intr-un numar prea mare), ajunge sa se localizeze pe tesutul necrozat care urmeaza a fi vindecat si atunci devine adaptabila, mutagena.
Va ajunge sa elibereze toxine periculoase in urma procesului de hranire, toxine care vor incapacita, infecta macrofagele(neutrofilele, eosinofilele-principalele celule albe de aparare) care au ca scop distrugerea agentului patogen, de acolo rezultand tumorile, care nu sunt altceva decat incercarea disperata a organismului nostru de a ne tine in viata.
Pt cei ce vor sa citeasca : https://en.wikipedia.org/wiki/Granuloma
„Granuloma is an inflammation found in many diseases. It is a collection of immune cells known as histiocytes (macrophages).[1] Granulomas form when the immune system attempts to wall off substances it perceives as foreign but is unable to eliminate. Such substances include infectious organisms including bacteria and fungi, as well as other materials such as keratin and suture fragments.[1][2][3][4].
………………..
Macrophages (specifically histiocytes) are the cells that define a granuloma. They often, but not invariably, fuse to form multinucleated giant cells (Langhans giant cell).[6] The macrophages in granulomas are often referred to as „epithelioid”. This term refers to the vague resemblance of these macrophages to epithelial cells. Epithelioid macrophages differ from ordinary macrophages in that they have elongated nuclei that often resemble the sole of a slipper or shoe. They also have larger nuclei than ordinary macrophages and their cytoplasm is typically more pink when stained with eosin. These changes are thought to be a consequence of „activation” of the macrophage by the offending antigen.
The other key term in the above definition is the word „organized” that refers to a tight, ball-like formation. The macrophages in these formations are typically so tightly clustered that the borders of individual cells are difficult to appreciate. Loosely dispersed macrophages are not considered to be granulomas.
All granulomas, regardless of cause, may contain additional cells and matrix. These include lymphocytes, neutrophils, eosinophils, multinucleated giant cells, fibroblasts and collagen (fibrosis). The additional cells are sometimes a clue to the cause of the granuloma. For example, granulomas with numerous eosinophils may be a clue to coccidioidomycosis or allergic bronchopulmonary fungal disease, and granulomas with numerous neutrophils suggest blastomycosis, granulomatosis with polyangiitis, aspiration pneumonia or cat-scratch disease.
In terms of the underlying cause, the difference between granulomas and other types of inflammation is that granulomas form in response to antigens that are resistant to „first-responder” inflammatory cells such as neutrophils and eosinophils. The antigen causing the formation of a granuloma is most often an infectious pathogen or a substance foreign to the body, but sometimes the offending antigen is unknown (as in sarcoidosis).[citation needed]”
1. Schimbarea dietei si excluderea unor alimente „daunatoare” pt bolnavul de cancer, din care amintesc:
– produsele care contin malt(inclusiv maltodextrin), otetul(in special cel balsamic si toate produsele care contin otet, aici incluzand si mustarul si ketchupul)), ciocolata(in special ciocolata neagra), muraturile(sau produsele murate), alcoolul(in special vinul rosu, berea, vodka precum si berea nealcoolica), branza invechita(cheddar, swiss, parmezan, in general branzeturile cu o aroma foarte puternica; permise sunt mozzarela, ricotta, branza feta[cele proaspete si ambalate cu zer, fara adaosuri de otet]
-de asemenea sunt interzise sosul de soia si alte produse care contin soia.
– fructoza si bauturile care contin fructoza.
-uleiurile, exceptie face uleiul de masline si cel de in.
-sosul Worcestershire.
Odata cu schimbarea dietei vor urma 3 pasi care au menirea de a detoxifia ficatul, de a distruge candida precum si sporii.
Voi reveni cu cei 3 pasi in curand(acum timpul meu este limitat).
Ciprian , mai multi cercetatori au identificat un microorganism PLEOMORF(insemnand care isi schimba forma functie de PHul mediului in care traieste dar si functie de IMUNITATEA organismului -https://tratamenteanticancer.wordpress.com/2013/11/16/alkalinity-cancer-mcrorbes-advanced-cancer-theory/):
https://tratamenteanticancer.wordpress.com/2013/11/08/cancer-fungus-the-link-between-the-microbe-and-cancer/
Dupa cum vezi multi cercetatori au observat ca este un microorganism in fiecare celula de cancer (microorganism care ii modifica si metabolismul si ADNul , fermenteaza glucoza, impiedica oxigenul sa intre in celula, formeaza colonii si face multe altele-vei intelege mai bine sper daca vei citi despre cauzele cancerului:https://tratamenteanticancer.wordpress.com/cauze-cancer-demonstrate-adevarate-primar-secundar/) insa initial acesti cercetari nu au putut preciza exact CARE este acest microorganism (poate pentru ca functie de PH isi modifica forma si dimensiunea putand fi cand drojdie cand bacterie cand fungus/miceliu/ciuperca ca si stare si la fel de mic ca un virus sau la fel de mare ca o celula rosie sange ca si dimensiune-cu cat mai scazut PHul mediului cu atat mai mare dimensiunea microorganismului https://tratamenteanticancer.files.wordpress.com/2013/11/naessens.jpg

) si fiecare a presupus ca e fie o ciuperca fie un virus etc functie de ce a observat fiecare cu instrumentele lui si a incercat sa trateze functie de ce a observat( poate de aceea nu au avut succesul asteptat pentru ca unii poate au mers si poate inca merg pe abordarea tip : doar ce am descoperit si stiu eu e bun sau cel mai bun.)
insa odata cu dezvoltarea tehnicii si inventarea microscoapelor mai avansate precum somatoscopul , cercetatori precum prof Gaston Naessens au putut observa ca de fapt e vorba de un microorganism pleomorf pe care toti il avem si cand suntem sanatosi (sanatosi in sensul avem IMUNITATE si/sau eventual si un PH celular corect , cele 2 lucruri care il tin sub control si nu il lasa sa ia una din cele 13 forme daunatoare noua si sa produca eventual cancer si alte boli ) in 3 forme inactive, inofensive
Judecand dupa felul in care se dezvolta aceasta boala( in conditii de IMUNIATE drastic scazuta/suprimata si PH acid) , cum se raspandeste(exact cum se raspandesc microorganismele-mi se pare atat de absurda teoria medicinei alopate care sustine ca incep celulele si migreaza prin sange) , metabolism si cum se comporta(fermentarea zaharului in conditii anaerobe fiind caracteristica microorganismeleor inferioare ) etc eu instinctiv le dau dreptate si spun instinctiv din observatii asupra celor bolnavi dar si pentru ca eu NU am un laborator specializat acasa cu care sa verific ce au descoperit acesti oameni de stiinta (ei au descoperit si facut si nu eu) .Si atunci singurul fel in care pot eu proba validitatea este prin rezultate PRACTICE-studii clinice in care se aplica pe esantion bolnavi cancer aceste descoperiri si conseciintele lor si REZULTATELE acestor studii.
Si avem in aceste pagini astfel de STUDII si REZULTATE.
de exemplu, cancerul raspunde la terapii de PH inalt( ridicare brusca a PHului) precum cea cu clorura de cesiu:
“Tratamentul cu clorura de cesiu a atins o rată de vindecare de 50% la pacienții cu cancer foarte avansat, din care unii erau deja în comă. 47 din cei 50 de pacienti au fost “fără speranță”, iar unii au avut doar câteva zile ramase trăit .”
https://tratamenteanticancer.wordpress.com/2014/02/01/clorura-de-cesiu/
sau, cei ce merg pe MODULAREA IMUNITATII au rezultate – de exemplu cu tratamentul Issels, asa-numitii pacientii cu cancer incurabil au trait fără cancer vieți, unii până la 45 de ani, chiar și ca follow-up/dupa tratamentul alopat, rata de vindecare este la fel de mare ca 87%.
Citește mai statisticile lor oficiale confirmate prin studii :http://issels.com/statistics/
Deci faptul ca este un microorganism care poate avea si comportamentul si forma Candidei (dar NU numai acest comportament si forma) PRIMESC dar mai trebuie sa vii si cu dovezi-studii , cazuri concrete – asa numitele ‘telenovele’ -eu te astept cu drag – sper sa avem cu totii ceva benefic de invatat pentru binele trupesc al celor bolnavi
Te astept cu drag sa revii cu bunavointa, rabdare, smerenie si mai ales dragoste pentru cel bolnav(din asta deriva de fapt si toate restul) pentru cei bolnavi care din pacate chiar nu prea au timp.
despre comentariul trimis de tine astazi nu vreau sa mai pomenesc, cred ca stii mai bine de ce – repet doar rugamintea de data trecuta: te rog sa nu imi dai motive de suparare.
iti multumesc!
Doamne ajuta!
Faci cateva erori din pacate.
Cancerul se dezvolta fara grija si lejer si intr-un mediu bine alcalinizat, ba mai mult fungul respectiv isi si creaza PH-ul necesar prin sintetizarea amoniacului.
2 la mana, acel microorgonism pleomorf de care amintesti este o coiperca, pt ca ciupercile au aceasta caracteristica. Daca iti pui mintea la contributie si INTELEGI ca patogenul implicat in cancer is obtine ATP-ul(ENERGIA CELULARA) prin FERMENTATIE iti vei pune firesc intrebarea „ce microorganism este capabil de asa ceva?!”. Daca vrei sa continui pe acest drum te vei uita la ce toxine sunt in sangele unui bolnav de cancer(sunt peste 70), din care amintesc acetaldehyda(un compus al ETANOLULUI) si acidul lactic, ambele toxine fiind deosebit de periculoase prin faptul ca streseaza ficatul si il fac sa transforme aceste toxine in GLUCOZA. Iti amintesc de ciclul KREBS spre edificare, care din punctul meu de vedere este OK, dar incomplet(voit sau nu).
Acest ciclu duce la Casexie dupa cum bine sti. Bolnavul cu cancer avansat va muri de toxicitate si de malnutritie, pt ca ficatul nu isi mai poate face treaba asa cum trebuie. Pe rand vor ceda si celelalte organe, plamanii, inima, rinichii. Vor aparea pericardite, micotice in opinia mea (explicatia medicilor este abracadabranta „DIN CAUZA CANCERULUI), apa la plamani, posibile candidoze(binenteles ignorate pt ca lumea se focuseaza pe cancer nu pe altceva….)
Arunca o privire sau cauta pe google „systemic candididis” si ai sa vezi rata mortalitatii.
Arunca o privire la http://www.myrevelar.com/files/docs/science/Breath-gas-aldehydes-as-biomarkers-of-lung-cancer.pdf (daca este acetaldehyde in aerul expirat cu siguranta va fi gasit si in sange).
(Sunt la inceput de drum si nu am timp de toate, am familie si am responsabilitati, dar cacealmaua asta numita Oncologie trebuie sa se sparga odata si odata si voi face tot ce imi sta in putere sa le demolez teoriile de cacat, si voi incepe metodic si sistematic in a colecta dovezi in privinta asta(.
Daca mai vrei sa citesti legat de fermentatie arunca o privire la https://microbewiki.kenyon.edu/index.php/Yeast_Ethanol_Fermentation
Deci acetaldehydul este o toxina produsa de CIUPERCI, nu de virusi, bacterii misterioase sau extraterestrii. Una din putinele metode care functioneaza in a curata sangele toxic este VITAMINA C administrata intravenos in cantitati MARI. Linus Pauling a si primit premiul Nobel pt cercetarile in domeniul chimiei si a folosit cu success Vitamina C in tratarea sau ameliorarea sanatatii pacientilor.
Mai vreau sa ma leg si de biopsiile facute care sunt INCORECTE si needificatoare pt stabilirea si identificarea patogenului.Mostra trebuie luata de la nivelul CORIONULUI nu de sus de pe tumoare cu o intepatura, pt ca la biopsie nu se vor vedea decat niste celule anormale de aparare(eosinofile, neutrofile), modificate dpdv celular din cauza fuziunii dintre ele, scopul fuziunii fiind atacarea cu success a agentului patogen care se afla la nivelul CORIONULUI. Interpretarea lor va fi „cancer”, cand de fapt tumoarea este doar un simptom al cancerului, nu si cauza!
Uita-te cu atentie mare la ce se intampla aici: https://www.youtube.com/watch?v=PwqY99gNipE
Voi reveni ulterior si cu alte informatii, binenteles daca nu le vei bloca de la aparitie.
Inchei cu http://www.ru.nl/english/research/prizes-achievements/spinoza-prize-winners/2016/mihai-netea-new-idea-immunology/
Voi prezenta un articol deosebit de interesant legat de metodele de evadare a fungilor indreptate impotriva sistemului imunitar al oamenilor….asta, in curand.
Numai bine tuturor!
ok. nu cred ca ai citit ce ti-am trimis-acel microorganism pleomorf se poate si se comporta si ca o ciuperca la PHul adecvat.dar acel microorganism NU este o ciuperca
multumesc
nu le resping doar ca le trec printr-un filtru mai intai si poate dura – sper ca realizezi ca oamenii sunt foarte bolnavi si e o mare responsabilitate sa scrii despre acest subiect si nu poti posta chiar orice sau sa ii trimit dupa cai verzi pe pereti.de aceea te rog sa nu uiti de acele studii si dovezi.
mai important, apreciez intentia ta de a face lumina in acest domeniu insa as vrea sa iti spun din experienta mea sa ai grija sa nu ajung sa osandesti pacatosul in loc sa urasti pacatul din el si sa te mahnesti pentru el-respectiv ai gria sa nu iti umplii sufletul de ura pentru cei ‘farma’ in loc sa ii compatimesti-daca vrei sa primesti sfatul meu -eu asa ma gresit . Doamne ajuta!
Dr Otto Warburg a observat celulele canceroase este dificil de a supraviețui într-un mediu cu pH de 7,5 sau mai mare de 7,5(atentie- supravietuiesc in medii cu pH 7,5 bine mersi atat timp cat au ZAHAR sa-l fermenteze sau imunitatea e slabita) .:
https://tratamenteanticancer.wordpress.com/2016/10/25/32111/
. La un pH ușor peste 7.4 celulele canceroase devin latente și la un pH de 8,5 celulele canceroase vor muri în timp ce celulele sanatoase vor trăi . Potasiu , rubidiu,și în special Cesiu sunt luate mai eficient de celulele canceroase
de aceea terapiile ce ridica PUTERNIC si RAPID PHUl celular dau rezultate in cancer, asa cum e terapia cu cesiu dau rezultate.:https://tratamenteanticancer.wordpress.com/2014/02/01/clorura-de-cesiu/
VORBIM DE PH IN INTERIORUL CELULEI DE CANCER – celula cancer in interior e usor alcalina, asa cum ii place acestei ‘bacterii’, in exrerior e acida de la secretiile acide-‘micotoxine’ si acid lactic
exemplul cu cesiu este relevant si pentru PLEOMORFISMUL somatidelor-sper ca intelegi engleza(daca nu , voi traduce):
„We can look at any calcium or cesium (and possibly baking soda) to understand what is going on inside the cancer cells.
As calcium or cesium get inside the cancer cells, the alkalinity of the cancer cells increases.
If the calcium or cesium gets inside the cancer cells fast enough, it may kill all of the microbes inside the cancer cells and the cancer cells will revert into normal cells(as now nothing holds the cell hostage and prevents it from restoring it’s normal functions).
However, in some cases the microbes may be able to survive the highly alkaline substances. As the alkalinity inside the cells increases, the microbes may die or may go into hibernation (the „Somatid” state in the above chart).
This happens especially if the alkalinity does not occur fast enough
These pleomorphic cancer microbes do not like environments that are high in oxygen/high PH/high alkaline, thus do not spread in these environments.Some of them will die in these environments but some will just go back to somatid form(just as they exist in a healthy person)
When this microbe is in hibernation, it cannot be killed by anything!! This has actually been observed by several different cancer researchers (who, by the way, called this microbe by different names, such as „bion,” BX or „microzyma”)!!
In the book: The Persecution and Trial of Gaston Naessens is this quote:
„… over the years somatids were revealed to be virtually indestructible! They have resisted exposure to carbonization temperatures of 200 degree C and more. They have survived exposure to 50,000 rems of nuclear radiation, far more than enough to kill any living thing. They have been totally unaffected by any acid. Taken from centrifuge residues, they have been found impossible to cut with a diamond knife, so unbelievably impervious to any such attempts is their hardness.”
page 5
While not in the somatid state, the alkalinity inside of cells makes these microbes lethargic, which largely neutralizes the damage they are doing. These microbes damage the body and cancer cells in several ways, but in this context I am talking about the fact that they can force the cancer cell to replicate very quickly.
If the alkalinity does not occur fast enough, and thus does not kill these microbes, the microbes may eventually go into the somatid or hibernation state.
If these microbes go into hibernation, the cancer cells will be able to restore their metabolism and will appear to be normal cells!!! In other words, when in hibernation these microbes do not intercept glucose and do not excrete mycotoxins. So just like when these microbes are killed, the cancer cells revert into normal cells.
But in these cases the cells appear to be normal cells, and act as if they were normal cells, but in fact they are still cancer cells in the sense that there are still microbes inside the cells!!
When the person stops or changes their cancer treatment, and goes off of their alkaline cancer treatment, and goes back to their old acidic diet, eventually the inside of the cancer cells gets acidic and the microbes come out of hibernation and the cancer „returns” in the same location it was before!!
I personally know people in these situation, i.e.people that used Cesium for 3 months , the tumor was declared inactive, and, when going back to old habits & lifestyle, cancer returned in the same location.
Actually, the cancer cells never left, they simply „went into hibernation” because the microbes were in hibernation. When the microbes came out of hibernation they started intercepting glucose again and excreting mycotoxins again. The cells again acted as if it were cancerous.
This is a key sign as to what is happening, the cancer returns in exactly the same location it was before!!”
cunosc personal oameni care au aplicat terapii ridicare PH , tumorile au devenit inactive si au redevenit active dupa o vreme-se intampla in practica ca in teorie-schimbi PHul celulei isi schimba forma si dimensiunea si comportamentul aceste microorganisme dar nu vorbim de o bacterie in sine.
nota: majoritatea tratamentelor alternative cancer inclus si suplimente antifungale /antibacteriene si probiotice pentru ca s-au facut aceste observatii referitor la bacterii si fungus si legatura cu cancerul de demult:
sunt sgur ca foarte multi stiu de dr Simoncini si candida si bicarbonat sodiu: https://www.cancertutor.com/simoncini/
http://candida-international.blogspot.ro/2007/03/is-cancer-caused-by-candida-fungus.html
https://www.google.ro/webhp?sourceid=chrome-instant&ion=1&espv=2&ie=UTF-8#q=candida+simoncini
simoncini are ‘aproape dreptate’
Am citit ce ai scris.
Citez un anume pasaj ” If these microbes go into hibernation, the cancer cells will be able to restore their metabolism and will appear to be normal cells!!! In other words, when in hibernation these microbes do not intercept glucose and do not excrete mycotoxins. So just like when these microbes are killed, the cancer cells revert into normal cells.”
Iti dau si eu o tema de studiat. Am cautat la repezeala ceva si uite ce am gasit:
http://www.fredhutch.org/en/news/center-news/2015/08/how-cells-put-themselves-to-sleep.html
Hibernarea, incapsularea si trezirea la viata cand vor fii conditii propice pt. asta, este o caracteristica a fungilor, a ciupercilor.
Ciprian, s-au studiat la somatoscop si alte microscoape performante (gen microscoape ‘dark field’ ) aceste somatide si s-a vazut cum isi schimba forma si dimensiune functie de PH si imunitate(si imunitate pt ca degeaba au PH favorabil daca le ucide imunitatea). Ele la un moment dat au si stare de funghi -ciuperci – bacterii(similar candida) ca atunci cand produc cancer dar NU sunt simplii funghi-ciuperci-bacterii ci mai mult de atat-daca imi demonstrezi ca si candida se comporta exact ca acestea si ia 3 forme nedaunatoare si 13 nocive -adica daca demontrezi ca aceste microorganisme= candida atunci primesc.insa daca citesti pe sarite vei intelege doar ce crezi tu ca e ok, respectiv aici faptul ca seamana in comportament in forma lor de ciuperci/funghi/ bacterii nu implica si egalitate.
atat de bine s-au vazut ca s-a vazut si cum modifica nucleul si ADNul celulei, si cum secreta enzime cu ajutorul carora migreaza etc
cu primul comentariul al tau sunt de acord si cam tot ce ai scris e deja pe site, inclusiv testul urina Navarro- HGC – care nu e precis mereu dar a ajutat pe multi sa monitorizeze pina la un punct cum evolueaza cu tratamentul, gcMAF si nagalaza , detoxifeirea ficatului, dieta ,apa suplimente si mult mai mult de atat(conteaza si odihna (inclusiv melatonina ) si soarele (inclusiv vitamina D3) si starea emotionala( inclusiv pacea interioara si nadejdea si sustinerea bolnavului – acestea conteaza IN MOD PRIMAR DUPA AJUTORUL DOMNULUI , nu dieta-poate omul sa ia tone de suplimente si sa tina cea mai buna dieta cancer-NU va functiona nimci daca sistemul imunitar e suprimat emotional de un factor de stress prelungit ) –
nu public primul comentariu pentru ca NU fac reclama la produse pe acest blog – da , m-a tentat si pe mine sa ma apuc sa aduc suplimente care le stiu de la bolnavi ca fiind bune dar consider ca este mai bine pt bolnavi sa ma limitez
ce vreau sa iti spun este ca ce stii este ok dar consider ca incomplet pentru ca te limitezi oarecum la candida – adica incearca sa vezi dincolo de candida-e un microrganism care seamana cu candida, sa spun altfel.
si ca dovada ca tumorile nu apar mereu in locuri de „tesut mort /lezat care se infecteaza cu candida”: cancerele METASTAZEAZA DUPA TIPIC (adica de la san se duce/migreaza la plamani si oase de cele mai multe ori, de la colon la ficat, de la plamani la creier etc) pentru ca aceste microorganisme secreta niste enzime cu care isi ‘croiesc drum’ /’ taie ‘/ digera acelasi tip de tesut si se duc dupa un tipic/sablon – nu crezi ca e cam
‘mare coincidenta’ sa migreze tipic – ce daca ai sanul lezat ai si plamanii lezati -toti la fel?!?! vezi ce a descoperit dr Matias Rath ref cancer – solutia celulara dr Rath cu cei 2 aminoacizi , vitamina C coq10 si ceai verde pentru intarirea matricii colagen pt cancerele din tesut
DA. suplimentele anticandidoza vor ajuta si cu cancerul. aceste microorganisme avand comportament de bacterii/ciuperci intr-o celula de cancer( ele chair asta/ in forma / stadiul asta sunt cand produc cancer-niste bacterii) , vor ajuta cu imunitatea(probioticele si nu numai ) dar nu ajunge.
NOTA: sunt convins ca nici eu si probabil nimeni in prezent nu are toata imaginea in fata (de aceea primesc si analizez orice punct de vedere poate aflu ceva nou) insa daca vrem sa ajungem undeva trebuie sa nu facem gresesile trecutului – mai stiu niste persoane care sustineau ca stiu ele cauza pentu toate cancerele si remediul pentru toate cancerele de la dr Geson si Kelley cu potasiu si enzimele pina la Dr Hulda Clark cu parazitii.
Exemplu tipic de afirmatie turfasa care din pacate te limiteaza si nu mai vrei sa iei in considerare ce poate aduce completari la ce stiu:
„Toate formele de cancer sunt asemanatoare. Toate sunt cauzate de un parazit. Un singur parazit! Acesta este trematodul intestinal uman.
Si, daca distrugeti acest parazit, evolutia cancerului se va opri imediat. Tesutul va redeveni normal.” Hulda Clark-si a murit de CANCER!!!
Da unul a vazut ca potasiu/lacalinitatea conteaza, altul a vazut ca enzimele pancreatice conteaza, altul a vazut ca eliminarea parazitilor conteaza etc etc dar in momentul in care spui ca DOAR EU stiu adevarul si COMPLET atunci devii orb din mandrie-asa a fost de la inceputul lumii de cand a cazut Luci din dragostea Domnului, din pozitia lui de capetenie a ingerilor – si problema la mandrie e ca nu te poti ridica , nu poti efectiv. Doamne ajuta!
inca ceva despre GcMAF:
https://tratamenteanticancer.wordpress.com/2017/01/21/tratament-cancer-colostrum-oral-gcmaf/
ce am vrut sa iti mai spun este …cel mai bine este sa ai in vedere mereu statistici studii si rezultate-asa daca eu ma uit la ce imi convine mie/creierului meu si nu rezultatele nu stiu cat ajut efectiv pe cel bolnav-de aceea ti-am mentionat de cei de la ISSELS-sunt oameni care lucreaza de ZECI DE ANI in domeniul asta alternativ si au ZECI DE MII DE PACIENTI tratatati alternativ si AU TOT INTERESUL sa faca treaba buna si AU SI REZULTATE- 87 $ remisii pe TERMEN LUNG chair si DUPA CHIMIO/RADIO ‘terapii’-oamenii astia stiu ceva si avem ce invata de la astfel de oameni – si nu numai de la ei ; avand in vedere ca treaba cu candida si cancer nu e ceva nou si cei care merg pe partea alternativa cunosc toti despre candida si cancer, daca ar fi fost asa simplu problema era rezolvaa de mult-dar nu e.
Pingback: ICRF Reference Manual | Natural Treatments at CancerTutor.com
Pingback: Marturie vindecat cancer san | TRATAMENTE CANCER EFICIENTE, NON - toxice